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Abstract
Studies of the tissues and molecules that regulate the migration of cranial 
neural crest cells in the chicken embryo: roles of Midline 1 and retinoic acid
Cranial neural crest cells (cNCC) emigrate from the neuroepithelium to form the 
cartilaginous structures of the face and much of the peripheral nervous system of the 
head. Several genetic disorders and drug compounds can disrupt the patterning of cNCC- 
derived tissues during development.
I have studied cNCC patterning in the chick embryo, focussing on one genetic disorder (X- 
linked Opitz syndrome, caused by mutations in the MIDLINE1 {MIDI) gene) and one drug 
compound (retinoic acid).
I demonstrate the expression pattern of the chick orthologue of M ID I and show that the 
Midi protein, via its effects on Protein Phosphatase 2A, controls the migration of cNCCs 
and regulates the timing of cranial gangliogenesis, likely by altering cNCC protease 
activities.
Retinoic Acid (RA) is a diffusible morphogen and well-known teratogen that causes 
patterning defects in cNCC migration. I provide evidence that the cranial mesenchyme 
adjacent to rhombomere 3 of the hindbrain is a potent responder to the presence of RA, 
resulting in cNCC mis-migration. Furthermore, I demonstrate that the 9-cis RA isoform is 
more potent than the all-trans RA isoform at causing cNCC mis-migration.
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Chapter 1
1. General Introduction
This chapter introduces the development of the head, specifically focusing on the 
hindbrain and cranial neural crest cells (cNCC). There is particular focus on the role of 
retinoic acid and other molecules involved in cNCC migration patterning as a background 
introduction to Chapter 4. Furthermore there is also a section on development of the 
peripheral nervous system (PNS) involving cNCCs and the role of proteases in 
development as background for Chapter 3.
1.1. Craniofacial development
Formation of the body plan during development, and tissue repair and turnover in adults 
require that cells undertake a series of highly stereotyped migrations and cellular 
differentiation programs. The mechanisms controlling how cells migrate and interact with 
their environment are still poorly understood. This thesis is concerned with improving our 
understanding of the mechanisms and molecules that control the migrations of cells which 
give rise to the peripheral nervous system and the skeletal structures of the head. Defects 
in the patterning of cell migration, cell survival and cell fate choice, can all lead to 
craniofacial abnormalities, which account for around one third of human congenital birth 
defects [1]. There are several craniofacial syndromes in which cell migration patterning 
abnormalities are thought to be involved, such as First Arch Syndrome [1], Treacher- 
Collins Syndrome [1] and DiGeorge’s Syndrome [2].
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1.2. The Developing Head
The developing head consists of three layers: an external sheet of ectoderm, the 
mesoderm, and in the centre, the neuroepithelium (Figure 1-1). Mesenchyme is the 
mesoderm once the cNCCs begin to migrate into it. Along the anterior-posterior axis of 
the head, the developing neuroepithelium is broadly divided into three regions: the 
forebrain, the midbrain and the hindbrain. The hindbrain neural tube is transiently 
subdivided into 7 lineage restricted metameric segmented units (Figure 1-1) called 
rhombomeres (r).
hindbrain
n
r2
r3
r4
r5
r6
r7
surface ectoderm 
neural tube
mesenchyme
notochord
neural tube
mesenchymehindbrain
A
forebrain
midbrain
Figure 1-1. Head structure in the early developing embryo
A -  a dorsal photo of a chick hindbrain at the 10 somite stage, depicting the areas of the brain 
and surrounding mesenchyme. B -  Structure of the chick hindbrain (dorsal view), depicting 
the segmentation of the neuroepithelium into rhombomeres (r l-r7 ) C -  schematic diagram of 
a cross section through the hindbrain portraying the major structures of the developing 
head, neural tube (neuroepithelium), mesenchyme and surface ectoderm.
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The positional identity of each rhombomere can be defined by the expression of a 
combination of transcription factors (Figure 1-2), such as members of the Hox family [3]. 
For instance, Krox20 is expressed by both r3 and r5, but r5 is distinguished by the 
additional expression of Hoxa3 and RARa. With regards to gene expression, the cells of 
odd-numbered rhombomeres resemble each other more closely; r3 and r5 both express 
Krox20, EphA4, EphB2 and EphB3, whereas r2, r4 and r6 do not. These molecular 
differences and similarities generate differential cell affinities, such that neuroepithelial 
cells from odd- and even-numbered rhombomeres, if mixed together, will migrate to re- 
segregate themselves into two separate odd- and even-populations [4]. This was shown 
to rely on Eph-Ephrin bi-directional signalling to prevent intermingling of cells from 
different rhombomeres [4], as Figure 1-2 shows EphA4, EphB2 and EphB3 receptors are 
expressed in r3 and r5, whereas the Ephrin ligands, Ephrin B2 and Ephrin B3 are 
expressed in all rhombomeres except r3 and r5.
15
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Krox20/ EphA4 / EphB2 / EphB3
RARa
RARp
ephrinB2 / ephrinB3
Hoxa3/Hoxb3
Hoxbl / EphA2 / Wnt8c
Hoxa2
Hoxb2
Figure 1-2. Gene expression patterns in the chick hindbrain
A schematic diagram representing the genes expressed in each rhombomere of the hindbrain. 
Although several genes are expressed in a repeated pattern in every other rhombomere, the 
combined expression pattern of these genes uniquely defines the identity of each 
rhombomere. Dark blue and pink represent strong expression of the gene, whereas lighter 
blue and pink represents weaker expression of that particular gene in the corresponding 
rhombomere.
1.3. The cranial neural crest
The population of cells that that is the subject of my thesis is the cranial neural crest 
(cNCC). cNCCs are neuroepithelial cells that can differentiate into connective tissues, glia 
and peripheral neurons of the cranial ganglia, cartilage and bone. Although crest is 
produced throughout the dorsal neuroepithelium of the neural tube, in the hindbrain crest 
only migrates from r2, r4 and r6 into the adjacent mesoderm (creating a mixture of 
epithelial and mesodermal cells, called the cranial mesenchyme). cNCC migration is 
constrained into three streams that do not enter mesenchyme adjacent to r3 or r5 (Figure 
1-3). Rhombomeres 3 and 4 do not output crest directly into their mesenchyme, the
16
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cNCCs they produce migrate rostrally or caudally to even numbered rhombomeres and 
join the crest streams there. Even though crest is produced by r3 and r5, there is a high 
level of apoptosis in these rhombomeres that limits the amount of cNCCs that they 
contribute to the head [5, 6], although this is not solely responsible for the formation of 
crest stream segregation. The r3 mesenchyme is maintained crest free by as yet 
uncharacterized growth inhibitory factors that rely on signals from r3 and its overlying 
surface ectoderm [7].
1.3.1. Neural crest cell induction and delamination of the neural 
crest from the neuroepithelium
There are 3 main stages the neural crest will go through before its differentiation into 
multiple cell types (Figure 1-3) (reviewed in [8] and [9]),
Induction -  the process by which the production of the neural crest cells is initiated
Delamination -  at this stage the neural crest cells undergo an epithelial to mesenchymal 
transition (EMT), leave the neural tube and enter the mesenchyme
Migration -  the neural crest cells migrate along defined paths to their point of 
differentiation
Induction of neural crest cells begins even before the neural tube is formed. At the neural 
plate stage of development, signals from the non-neuronal epidermal ectoderm, 
specifically Bmp4, Bmp7 and Wnt6, act upon the neural plate border region and induce 
NCC formation. The neural plate then invaginates and both sides of the neural plate 
border come into contact and close to form the neural tube.
17
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Delamination of the neural crest cells can then occur from the dorsal neural tube, this 
process is called an epithelial to mesenchymal transition (EMT). This involves a change 
in the cell-cell contacts between the NCCs and the surrounding cells of the dorsal neural 
tube allowing the NCCs to release themselves from the neural tube and migrate into the 
adjacent mesenchyme. At this point, the cell adhesion molecules N-CAM, N-cad and 
cadherin-6B are all down regulated, while cadherin-7 is upregulated. Studies in chick 
have shown that down regulation of cadherin-6B causes early emigration of NCCs from 
the neural tube, whereas up regulation of cadherin-6B leads to reduced EMT and cNCCs 
remaining in the neural tube [8].
Figure 1-3. Induction, formation and migration of the cranial neural crest.
Schematic diagrams depicting the induction, formation and migration of the neural crest. A -  
neural plate stage, non-neural ectoderm [yellow) signals induce the production of NCCs 
[Blue) at the border of the neural plate [pink). B -  the neural plate invaginates to form the 
neural tube with the NCCs meeting at the dorsal part of the forming neural tube. C -  the 
neural tube forms and the NCCs begin to delaminate from the neural tube and migrate into 
the surrounding mesenchyme. D -  schematic diagram showing the migration pattern of the 
cNCCs [pink) from the hindbrain [blue). NP -  neural plate, NC -  notochord, E -  ectoderm, OV 
-  otic vesicle, r -  rhombomere, arrows depict the direction of migration.
18
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The cNCCs, once having undergone EMT, migrate through the mesenchyme in highly 
defined streams towards the branchial arches. There are three streams of cNCCs, the 
trigeminal, which is adjacent to rhombomeres 1 an 2, the hyoid, adjacent to rhombomere 
4 and the post-otic, adjacent to rhombomeres 6 and 7 (Figure 1-3). The cNCCs that 
migrate in these streams originate from the rhombomeres immediately adjacent to them 
and also contain a proportion of cells from r3 and/or r5. The majority of cNCCs produced 
by r3 and r5 undergo apoptosis; however those that do survive migrate within the neural 
tube towards an adjacent even numbered rhombomere and then leave the neural tube 
with that cNCC stream..
1.4. Neural crest and development of the face
The development and migration of the cranial neural crest cells (cNCCs) are essential 
processes in the early development of the head. Inadequate induction of cNCC 
development, delamination from the neural tube or incorrect migration of the cNCCs to 
their point of differentiation leads to craniofacial structural defects, such as cleft lip and 
palate [1,10]. Figure 1-4 demonstrates the origins of the lower facial region are from the 
maxillomandibular processes, which is cNCC derived [11].
19
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|  Median nasal prominence 
|  Lateral nasal prominence 
Maxillomandibular prominence
Figure 1-4. Development of facial structures.
A schematic diagram of frontal views of a developing embryo, depicting the origins of the 
facial prominences. The maxillomandibular processes (also known as branchial arch 1, BA1), 
of which the cNCCs originate from r l/ r 2 ,  are highlighted in green, lateral prominences in blue 
and median nasal prominences in red. The work in this thesis focuses on stage A, which 
equates to around 3 weeks of human embryo development and 1.5 days in chick. Human 
embryo development progresses to stage B by about week 4, stage C by week 5 and stage D 
by around week 6. In comparison chick embryos reach stage B by 2.25 days, stage C by 3 
days and stage D by 4.75 days in development. Adapted from Tapadia, Cordero et al. 2005 
[11].
1.5. Environmental factors that control the migration 
pattern of cranial neural crest cells
1.5.1. Mechanisms controlling cell migration
Neural crest cells, like other migratory cell types, integrate growth promoting and growth 
inhibitory cues from their environment. Cell migration begins by the leading edge of the 
cell extending the plasma membrane, stabilized by nascent cell adhesions, which 
strengthen as the cell forms a point of traction over which it can move (reviewed in [12]).
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Members of the intracellular second messenger Rho family of small guanosine 
triphosphotases (GTPases) control cell movements by regulating the formation of these 
adhesions (Rho) and the formation of the extensions (Rac, Cdc42), the type of extension 
also depends on which GTPase is activated. Rac activation causes broad extensions 
called lamellipodia, whereas activation of Cdc42 leads to the formation of long thin 
extensions called filopodia. These filopodia continuously survey their surrounding 
microenvironment and recognise guidance cues. There are some growth inhibitory 
molecules, such as the Semaphorins, that will bind to the cell surface Neuropilinl/plexinA 
receptor complex and affect second messenger signalling to prevent cell adhesions from 
forming and cause the filopodia to collapse and thereby turn away from the inhibitory 
source [13].
1.5.2. Cues that pattern cranial neural crest cell migration
NCCs use both lamellipodia and filopodia to pathfind, maintaining nearly constant contact 
with neighbouring NCCs via lamellipodia and filopodia and keep long distance contact 
with the local environment through use of filopodia [14]. NCCs will also often change 
direction to follow neighbouring cells [14] and tend to migrate in chains of cells [15]. 
Integration of the mechanisms that control the patterning of NCC migration have yet to be 
elucidated, however several tissues and genes have been shown to be involved in 
maintaining the segregation of cranial crest streams.
Here the observed defects in cranial NCC migration have been classified into two groups 
(Figure 1.5). Firstly a phenotype in which a thin stream of cells connects the r4 and r2 
crest streams through r3 mesenchyme (referred to as a Typel phenotype in this report). 
Secondly a phenotype that shows cells from the r4 stream disregarding the r3 crest free 
zone altogether and spreading throughout the r3 mesenchyme (referred to as a Type2 
phenotype in this report).
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The Typel phenotype is observed in several situations (Figure 1.5): e.g. following ablation 
of r3 neuroepithelium or r3 surface ectoderm (SE), or interference with the signalling 
pathways of ErbB4 (a receptor tyrosine kinase of the EGF receptor family) or Sema3 (a 
ligand for Neuropilin receptors) or after over stimulation with retinoic acid (RA), (see figure 
1.5 for references). The Type2 phenotype occurs in knockouts of Twist, a bHLH 
transcription factor [16].
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Loss of r3 [7]
Twist knockout [16]
Removal of r3 surface [7]
Retinoic Acid exposure [45]
ErbB4 knockout [24]
Loss of ErbB4 signalling [17]
Sema3A signalling interference [27]
Msx1/Msx2 double knockouts [40]
Cyp26C knockouts [68]
F Type 1 Type 2
■Thin, discrete band of ■Wide band of cNCCs
cNCCs ■Migrates from the r4
■Migrates from the r4 j cNCC stream
cNCC stream ■Migrates through r3
■Migrates through r3 adjacent
adjacent mesenchyme vo v ) mesenchyme
■Joins r2 stream of ■Joins r2 stream of
c n c c s cNCCs
Figure 1-5. Summary and classification of cranial neural crest mismigration 
phenotypes.
The figures A-D show published examples of cNCC mismigration phenotypes, B shows an 
example of a typical Type 1 phaenotype as referred to here, showing a discrete band of cNCCs 
migrating through the r3 mesenchyme. A -  control. A-B, soxlO staining following r3 removal 
[17]. C shows an example of a Type2 phenotype, consisting of a more wholesale movement of 
cNCCs through the r3 mesenchyme, rather than a thin band of cells. D -  control, A-B soxlO 
staining for cNCCs in a tw ist knockout mouse [16]. E -  table of published instances of each 
migration phenotype. F -  schematic diagram of the cNCC migration pattern and summary of 
a Typel and Type2 migration phenotype. cNCCs are shown in pink.
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1.5.3. Tissues and molecules involved in patterning cranial 
neural crest migration
In this section the various tissues that have been found to play a role in maintaining 
correct cNCC migration patterning will be reviewed, followed by the specific molecules 
which have been identified to be involved in maintaining correct cNCC migration 
patterning.
One such tissue responsible for cNCC migration patterning is rhombomere 3, when 
removed in either mouse or chick embryos a Type 1 mismigration pattern of r4 cNCCs 
through the r3 adjacent mesenchyme is observed [7, 17]. Rhombomere 5 also has a 
cNCC free adjacent mesenchyme, however it has been shown that r3 is distinct from r5 as 
unlike r3, r5 is unable to maintain r3 adjacent mesenchyme cNCC-free, when transplanted 
in place of r3 [17], Rhombomere 5, unlike r3, is not necessary to maintain the r5-adjacent 
NCC-free zone, when r5 is removed the cNCC migration pattern is not affected.
Another tissue found to be important in the maintenance of correct cNCC migration 
patterning is the surface ectoderm (SE) at the level of r3. When removed from chick 
embryos the cNCCs migrated through the r3 adjacent mesenchyme towards the r2 cNCC 
stream, in a Typel phenotype [7]. Interestingly when the same experiment is repeated 
with the r5 SE, cNCC mismigration is observed [17]. Thus, it appears that r3 and its SE 
cooperate to maintain the r3-adjacent cNCC-free zone, whilst the r5-adjacent cNCC-free 
zone is maintained primarily by the SE over r5.
Eph receptors and their Ephrin ligands are membrane bound proteins involved in bi­
directional signaling, transducing both repulsive and attractive growth signals, depending 
on the cellular context. It has been shown previously that Eph and Ephrin signaling is 
involved in axon growth cone repulsion, and it has been suggested that a similar
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mechanism may be responsible for cNCC guidance, ensuring migration of cNCCs to their 
appropriate branchial arch and preventing intermingling of cNCCs from different streams 
[18,19]. In support of this, chick and Xenopus cNCCs express EphrinB2, while either side 
of the cNCC streams the mesenchymal cells express EphB2 [19, 20]. Furthermore 
EphB2 and EphrinB2 signaling prevents cNCCs of the second and third branchial arch 
from intermingling and also correctly targets third arch cNCCs [19].
Ephrin-B1 null mutants exhibit cNCC migration defects, including aberrant neuronal 
development and abnormal skeletal structures, the cNCCs themselves exhibit a 
‘wandering’ pattern of migration. Although this might be a Typel like phenotype, as the 
EphrinBI null mice show cNCCs from the r6 and r7 joining in a thin stream across the 
mesenchyme adjacent to r6/r7, it is unclear if this happens through the r3 adjacent 
mesenchyme [21].
The signaling between ErbB4 and Neuregulin (NRG) is essential to maintain the r3- 
adjacent cNCC-free zone. Neuregulin 1 (NRG1) is expressed in r4 in chick embryos and 
in r2 and r4 in mice [22, 23]. The receptor for NRG1, ErbB4, is found expressed in r3. 
When ErbB4 signaling activity is suppressed in chick, or knocked out in ErbB4 null mice, 
the cNCCs from r4 show a Typel migration pattern [17, 24]. Moreover when WT r4 
cNCCs are transplanted into an ErbB4 null mouse embryo, the same Typel mis-migration 
pattern is observed, conversely if ErbB4- r4 cNCCs are transplanted into a WT embryo 
the cells migrate normally [24]. Therefore in this case the effect seen is not cNCC 
autonomous, but is environmental.
Semaphorin (Serna) 3A and 3F also contribute to correct positioning of the cNCC 
migration pattern. Semaphorins were initially characterized for their importance in axon 
guidance and nervous system development and act through binding to neuropilins (NRP)
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and plexin [25]. It has recently been shown that loss of either SEMA3A or NRP1 causes 
incorrect migration of cNCCs to the point of differentiation, which leads to ectopic nerve 
development [26]. Sema3A and Sema3F are found expressed in r1, r3 and r5 in chick 
hindbrain at 11ss [27]. Sema3F additionally is found expressed strongly in r3 alone at 9ss 
[27]. Therefore at the stage when the r3 cNCC free zone is important, Sema3A and 
Sema3F are expressed in r3, making them candidates for maintenance of correct cNCC 
migration patterning. Indeed when their signaling is impaired, via use of a Neuropilin-Fc 
or in SEMA3A or NRP1 knockout chicks, a Typel migration phenotype occurs [27] [28].
The Msx proteins, Msx1 and Msx2, are involved in cell proliferation, differentiation and 
survival [29-34]. They are downstream effector proteins in the Bmp pathway and in 
addition are effectors for the Fgf and Wnt siganlling pathways in some tissues [32, 35-38]. 
In models where defects of Msx1 or Msx2 are present, a variety of NCC development 
defects have been observed, including cleft palate and cranial skeletal abnormalities [39]. 
Thus Msx function in cNCCs was investigated; both Msx1 and Msx2 are expressed in 
premigratory and migratory cNCCs, moreover Msx1/Msx2 double knockout mice the 
cNCCs exhibit a Typel phenotype [40]. Therefore the Msx proteins play a vital role in 
correct cNCC migration patterning.
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1.6. Retinoicacid
Retinoic acid (RA) and the Cyp26 group of retinoic acid metabolizing enzymes, are also 
involved in maintaining correct cNCC patterning.
Retinoic acid is a potent teratogen and was first realized to have an important role in 
development when rat pups were born with severe congenital deformations to mothers fed 
on a Vitamin A deficient diet [41]. Correct RA signaling during development is vital for 
correct formation of an embryo, gradients of RA in the neural tube are used to define 
antero-posterior patterning, increased local concentrations of RA lead to more posterior 
cell fates [42]. Furthermore in the hindbrain region RA directly regulates patterning genes, 
such as the Hox family of transcription factors (reviewed in [42]).
RA has a number of possible isoforms, of these all-trans RA and 9-cis RA receive much 
attention due to their ability to mediate gene regulation [43]. Endogenous RA is produced 
from Vitamin A by ADH, producing Retinaldehyde, which is then acted on by RALDH to 
produce RA (Figure 1-6).
1.6.1.1. Retinoic acid and cranial neural crest migration
patterning
It has long been known that overexposure of developing embryos to retinoic acid leads to 
a range of birth defects, called retinoic acid embryopathies, consistent with NCC 
mismigration [44]. In line with these early observations, exposure of whole embryos to 
all-trans RA leads to a Typel cNCC phenotype, further studies have shown that this can 
be caused by specifically targeted exposure of r4 to all-trans RA [45]. A study by Gale 
and Prince [45] showed that injections of all-trans RA into r4 gave a Typel phenotype, 
and also altered rhombomere gene expression patterns. Rhombomere 4 showed ectopic 
Krox20 and a loss of Hoxbl, perhaps indicating a change in r4 to being more r3/r5 like
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(Figure 1-2). The study also showed that RA injections into r2 or r6 gave no cNCC 
mismigration, as well as injections of RA into the r2, r3 and r4 adjacent mesenchyme.
1.6.2. Cellular retinoic acid binding proteins (CRABPs)
Cellular retinoic acid binding proteins (CRABPs) are involved in regulating the localisation 
of RA within the cell. CRABPII is most likely responsible for transporting RA into the 
nucleus, when RA binds to the CRABPII protein it causes a change in conformation, 
exposing a nuclear localization signal [46]. Another finding to further support this function 
of CRABPII is the observation that over-expression of xCRABP in xenopus leads to a loss 
of anterior structures, such as that seen in xenopus following RA treatment [47]. This 
suggests that when more CRABPII is available, transport of RA to the nucleus is more 
efficient and therefore mimics the effect of having more available RA.
Conversely CRABPI has been shown to have the opposite effect on RA transport, by 
binding RA and remaining in the cytoplasm, therefore preventing RA signalling. A study in 
F9 murine carcinoma cells reports that when CRABPI is overexpressed cells become less 
sensitive to treatment with RA, however when CRABPI expression is reduced, cells 
become more sensitive to RA [48, 49].
1.6.3. Retinoic Acid Receptors
The retinoids have two known receptors; the retinoic acid receptors (RAR) and the retinoid 
X receptors (RXR). Both the RAR and RXR have three isotypes, a, (5 and y, which are 
each encoded by separate genes [50-52]. These RAR and RXR receptors have been 
shown to form both RAR-RXR heterodimers and homodimers [53], additionally RXR has 
been shown to also form heterodimers with other nuclear receptors, including peroxisome
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proliferator- activated receptor (PPAR-y), thyroid hormone receptor (TR), vitamin D3 
receptor (VDR) and the liver X receptor (LXR)[54-58].
RAR has been shown to mainly bind all-trans RA, whereas 9-cis RA binds to both the 
RAR and RXR receptors, however 9-cis RA has a much lower binding affinity, around 40 
times less, to the RAR receptor than the RAR receptor [59]. A study by Shulman and 
Larson [60] showed that the RXR receptor when dimerised with RAR cannot on its own 
initiate responses unless the RAR receptor has also been activated. They also show that 
the RXR receptor under different conditions, such as when dimerised with PPAR-y, is 
sensitive to ligand on its own.
1.6.3.1. Retinoic Acid Response Elements
Retinoic Acid Response Elements (RAREs) are binding domains located in the promoter 
region of target genes. The RARs and RXRs can bind as either hetero or homodimers to 
the RAREs and repress or enhance transcription of the targeted gene when activated by 
RA [61]. RAR and RXR hetero or homodimers bind to the RAREs and in the absence of 
RA binding act to repress gene transcription. This is achieved by the binding of a 
transcriptional repression complex, which includes a histone deacetylase that represses 
transcriptional activity [62, 63]. In the event that RA binds to the RA receptors, the 
transcription repression complex is released and replaced by a transcriptional activator 
complex, which contains histone acetyltransferase activity, thus allowing a conformational 
change in chromosomes allowing promoter activation and transcription of the gene [64]. 
RAREs play a role in early development; both Hoxal and Hoxbl have been shown to 
have RARE sites in their promoter region, due to the importance of Hox genes in the 
correct development of the hindbrain, this indicates the significance of correct RA 
signaling during these processes.
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1.6.3.2. Cyp26s and retinoic acid metabolism
The RA metabolizing enzymes, Cyp26A, Cyp26B and Cyp26C are all expressed in 
embryo hindbrain and mesenchyme during early development. Cyp26A is upregulated by 
RA and acts to inhibit the metabolism of RA into its metabolites, including 5,6 Epoxy RA, 
4-OH RA and 4-oxo RA. These metabolites promote upregulation of Cyp26A and Cyp26B 
in a positive feedback loop. Conversely Cyp26C is down regulated by RA.
At the 10 somite stage Cyp26A is expressed in the r3 and the r6 adjacent mesenchyme, 
Cyp26B is expressed in r4 and the r6 adjacent mesenchyme and Cyp26C is expressed in 
r2/r3 and the r2/r3 adjacent mesenchyme [65-67]. Therefore Cyp26 proteins are 
expressed in the correct areas and at the stages of development when cNCCs are 
migrating and their guidance can be affected.
Cyp26A/Cyp26C double knockouts show r4 cNCCs exhibiting a Typel phenotype [68]. 
The Cyp26 inhibitor, Fluconazole, when applied globally to rat embryos, also causes a 
Typel phenotype, further supporting their importance in cNCC guidance.
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Figure 1-6. Metabolism and function of Vitamin A
Flow chart of the metabolism of Vitamin A into RA and the function of RA before its 
degradation into its metabolites. Blue text indicates enzymes, red arrow indicates positive 
upregulation. ADHs -  alcohol dehydrogenase, RALDHs -retinaldehyde dehydrogenase
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1.7. Development of the cranial Peripheral Nervous System
The cranial neural crest is a pluripotent group of cells that have the ability to form 
melanocytes, connective tissues, cartilage and bone and also form the neurons and glia of 
the cranial ganglia. The first cell type to differentiate from cNCCs are the cranial ganglia. 
Thus, the cranial ganglia are the first “victim” of cNCC patterning defects. The peripheral 
nervous system in the developing head of an embryo receives contributions from two 
progenitor cell types. First, there are the cranial neural crest cells, which give rise to 
neurons and glia of the cranial ganglia. Secondly there are the cells of the neurogenic 
placodes, these cells contribute neurons to some of the cranial ganglia, the ratio of 
neurons originating from a cNCC or placode progenitor varies depending on the particular 
ganglion (Figure 1-7).
1.7.1. The ectodermal placodes
The placodes are recognized as transient focal thickenings in the cranial ectoderm (Figure 
1-7). Whilst the neural crest develops both in the head and the trunk of an embryo, the 
neurogenic placodes develop exclusively in the cranial region. Placodes can also be 
recognized by their increased cell proliferation rate, in comparison to the surrounding 
ectoderm [69, 70]. In addition when placodal cells delaminate from the placode, unlike 
neural crest cells, they do not undergo EMT [70].
The cranial placodes identified to date include the adenohypophyseal, olfactory, lens, 
trigeminal, profundal, otic, lateral line and epibranchial and hypobranchial placodes [71]. 
Of these, many are found in vertebrates, with the exception of the hypobranchial placodes 
which have only been identified in amphibians [71].
32
Chapter 1
The trigeminal placode, in chick, has two subdivisions, the maxillomandibular and 
ophthalmic placode [72]. These produce migratory placodal cells, which convene with 
neural crest cells from the r1 /r2 stream, and form the sensory neurons of the trigeminal 
placode, the maxillomandibular placode contributing to the maxillomandibular processes 
of the trigeminal and the ophthalmic placode contributing to the ophthalmic processes 
[73]. One distinct difference observed between the two trigeminal placodes is that the 
maxillomandibular, like many other placodes, outputs mitotically active cells, whereas the 
ophthalmic placode produces cells which are post-mitotic [73]. The two trigeminal 
placodes can also be distinguished by their expression of different neurogenin genes, the 
maxillomandibular trigeminal placode, along with all the other placodes, expresses 
neurogenin-1, whereas the ophthalmic trigeminal placode expresses neurogenin-2 [73].
The epibranchial placodes include the geniculate, nodose and the petrosal placodes. 
Each of these produce neural progenitors that migrate away from the placode and 
differentiate into sensory neurons that form part of the geniculate ganglion, vagal nerves 
(nodose) and the glossopharageal (petrosal) ganglion respectively [74]. The development 
of the epibranchinal placodes are induced by the nearby pharangeal endoderm [75]. In 
particular BMP7 and FGF signaling have been shown to play an important role in placode 
initiation, loss of FGF3 and FGF8 function leads to a block in the development of the otic 
and epibranchial placodes [76-79].
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Figure 1-7. Location of the ectodermal neurogenic placodes and contribution of cNCC and 
placodal cells to the cranial ganglia.
Schematic diagram showing the location of the otic, trigeminal and epibranchial placodes in a 
developing chick head and their contributions to subsequent development of the cranial 
ganglia. The locations of the placodes within the embryo head are shown on the right. Green 
portions of ganglion represent cells that originated from the neural tube, ie cNCCs and other 
sections of ganglia are colour coded according to the placode from which the cells originated. 
Eg -  Epibranchial geniculate, En -  Epibranchial nodose, Ep -  Epibranchial petrosal, Ot -  Otic, 
Tm -  Trigeminal Maxillomandibular, To -  Trigeminal Ophthalmic.
In order for the placodal cells to begin delaminating from the placode and migrating into
the mesenchyme to the point of ganglion development, the placode requires contact from
the neural crest in order to initiate detachment from the placode [70] (Figure 1-8). In the
absence of cNCCs placodal cells do not migrate from the placode, however if the cNCCs
make contact with the placode but the stream of cNCCs is discontinued then the neuronal
projections from the ganglion that innervate the hindbrain overshoot their destination [80].
Furthermore once the cells of the placode have detached from the placode they use the
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neural crest as a scaffold, using them to migrate up the stream of cNCCs, in the opposite 
direction to the general stream of cNCCs to the point of ganglion development [80].
Surface
Ectoderm
Neural
Tube
Placode
Mesenchyme
Placode cell 
Neural crest cell 
Neuron
Figure 1-8. Initiation of placodal cell migration by neural crest cells.
Schematic diagram depicting the initiation of placodal cell migration following cNCC 
migration to the placode location and the subsequent differentiation of the placodal cells at 
the site of ganglion development. Arrows indicate migration direction of cells, pink cells 
represent cNCCs, blue cells represent placodal cells and green cells represent neurons.
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1.8. Proteases in development
Proteases are enzymes which have the ability to degrade proteins and play a role in 
development processes, including cNCC EMT and migration (Figure 1-9). Matrix 
metalloproteinases (MMP’s) are a family zinc-dependent proteases, they have the 
capability of degrading many types of extracellular matrices and make up a subgroup of 
the metalloprotease(MP) protein superfamily. The MP super family includes several 
subgroups, including the ADAMs (A Disintegrin And Metalloprotease), ADAMTs (A 
Disintegrin-like and Metalloprotease with Thrombospondin motifs), membrane bound 
MMPs (MT-MMPs), and the ‘classical’ MMPs. Many are expressed during hindbrain 
development and some have been shown to be not only expressed in neural crest cells 
but also necessary for their migration.
MMP2, MMP8, AdamlO, Adam13, MT1-MMP and Timp2 have all been shown to be 
expressed by neural crest cells [81-86]. MMP2 has been shown to be expressed in NCCs 
in chick [82, 87, 88] and MMP8 in NCCs in mice [84]. MMP2 has also been found to be 
essential for EMT, inhibition of MMP2 leads to failed EMT of NCCs from the neural tube 
[88], MMP2 is also required for correct migration/delamination of the NCCs from the 
neural tube [87].
AdamlO is expressed in avian NCCs in vitro [85] and Adam13 is expressed in xenopus 
NCCs [81]. Work to date has shown that when defective Adam13 NCCs are transplanted 
into a normal embryo the NCCs do not migrate, furthermore when normal NCCs are 
transplanted into a Adam13 defective embryo the WT NCCs can migrate correctly [89].
The expression pattern of MT1-MMP (also recently referred to as MMP14) in xenopus has
shown it to be expressed in cranial NCCs [86], in chick however the findings are that MT1-
MMP is found in the cardiac NCCs [83]. One activity of MT1-MMP is to activate MMP2
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[90], therefore it is possible that MT1-MMP is required for NCC EMT and migration as it is 
upstream of MMP2. Tissue inhibitor of metalioproteinases, (TIMPs) act as regulators of 
MMP activity, one of these, Timp2, can be found expressed in chick cardiac NCCs. High 
levels of Timp2 will prevent activation of MMP2 by stopping MTI-MMP action, whereas low 
levels of Timp2 actually promotes formation of active MMP2 through the promotion of a 
MMP2-Timp2-MT1-MMP complex [91-93]. Therefore the correct regulation of Timp2 
protein levels is most likely important for correct NCC EMT and migration due to its role in 
both complex formation for activation of MMP2 and also its inhibitive role for MT1-MMP.
MMP2 (Gelatinase A) Head and cardiac region (10ss+) Gelatin, Collagens, laminin-5 [82,87,88]
MMP3 (Stromelysin 1) - Collagens, laminin-1,fibronectin [152]
MMP8 (Neutrophil 
Collaqenase) Mice NCCs Collagens [84]
MMP10 (Stromelysin 2) - Collagens, laminin-1,fibronectin [152]
MT1-MMP (MMP14) Xenopus cNCCs, Avian cardiac NCCs Pro-MMP2, gelatin, collagens, laminin-5 [86]
AdamlO Avian NCCs in vitro N-cadherin [85]
Adam 13 Xenopus NCCs, Avian head mesenchyme [81]
Figure 1-9. Table of proteases involved in development
A table of some proteases available during development, particularly those relevant to NCCs 
and head development, and their known substrates.
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1.9. General Aims
The work presented in this thesis aims to further elucidate the mechanisms involved in 
correct cNCC migration patterning. Particular focus is on identifying if there is a possible 
common mechanism behind the Typel mismigration phenotype as described here. At the 
centre of this query is the role of retinoic acid in cNCC migration patterning.
Furthermore the role of Midi in the cNCC cell migration, formation and patterning of the 
cranial ganglia forms a major part of this research work. Midi is the gene found mutated 
in X-linked Opitz Syndrome, patients present with craniopfacial birth defects, including 
cleft lip and palate and widely spaced eyes (hypertelorism). This is further explained in 
section 3.1. A spatio-temporal study of the gene expression pattern of the MID genes 
during development aims to elucidate the presence of Midi during cNCC emigration. In 
addition, the role of Midi during early development, with focus on cNCCs, will be 
investigated by use of expression constructs for Midi, PP2A (a Midi target) and a 
dominant-negative Midi and Okadaic acid (a PP2A inhibitor). Finally the role of Midi in 
the formation of the cranial ganglia will be investigated.
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2. Materials and methods
2.1. Materials
2.1.1. Sources of reagents
Reagent (listed alphabetically) Manufacturer Catalogue Number
9-cis retinoic acid Sigma R4643
Agar Fisher Scientific A/1080/48
Agarose Invitrogen 15510-019
All-trans retinoic acid Sigma R2625
Ammonium acetate Sigma A1542
Ampicillin Sigma A9518
B27 Supplement 100x Gibco 17504
Beads (Bio-Rad AG 1-X2 resin, 200-400 
mesh, hydroxide form)
BioRad 143-1255
Beads affi-gel blue (100-200 mesh) BioRad 153-7302
Blue/Orange Loading dye 6x Promega G1881
BM Purple (alkaline phosphotase 
substrate)
Roche 11 442 074 001
Boehringer blocking reagent Roche 1 096 176
Cell tracker CM-Dil Molecular Probes C7000
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Cell tracker CM-FDA Invitrogen C2925
C02 Independent Medium Gibco 18045-054
Diethyl pyrocarbonate (DEPC) Sigma D5758
Dimethyl sulfoxide (DMSO) Sigma D5879
ECL Western Blotting analysis system Amersham RPN2109
EDTA Sigma E5134
Ethanol (EtOH) VWR 20 819.298
Ethidium Bromide Fisher Scientific E/P800/03
Fast Red tablets (alkaline phosphotase 
substrate)
Roche 11 496 549 001
Fetal bovine serum Sigma F-7524
Fibronectin R&D systems 1030-FN
Fluorescent Mounting Medium DakoCytomation S3023
Formamide Aldrich 22,119-8
Glycerol Sigma G9012
Hybond nitrocellulose membrane Amersham RPN303F
Ipegal CA-630 detergent Sigma 18896
L-Glutamine Sigma G8540
Lipofectamine LTX reagent Invitrogen 15338-100
Magic Mark Invitrogen LC5602
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Marval skimmed milk Tescos
Methanol (MeOH) BDH 101586B
Molecular Weight ladder 1 kb NEB N3232S
Molecular weight ladder -low NEB N3233S
N2 Supplement 50x Gibco 17502048
Okadaic Acid -  sodium salt Calbiochem 459620
Paraformaldehyde (PAF) Sigma P6148
Phosphate Buffered Saline (PBS) 
Tablets
Sigma P4417-100TAB
PLUS reagent (lipofection reagent) Invitrogen 11514-015
Potassium chloride (KCI) Sigma P9541
Ready Gel 10% Tris-HCL BioRad 161-1155
RNaseOUT™ ( Ribonuclease Inhibitor) Invitrogen 10777-019
Sheep serum Sigma S3772
Sodium chloride (NaCI) Sigma SS7653
Sodium citrate-tribasic dihydrate Sigma C8532
Sodium Deoxycholate Sigma D6750
Sodium dodecyl sulfate (SDS) Sigma L4390
Sodium hydroxide (NaOH) Fisher Scientific S/4920/53
Sucrose Fisher Scientific S/8600/60
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SureClean (DNA cleanup kit) Bioline BIO-37042
Tris-Borate-EDTA buffer 
Concentrate
10x
Sigma T4415
Triton X 100 detergent Sigma T8787
tRNA from baker’s yeast Sigma R5636
T ryptone Fisher Scientific BPE1421
Tween 20 detergent Sigma P9416
Yeast extract Fisher Scientific BPE1422
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2.2. Antibodies
2.2.1. Primary antibodies
Antibody Species Immunogen / 
Clone
Application* 
and dilution
Company Catalogue
Number
Actin Mouse (3-actin N- 
terminus
WB - 1 :2000 Sigma A1978
BrdU Rat BrdU
(clone
BU1/75)
IF -1 :5 0 0 Abeam Ab6326
DIG-alkaline
phosphotase
(AP)
conjugated
Sheep Digoxigenein
(DIG)
ISH
1:1500
Roche 11 093 274 
910
FITC Goat FITC IF -1 :1000 Abeam ab19224
FITC- alkaline
phosphotase
(AP)
conjugated
Sheep Fluorescine
(FITC)
ISH
1:1500
Roche 11 426 338 
910
GFP Rabbit whole GFP 
molecule
IF -  1:3000 Abeam ab290
HNK-1 Mouse Clone VC1.1 IF -1 :2000 Sigma C0678
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Laminin Mouse IF -
Neurofilament Mouse phosphate IF -1 :1 0 0  Zymed 13-0700
independent
epitope in
carboxy
terminus
(Clone RMO-
270)
Pax2 Rabbit aa 188-385 of IF -1 :1 0 0  Abeam ab37129
Pax2
Pax3 Mouse C-terminal IF -1 :1000 Development
region al Studies
(aa298-481) Hybridoma
Bank
PP2A Rabbit PP2A WB -1:1000 Cell 2038
catalytic Signalling
subunit (A Technologies
and B forms)
*IF -  Immunofluorescence, ISH -  In-situ hybridisation, WB -  western blot
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2.2.2. Secondary antibodies
Antibody Species
Immunogen 
/ Clone
Application* 
and dilution
Company
Catalogue
Number
Alexa Fluor Molecular
Goat Anti mouse IF -1 :20 0 A11029
488 probes
Alexa Fluor Molecular
Goat Anti rabbit IF -1 :20 0 A11034
488 Probes
Alexa Fluor Molecular
Goat Anti rat IF -1 :20 0 A11006
488 Probes
Alexa Fluor Molecular
Goat Anti mouse IF -1 :2 0 0 A11032
594 Probes
Alexa Fluor Molecular
Goat Anti rabbit IF -1 :20 0 A11037
594 Probes
HRP WB
Goat Anti mouse Pierce E7756556
conjugated 1:15000
HRP WB
Goat Anti rabbit Pierce E7756789
Conjugated 1:15000
*IF -  Immunofluorescence, WB -  western blot
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2.2.3. Kits
Kit Company Catalogue Number
ApopTag Red In Situ Apoptosis 
Detection kit
Chemicon S7165
DC assay BioRad 500-013,500-014, 500-015
HiSpeed Plasmid Maxi kit Qiagen 12662
QIAprep Spin Miniprep kit Qiagen 27106
Spin Prep Gel DNA kit Novagen 70852-3AT
2.2.4. In-situ hybridisation mRNA probes
Probe target Plasmid vector
Restriction 
Enzyme for 
linearisation
Polymerase for
antisense
probe
Reference
cCyp26A
pGEM-T Easy vector
BamHl T7 [94]
cCyp26B
pGEM-T Easy vector
Kpn\ T7 [66]
cCyp26C
pGEM-T Easy vector
Sal\ T7 [67]
cErbB4 pCR-Script SK + Hindi II T3 [23]
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cKrox20 Hind\\\ T7 [95]
cMidl pCA(3 Non T3 [96]
cMid2 pCAp Non T3 [97]
cSoxI 0 pBluescript SK- Hind\\\ T3 [98]
2.2.5. Expression constructs
Recombinant proteins Vector Reference
cMidl - IRES eGFP pCA(3 [96]
dN.cMid1/2 - IRES eGFP pCA(3 [97]
2.2.6. Enzymes
Enzyme Buffer Company
Catalogue
Number
EcoRI Roche Buffer H Roche 10 703 737 001
Hind\ II NEB 2 NEB R0104S
Proteinase K Sigma P-2308
Sa/I NEB 3 NEB R0128S
Sp6
polymerase
RNA 10x RNAPol Reaction 
Buffer
NEB M0207S
T3
polymerase
RNA
Transcription Buffer Roche 11 031 163 001
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T7 RNA 10x RNAPol Reaction
NEB M0251S
polymerase Buffer
Xba\ NEB 2 NEB R0145S
Xho\ NEB 2 NEB R0146S
Not\ NEB 3 NEB R0189S
BamH\ NEB Bam HI buffer NEB R0136S
Kpn\ NEB 1 NEB R0142S
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2.2.7. PCR primers
mRNA Forward Primer sequence Reverse primer sequence Reference
cAdamIO CCAAACTCACAGTGGGACCT T G C ATT CC ATT C CAG AAT C A *
cMMPIO GCCCTT CAGAAAAATGGTCA CACTT CT GGAGCAAATGCAA *
cMT1-
MMP
GAAGTGTCGACCCGGAAAC GGTT CT G AAGGCAGAAGGT G ★
cTimp2 GAACCCCAT CAAGCGAAT CC GGCGT GGACCAGT CT AACAT [83]
GAPDH TGGGTGT CAACC AT GAG AAA CATCCACCGT CTT CT GT GT G [99]
* Primers were designed using Primer-Blast (Pubmed)
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2.2.8. Equipment
Equipment Company Catalogue / 
Model number
Electrode holder (single) Intracel 01-927-09 and 
01-926-09
Borosilicate capillary glass Clark electromedical 
instruments
GC100F-10
Footswitch Intracel 01-920-09
Silver electrode (offset pole) Intracel 01-929-06
TSS20 Ovodyne electroporator Intracel 01-916-02
Tungsten electrode (5mm tip) Intracel 01-935-06
Hybaid shake ’n’ stack hybridisation 
oven
Thermo
Corporation
Electron
Dissecting microscope Motic SMZ168
Fluorescent dissecting microscope Nikon DS-L2, SMZ1000, 
P-FLA2, C-HGFI
Vibratome
Time-lapse microscope
Twist shaker Finemould 
Ind. Co.
Precision TW3
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2.3. Reagent preparation
2.3.1. Transformation and plasmid preparation
Transformation of XL1-Blue competent cells (Stratagene) was carried out following the 
manufacturer’s instructions. Transformed cells were grown overnight before plasmids 
were extracted and purified (Qiagen QIAfilter Plasmid Maxi kit). For use in 
electroporations, plasmids were further concentrated (Bioline Sure Clean system) to 
10pg/pl.
2.3.1.1. Creating a PP2Ac expression construct
A PP2A expression construct was made by excising the PP2Ac DNA from a pCMV 
plasmid [100] and inserting it into the pCAB - IRES eGFP empty vector [96]. This was 
achieved using the Sail restriction enzyme to remove the PP2Ac fragment from the pCMV 
vector, the fragment was then isolated by running the digest on a 2% agarose gel with 
ethidium bromide. The PP2Ac was then cut from the gel following visualisation on a low 
energy UV lightbox and purified using a Quiagen Gel Extraction Kit. The pCAB vector 
was then linearised using a BamHI-Clal double digest. The linear pCAB vector and 
PP2Ac fragment were then blunt ended using Klenow DNA polymerase. The pCAB 
vector was then incubated in Shrimp alkaline phosphatase (SAP) to dephosphorylate the 
ends and prevent recircularisation. Following this the mix was then heated to 65°C to 
inactivate the SAP. The pCAB vector and PP2Ac fragment were then ligated together 
using T4 DNA ligase. The resulting plasmid was then used to transform XL1 Blue 
competent cells. Transformed cells were grown overnight before colonies were picked 
and the DNA extracted and purified (Qiagen QIAfilter Plasmid Maxi kit). The isolated 
plasmids were then checked for correct orientation of the PP2Ac insert using a Sall-Kpnl 
sequential digests. One plasmid with a correctly orientated PP2A fragment was selected 
and prepared for electroporations as in 2.3.1.
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2.4. Solutions
2.4.1. Paraformaldehyde (PAF) fixative
To make a 4% PAF / 4% DMSO solutionl 6g of paraformaldehyde and 2 PBS tablets were 
dissolved in 360ml of ddH20  by heating on a magnetic stirrer. Once warm a little 
concentrated NaOH was added to the solution until the paraformaldehyde had dissolved. 
After the solution had cooled 40ml of DMSO was added and the pH was adjusted to pH7 
and then stored at -20 °C.
2.4.2. DEPC treatment of water
1 ml of DEPC was added to a litre of sterile ddH20 , thoroughly mixed and then incubated 
overnight in a water-bath at 37QC, the H20  was then autoclaved before use.
2.4.3. Composition of various solutions
Solution Ingredients Application*
Blocking buffer 2.5g Marvel, 50ml TTBS Western Blot
Dent’s fix 20% DMSO, 80% MeOH IF
ISH Detergent 
Solution
1% IPEGAL, 1% SDS, 0.5% Sodium 
Deoxycholate, 50mM Tris-HCL (pH 8), 
1 mM EDTA (pH8), 150mM NaCI
ISH
ISH Wash solution 50% Formamide, 2x SSC, 1% SDS ISH
Luria Bertani 
agar
(LB) 10g Tryptone, 5g yeast extract, 5g NaCI, 
15g agar, made up to 1 litre dH20 (pH7.5) 
+ampicillin (100ng/ul)
Transformations
Luria Bertani 
media
(LB) 10g Tryptone, 5g yeast extract, 5g NaCI, 
made up to 1 litre dH20 (pH7.5) +
Transformations
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ampicillin (1 OOng/ul)
Lysis buffer 1xTNE buffer, 1% Triton X100, inhibitor 
cocktail (Aprotinin, Leupeptin, Pepstatin) 
at 1/100 dilution
Western Blot
NTMT 100mM NaCI, 100mM Tris-HCL (pH 9.5), 
50mM MgCI2, 1% Tween 20
ISH
PAF fixative 4% PAF, 4% DMSO, pH7 IF, ISH
PBST PBS, 0.1% Tween 20 IF
Pre-Hybridisation
Solution
50% Formamide, 5x SSC, 2% SDS, 
200ug/ml RNA, 2% Boehringer Blocking 
Reagent, 50ug/ml heparin
ISH
PTW PBS, 1 % Tween 20 ISH
Running buffer 30.3g Tris base, 144g Glycine, 10ml 10x 
SDS in 1 litre dH20
Western Blot
Sample Buffer 2% SDS, 10% Glycerol, 2.5% 
Mercaptoethanol, 125mM Tris pH 6.8, 
Bromophenol blue crystals
Western Blot
SOB 20g Tryptone, 5g yeast extract, 0.5g 
NaCL, 10ml filter sterile 1M MgCI2, 10ml 
filter sterile M gS04 in 1 litre dH20
Transformations
TAE 50x 50mM EDTA, 5.71% acetic acis, 2M Tris- 
HCI
Electrophoresis
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TBS 250mM Tris-HCL (pH 7.5), 1.36M NaCI, 
26.8mM KCI
ISH
TBST TBS, 1% Tween 20 ISH
Transfer buffer 3.03g Tris base, 14.4g Glycine, 200ml Western Blot
methanol in 1 litre dH20
TTBS 500pl Tween in 1 litre TBS Western Blot
*IF -  Immunofluorescence, ISH -  In-situ hybridisation
2.5. In ovo manipulations
2.5.1. Egg preparation
White leghorn fertilised eggs (Joice and Hill, Norfolk) were placed horizontally in egg trays 
and sprayed with 70% ethanol before incubating in a humidified incubator at 38 °C (±1 °C) 
until the embryos reached the appropriate Hamburger Hamilton (HH) stage. A small hole 
was made in the wide end of the horizontal egg and 2ml of albumin removed using a 
needle and syringe. A window was then cut in the side of the egg (~2cm in diameter), and 
contrast to the embryo provided by injecting a solution of Sugarflair Colours paste 
(Liquorice) in PBS (1% v/v) underneath the embryo through the blastodisk. After 
experimental manipulations (detailed in 2.2.2) the eggs were resealed using sellotape and 
placed back into the incubator for the required incubation period.
2.5.2. Labelling with cell tracker dyes
Cell tracker dyes are lipophilic fluorescent dyes that intercalate into the cell membrane
and allows the labelled cells to be tracked, labelling is also passed onto daughter cells
allowing cells to be tracked through several cell divisions. Two spectrally distinct cell
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trackers were used: one red (CM-Dil, excitation at 553nm and emission at 570nm) and 
one green (CM-FDA, absorption at 492 nM and emission at 517 nm). CM-Dil is still 
present after fixation and permeabilization as it is a Dil derivative that binds covalently to 
thiols in the cell membrane. For use in ovo the cell tracker was prepared by dissolving 1 
vial of cell tracker (50pg) in 10pl of DMSO, then 90pl of 20% sucrose was added and the 
vial vortexed. Prepared dyes were stored at 4°C for up to 4 months.
2.5.2.1. Surface ectoderm labelling
To label cells of the surface ectoderm, the vitelline membrane was removed and 2pl of the 
cell tracker solution was pipetted over the head of the embryo. This was done 10 mins 
after electroporations to allow the neural tube to close up a little and bubbles to dissipate, 
or 10 mins before bead placement to allow labelling of the SE without the bead 
obstructing any tissues.
2.5.2.2. Neural crest labelling
Cranial neural crest cells were labelled by flooding CM-Dil into the lumen of the neural 
tube. First a small puncture was made in the neural tube using a glass needle at the 
anterior forebrain to relieve pressure, and then the CM-Dil was injected into the neural 
tube at the level of the first/second somite. The embryos were given at least 30 mins to 
allow the dye to label the cells. The excess dye was then flushed out of the neural tube 
with PBS to prevent spreading of the dye during further manipulation of the embryo.
2.5.3. Bead implantation/placement
Beads were used to provide a localised, sustained exposure of the compound to the 
targeted tissue [101]. Three different types of implant/placement were employed
• Implantation of a bead into the cranial mesenchyme adjacent to r2, r3 or r5.
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• Insertion of a bead into the lumen of the neural tube at the level of r2, r3 or r4.
• Placement of a bead over the surface ectoderm.
Three different types of bead were used to deliver compounds to the tissues, hydroxide 
and formamide ion-exchange beads and affi-gel blue beads. The hydroxide and 
formamide beads were used to deliver the retinoic acids due to the ability of the beads to 
adsorb charged molecules. The Affi-gel blue beads have the ability to bind neutral 
molecules and so were used to deliver the Cyp26 inhibitors and Okadaic Acid.
The hydroxide beads were prepared by washing in PBS ( 1 x 5  mins), spinning down the 
beads and removing the supernatant, then washing the beads in DMSO ( 1 x 1 0  mins), 
before spinning down, removing the supernatant and finally resuspending the beads in RA 
diluted in DMSO. Formide beads were prepared by washing the Hydroxide beads in 
dH20  ( 1 x 5  mins), then incubated in 1M formic acid for 10 mins, before washes in dH20  
( 2 x 5  mins). The beads were placed in DMSO ( 1 x 5  mins) before adding the retinoic 
acid of the appropriate concentration. Both formamide and hydroxide beads were left to 
incubate in the dark for 30 mins before a wash in PBS just before use. To prepare the 
affi-gel blue beads the beads were washed in PBS ( 1 x 5  mins, then 2 x 1 0  mins) before 
incubating the beads in a solution at the correct concentration of the required compound 
for at least 30 mins. Beads were washed briefly in PBS immediately before use.
Individual beads were maneuvered into place using a glass needle, for implants incisions 
were made where the bead was to be placed and the tip of a glass needle used to push 
the bead into the incision. The eggs could then be sealed and returned to the incubator.
When beads were placed over the r4 surface ectoderm, before removal it was always 
checked that the bead had stayed on the correct side of the embryo, as the beads are not 
fixed in place, and as the embryos turn as they grow the beads could move out of
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position. Most of the time beads settled in the developing otic vesicle, which means that 
the r4 mesenchyme should still be receiving an effective dose of OA.
2.5.3.1. Retinoic acid (RA)
9-cis retinoic acid and all-trans retinoic acid were dissolved in DMSO to a stock 
concentration of 0.1 M (stored at -20°C), working concentrations were made by diluting the 
stock further in DMSO. The retinoic acid was kept in the dark and only used under a safe 
light. The light exposed RA was made by exposing 50mM all trans RA to direct sunlight 
(in summer) for a day.
2.5.3.2. Okadaic acid (OA)
Okadaic Acid salt was dissolved in ddH20  to a stock concentration of 30.2pM and kept at 
-20°C in a dark container. Concentrations used were 10nM for beads (2.2.3.2) and 1nM 
for the cell cultures (2.4.4). The OA was always stored in the dark and only used under a 
safe light due to the light sensitivity of OA.
2.5.4. Retinoic acid injections
Injections were also used as an alternative delivery method for RA to beads as used in 
previous studies [45]. Various concentrations of RA (all-trans, 9-cis and light exposed) in 
CM-Dil (2.5pg/pl) were used to target one side of a single rhombomere by injection. The 
CM-Dil allowed the injection site to be confirmed and also labelled the neural crest 
allowing quick identification of embryos with a phenotype. Glass needles were used to
deliver the solution into the rhombomere, a mouthpiece was used to fill the needle and
subsequently inject the targeted tissue.
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2.5.5. Electroporations
Electroporations were carried out using an Intracel system (2.1.7) with a flat positive silver 
electrode and pointed negative tungsten electrode. The lumen of the neural tube was 
flooded with the desired plasmid by puncturing the front of the forebrain and then injecting 
the plasmid at the level of the second somite. The negative tungsten electrode was 
placed inside the neural tube while the positive silver electrode was placed on the surface 
of the embryo. Two parameters for electroporations were used, one for targeting single 
rhombomeres, which is localised to the middle of the dorsal-ventral axis of the 
rhombomere. The second gives good electroporation results throughout the whole dorsal- 
ventral axis of the neural tube on the targeted side with a spread of around 6 
rhombomeres.
Very localised single unilateral rhombomere targeting - 7V, 2 pulses, 20ms pulse width, 
200ms space. This technique was most commonly used for in ovo electroporation.
Widespread unilateral rhombomere targeting - 20V, 2 pulses, 50ms pulse width, 200ms 
space. This second technique causes substantial damage to the rhombomeres 
immediately targeted, therefore tissue 3 rhombomeres up or down from the targeted area 
was electroporated. Due to the wide spread targeting of the technique the intended 
rhombomere was well electroporated without any tissue damage. This technique was 
used for electroporation of tissue for western blotting.
2.5.6. Rhombomere transplantations
To label all the cells in an explant, rhombomeres were removed from donor embryos of
the appropriate age and incubated at 37°C for 4 hours in complete DMEM (2.4.1.1)
containing RA and CM-FDA (1:1000). The explants were then washed in fresh warm
media ( 1 x 5  mins, then 2 x 30 mins). The NCC’s in host embryos were labelled by
flooding the neural tube with CM-Dil (2.2.2.1) for 30 mins, the neural tube was then
58
Chapter 2
washed by injecting PBS to flush out the unbound CM-Dil. The host rhombomere could 
then be removed and replaced with the labelled donor tissue.
2.6. Embryo tissue processing
2.6.1. In-situ hybridisation
2.6.1.1. Riboprobe synthesis
Insitu-hybridisation riboprobes were synthesised by first linearization of the plasmid DNA 
using a restriction enzyme (RE) with a cut site at the beginning of the gene. The 
antisense probe is then synthesised using a DNA polymerase with a primer site at the end 
of the gene and dNTP’s labelled with either a digoxigenein (DIG) or fluorescine (FITC) tag
(2.1.1.4).
The template DNA is first linearised using the following recipe. This ensures that the 
riboprobe is only as long as the gene by preventing the DNA polymerase from continuing 
further around the plasmid past the beginning of the gene.
Ingredient Volume
plasmid DNA (10|jg/pl) * 1M*
restriction enzyme * 5pl (100units)
10x buffer * 5 pi
dH20 39pl (or 34pl dH20  and 5pl 10x BSA if required)
* see table 2.1.4 for exact combinations of plasmid, restriction enzyme and buffer
Incubation was at 37°C for 1 hour, then heat inactivated by incubating at 6 5 ^  for 15 mins.
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The linear plasmid DNA product of this RE digest was then used as a template for 
riboprobe synthesis using the following protocol.
Ingredient Volume
linear DNA (0.2pg/pl) from 2.3.2.2 * 3pl
10x DIG or FITC labelling mix 2pl
10x transcription buffer 2pl
RNase Inhibitor 0.5pl
Polymerase * 2pl
dH20 8.5pl
* see table 2.1.4 for exact combinations of polymerase and plasmid
Samples were incubated at 37°C for 2hours. The riboprobe was then precipitated by 
addition of the following to each sample.
Ingredient Volume
0.2M EDTA pH8 2pl
7.5M NH4Ac 3.3pl
dH20  30pl
The samples were vortexed and then 160pl of ice cold ethanol was added to the mixture
and incubated at -20 °C for 1 hour. The samples were spun at 4°C at 23,000 xg for 30
mins and the supernatant discarded, the precipitated riboprobes were then washed in
300pl of 70% ethanol, and spun at 4°C for 15 mins, the supernatant was removed. The
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remaining pellet was air dried for 5 mins to remove residual ethanol then resuspend in 
25pl TE /  25pl formamide. This method generates a huge excess of riboprobe to template 
therefore the template is not removed. Riboprobes were maintained at -20 °C (or -80 °C for 
long term storage).
2.6.1.2. Gel electrophoresis
DNA digests, plasmids preps and probes were run on 0.8% agarose gels, made with 2 x 
TAE and 0.5pg/ml of ethidium bromide. Gels were run in 2 x TAE at 50V for 40 mins and 
then visualised using a FirstLight UV transilluminator and the VisionWorks LS image 
capture software.
2.6.2. In-situ hybridisation on wholemount embryos
Embryos were dissected to remove excess tissues and membranes, and left in PAF 
fixative overnight at 4°C. The embryos were then washed ( 3 x 5  mins) in PTW before 
being dehydrated in increasing concentrations of methanol (25%, 50%, 75%, 100%) in 
PTW with a 5 min incubation in each concentration. Embryos could then be stored at - 
80 °C until needed.
Embryos were rehydrated in decreasing concentrations of methanol (75%, 50%, 25%) in 
PTW, before 2 washes in PTW only, each incubation and wash was 5 mins. Tissues were 
then bleached in 6% H20 2/ PTW for 1 hour and washed again in PTW ( 3 x 5  mins).
The embryos were placed in ISH detergent solution for 1 hour with 3 changes of wash, 
before refixing in 4% PAF / 0.2% Glutaraldehyde. The fixatives were washed out of the 
tissue with PTW ( 3 x 5  mins).
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Embryos were then incubated in pre-heated pre-hybridisation solution for 1 hour at 70 °C. 
The pre-hybridisation solution was then replaced with hybridisation solution containing the 
RNA probe/s and incubated at 70°C overnight.
The probe and hybridisation solution were removed and the embryos washed in pre­
heated (70°C) ISH wash solution (first 2 x 5  min, then 6 x 30 mins). The ISH wash 
solution was then washed out of the tissues using TBST ( 3 x 5  mins) before blocking in 
10% sheep serum /  TBST for 2 hours. The embryos were then incubated in the AP- 
conjugated antibodies (a-DIG or a-Fitc, see 2.1.2.1) overnight in 2% sheep serum / TBST 
at 4°C.
The embryos were washed in TBST (first 2 x 5  mins, then 5 x 1 hour and finally overnight) 
before incubating in NTMT ( 3 x 1 0  mins). The chromogenic AP substrate (BM purple or 
fast red) was then added to the embryos and incubated in the dark at 4°C to allow the 
colour to develop.
Once the colour had developed sufficiently, the reaction with the substrate was stopped 
by addition of 0.1% Tween 20 /  1mM EDTA/ PBS ( 3x10  mins).
For a double insitu the activity of the first antibody was eliminated by dehydrating the 
embryos in 100% methanol for 15 mins. The tissues were then rehydrated into TBST (2 x 
5 mins) and re-blocked for 1 hour in 10% sheep serum /  TBST. The embryos are then 
incubated with the second antibody overnight in 2% sheep serum / TBST. The steps 
following were the same as for the first antibody only a different substrate is used. The 
weakest probe is stained for first, as the message can degrade with time and processing.
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All steps were carried out on a rocking platform, at room temperature unless otherwise 
stated. All solutions were made using DEPC treated dH20  to prevent contamination by 
RNases.
2.6.3. Immunostaining wholemount embryos
2.6.3.1. PAF fixative protocol
Embryos were dissected, removing all excess membranes and the caudal end of the 
embryo from about the 3rd somite. Embryos were then fixed in PAF fixative overnight at 
4°C.
Embryos were washed in PBS 3 times for 5 mins, and then permeabilised and blocked in 
0.3% TX100 /  20% sheep serum in PBS. The primary antibodies (2.1.2.1) were added in 
0.1% TX100 and incubated on a rotating platform at 4°C for 2 days. Embryos were then 
washed for 8 hours on a rotating platform at room temperature in 0.1 %TX100/PBS with 
regular changes of solution.
The only exception was the HNK1 primary antibody, as it is a IgM antibody it is around 5 
times larger than an IgG antibody and required higher concentrations of detergent and 
longer incubations to achieve adequate tissue penetration. The embryos were 
permeabilised and blocked in 1% TX100 /  20% sheep serum in PBS and the HNK 
antibody was diluted in 0.3% TX100 /  PBS. The embryos were incubated in the primary 
antibody for 3 days. Embryos were then washed for 8 hours on a rotating platform at 
room temperature in 0.1%TX100/PBS with regular changes of solution.
Secondary antibodies (2.1.2.2) were added overnight in 0.3% TX100/PBS on a rotating 
platform at 4°C. The embryos were washed several times in 0.1%TX100 / PBS before 
viewing.
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2.6.4. In-situ apoptosis detection
Cell death by apoptosis was detecting using the ApopTag red In Situ apoptosis detection 
kit, which identifies degraded nuclear DNA in the late stages of apoptosis. Embryos were 
fixed in PAF fixative for 8 hours or O/N at 4°C before being washed in increasing 
gradients of ethanol (75%, 95% 100%) for 15 mins each.
Embryos were then rehydrated in decreasing gradients of ethanol (75%, 50%) in PBST for 
15 mins each, and then washed in PBST ( 2 x 5  mins). Samples were Proteinase K 
digested (1 min per HH stage) at room temperature without agitation. The digestion was 
stopped by washes in dH20  ( 4 x 5  mins).
Embryos were then incubated in equilibration buffer for 30 mins before incubation in the 
reaction buffer with TdT enzyme (1hour at 4°C, followed by 1hour at 37°C). The Tdt 
enzyme adds a fluorescein nucleotide to the 3’ OH end of the DNA. The reaction was 
stopped by addition of stop wash buffer /  0.1%TX100 (1 hour at 4°C) to the embryos. The 
samples were washed in PBST ( 3 x 5  mins) and then blocked for 1 hour in 10% sheep 
serum /  0.1 % TX100 /  PBS.
The fluorescein antibody was added for 2 days at 4°C in 0.1% TX100 /  PBS and then the 
embryos washed thoroughly in 0.1% TX100 / PBS ( 2 x 5  mins, then 4 x 1hour) before 
viewing.
2.6.5. Sectioning embryos
Embryos were dissected to retain the hindbrain area and a couple of somites, and placed
in 20% gelatine / PBS at 37°C. The embryos were incubated for 1hour inverting
occasionally. The embryos were then transferred into some fresh molten 20% gelatine /
PBS in the lid of a 1.5ml eppendorf tube and arranged to an appropriate angle for
sectioning. Once the gelatine had set, the lids were incubated in 4% PAF at 4°C
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overnight. After a brief wash in PBS, the gelatine blocks containing the embryos were 
removed from the lids and pared down to an appropriate size for sectioning. The blocks 
were attached to a cutting platform with a drop of superglue and sections were cut at 70 
microns using a vibratome. Sections were placed on slides and mounted using 
DakoCytomation fluorescent mounting media and glass coverslips. Slides were sealed 
using nail varnish for long term storage and kept at 4°C.
2.7. In vitro cell cultures and processing
2.7.1. Cell culture of neural crest
Cell culture plates were coated using fibronectin (1/1000) diluted in DMEM and incubated 
at room temperature for 1hour. The fibronectin media was removed and the plates 
allowed to air dry for a few minutes before adding complete DMEM (2.4.1.1) or C 0 2 
Independent media (2.4.1.2) to the wells. Tissue explants were added to the plates and 
manoeuvred until spread out and separate in the centre of the dish, and allowed to sit 
undisturbed for 10 mins to allow the tissue to adhere. Cultures were incubated overnight 
at 37°C /  5% C 0 2 to allow NCC’s to migrate out of the tissue. The tissue explants were 
then removed the next day. For standard cell culture cells and explants were incubated in 
complete 10% FCS/Pen/Strep/L-glut DMEM, along with the supplements N2 and B27 at 
37°C /  5% C 0 2. To allow incubation of the cells without C 0 2, ceils were incubated at 37°C 
in a humidified chamber in complete C 0 2 Independent media containing 10% FCS / 
Pen/Strep / L-Glut. This method was used for time-lapse of the cells, it was found to be 
more effective than gassing the time-lapse chamber with C 0 2.
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2.7.2. Cell tracker labelling of rhombomere specific NCC 
populations
Tissue explants were placed in uncoated non-tissue culture plastic dishes, to prevent 
adherence, in complete media with 1/1000 dilution of a concentrated cell tracker (5pg/pl) 
and incubated at 37°C for 30 mins. The explants were then washed in 37°C media 4 x 20 
mins to remove excess dye. The labelled explants were then transferred to coated plates 
to culture the neural crest as in 2.4.1.
2.7.3. Immunostaining cells in vitro
Live cells were fixed in PAF fixative for 30 mins at room temperature, washed twice with 
PBS and then permeabilised in 0.1%TX100 /  PBS ( 1 x 1 0  mins). Cells were then washed 
in PBS ( 2 x 5  mins) before blocking in 20% sheep serum / 0.25%TWEEN /  PBS for 30 
mins.
Primary antibodies were added to the cells in 0.25% TWEEN /  PBS and incubated 
overnight at 4°C. Cells were washed in PBS ( 5 x 5  mins) and then the secondary 
antibodies added in 0.25% TWEEN /  PBS for 1 hour. The cells were viewed after washes 
in PBS ( 3x10  mins).
All steps were carried out on a rotating platform (once the cells were fixed) at room 
temperature unless otherwise stated.
2.7.4. Time-lapse studies
Neural crest was cultured from explants as in 2.4.1 using the C 0 2 Independent media. 
Time-lapse pictures were taken of the cells every 2 mins using a 20x objective using the 
MediaCybernetics In-Vivo software package. For cultures on fibronectin where OA
(2.2.3.4) was added to the cells, the cultures were first filmed without OA for 2-4 hours, 
before adding the OA, the same field of view was then filmed for another 10 hours.
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The average speed of each cell within 2 hour bins was calculated using the ImageJ 
software package using the plugin mtrackj [102].
2.7.5. Adherence assay
Tissue from dorsal r4 were removed from embryos at 10ss and incubated in C 0 2 
independent media overnight at 37°C either with or without 1nM OA added to the media. 
The rhombomere tissue was then removed with the end of a pipette tip, before 
photographing the remaining cNCC’s. The tissue culture plates were then placed on a 
horizontal shaker at full speed for 1 hour. The cells in the same frame were 
rephotographed and the cells before and after shaking were counted using the ‘cell 
counter’ plugin in ImageJ [102]. The percentage loss in cell numbers was calculated to 
make it easier to compare counts due to the high difference in cell numbers in different 
photo frames.
2.7.6. Western blot
Tissue samples were placed in lysis buffer and then broken down by freeze-thawing, 
repeated pipetting and finally sonication. The protein concentration was then determined 
using a DC assay (BioRad) and the absorbance read using a plate reader at 650nM. 
Tissue homogenates were then diluted in sample buffer to 1 pg and then boiled for 4 mins. 
Diluted samples were then loaded onto a 10% SDS gel and ran at 180V until the dye front 
reached the bottom of the gel. The gel and nitrocellulose membrane were soaked in 
transfer buffer before mounting in a cassette in more transfer buffer and the proteins 
blotted onto the membrane at 80V for 2 hours at 4°C. The gel was mounted he following 
order in the transfer cassette, cathode, filter pad, 2x3mm filter paper, gel, nitrocellulose 
membrane, 2x3mm filter paper, filter pad, anode. The membrane was removed from the 
cassette and washed in TTBS (1x10 mins) before blocking in blocking buffer (1hour RT).
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The primary antibody was diluted in blocking buffer and the membrane incubated in the 
solution (2 hours RT). The membrane was washed in TTBS (3x10 mins) before 
incubation in the secondary antibody diluted in blocking buffer (1 hour RT). The 
membrane was washed again (3x10 mins) before draining the membrane and then 
incubating it in 1:1 ECL solution for 1 min. The membrane was then dried between two 
pieces of 3mm filter paper before exposing it to the film. The film was then processed 
using an X-Omat developer. The membranes were then taken and washed in TTBS (2x5 
mins), before incubation in actin antibody diluted in blocking buffer overnight at 4°C, the 
membrane was washed in TTBS (3x1 Omins) before incubation in the secondary antibody 
diluted in blocking buffer (1hour RT). The membrane was dried and developed as before.
All washes and incubations took place on a horizontal rotational shaker.
2.7.7. PCR
Rhombomere 4 tissue was dissected from chick embryos at HH10 (10ss), and incubated 
in complete DMEM (2.4.1.1) either with or without the presence of 1nM OA for 5 hours. 
The tissue was washed in fresh media before addition of 1 ml trizol to the tissue (10xr4 for 
each condition) before being placed at -20°C overnight. The tissue was then 
homogenised by passing it through a 30 gauge syringe tip. The RNA was extracted 
through addition of chloroform (200pl), mixing the solution before incubation (3mins RT), 
the solution was then spun (15mins 4°C 12000xg). The supernatant was discarded and 
the pellet washed with 75% ethanol (1ml) before another spin (5mins 4°C 12000xg). The 
supernatant was discarded and the RNA was air dried to remove residual ethanol (5 
mins). The RNA was then resuspended (10pl DEPC dH20).
The RNA was DNase treated through the following steps
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Ingredient Volume
RNA 8jli
DNasel buffer x10 1 |al
DNasel (1u/|il) 1^ 1
The mix was then incubated (15mins RT) before addition of 1|il 25mM EDTA. The 
solution was then incubated again at 65°C (10 mins). From this mix 4\i\ was taken for first 
strand synthesis as follows.
Ingredient Volume
RNA (DNase treated) 4|il
O ligo(dT) 12-18 500|ig/ml 2|il
dNTP mix (1 OmM each dNTP) 2|al
dH20  16|al
This mix was then incubated at 65°C (5 mins) before being cooled on ice, the following 
was then added to the above mix.
Ingredient Volume
First strand buffer x5 8|il
DTT0.1M 4|il
RNase Out 2\x\
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The solution was then incubated at 42 °C (2 mins) before being split into two 19|il aliquots. 
One was used for the positive RT-PCR to which 1 pil of superscript II reverse transcriptase 
was added and the other aliquot for the negative control RT-PCR (-reverse transcriptase) 
to which 1 pil of dH2) was added. Both tubes were then incubated at 42°C for 50 mins, 
before incubation at 70 °C for 15 mins. The PCR reaction was then set up as follows.
Ingredient Volume
cDNA (from last step) 1pl
PCR buffer x10 2.5|il
MgCI2 50mM 0.75|il
dNTP mix (10mM each dNTP) 0.5pl
Forward primer (1 ;10 of 10pM stock) 0.5|il
Reverse primer (1; 10 of 10pM stock) 0.5pl
Taq polymerase 0.2pl
dH20  -  DEPC treated 14.05|il
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The mixes were then run on the following PRC program
Temperature Time
Start 95 °C 5 mins
40 cycles of:
95 °C 30 secs
60 °C 30 secs
72 °C 30 secs
End Cycles
Finish 72°C 5 mins
Each of the reactions were then loaded onto a 2% agarose TBE gel, using molecular 
weight ladders (Low molecular weight ladder, 1 kb ladder both NEB) and run at 40V for 45 
mins before being visualised using a FirstLight UV transilluminator and VisionWorks LS 
image capture software.
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3.The role of Midlinel (Midi) in cranial development
3.1. X-linked Opitz BBB/G Syndrome and Midi
3.1.1. X-linked Opitz BBB/G Syndrome
X-linked Opitz BBB/G syndrome (XLOS) is a very rare condition characterised by midline 
developmental abnormalities. Patients present with a range of abnormalities that involve 
the ventral midline, these include ocular hypertelorism and/or telecanthus (100% of 
patients), hypospadias (90%), laryngo-tracheo-esophageal deformities (70%), mental 
retardation and developmental delay (>50%), cleft lip/palate (>50%), congenital heart 
defects (>50%) and ectopic or imperforate anus (>50%) [10].
3.1.2. The Midi Gene
Mutations in the gene Midlinel {Midi), located on the X chromosome, are responsible for 
XLOS (OMIM 300000) [103]. Midi is around 300kb in size, 9 exons have been shown to 
be constitutively expressed leading to an open reading frame of around 2kb [104]. 
Fourteen other exons have been discovered, which may contribute to alternative Midi 
transcripts, the Midi mRNA transcripts found to date are 3.5kb, 4.5kb and two at around 
7kb [105]. The Midi gene in affected patients shows a variety of mutations, including 
nonsense and frameshift mutations (68%), missense mutations (18%), in frame deletions 
(14%) and in frame insertions (3.6%) [104]. In XLOS patients most of the mutations found 
in the Midi gene are at the 3’ end of the ORF (68%), which encodes the C-terminus of the 
Midi protein [104].
72
Chapter 3
3.1.3. Protein Structure of Midi
The Midi protein belongs to the RBCC family of proteins. These consist of a RING-finger 
domain, either one or two B_boxes, and a Coiled Coil domain [106]. The Mid 1 protein 
itself is 667 amino acids in length and has a molecular weight of 72kDa, it has the RING- 
finger domain, as well as 2 Bboxes, and the coiled coil domain (Figure 3-1).
C RING, Bbox1 B 2^)X,L  |Coiled-coiH FNIII 3C B30.2
~1----------  K
Binds to For
a4 dimerisation
 I----------
Localisation to 
microtubules
Figure 3-1. M id i -  the X-linked Opitz Syndrome protein
Schematic diagram portraying the protein structure of Midi and its domains, including 
known domain functions.
Many of the various domains identified in the Midi protein have had their function 
elucidated. The coiled-coil domain involved in dimerisation, Midi functions most 
efficiently in dimers, either as a homodimer or as a heterodimer with the homologue Mid2 
(introduced later) [97,107]. The Bbox domains and the B30.2 domain are required for the 
two known functions of Midi, firstly the B-Box domains are responsible for binding to the 
a4 protein [108], secondly the B30.2 domain is responsible for the localization of Midi to 
the microtubules [109]. Both of these functions are described in more detail in section
3.1.5.
Deletion of the RING-finger or B-Box domains leads to a loss-of-function mutation,
furthermore the defective Midi protein then acts as a dominant negative, preventing the
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regular function of any normal Midi protein that it binds to [97]. It has also been found 
that deletion of the C-terminus leads to a loss of function; therefore as many XLOS 
patients have mutations in the C-terminus, it is possible that XLOS is caused by a loss-of- 
function mutation [97].
3.1.4. Expression Pattern of the Midi Gene
Midi has been found to be expressed from a very early stage of development, indeed in 
chick cMidl has been found to be expressed as early as stage 4 (primitive streak). At this 
point cMidl is expressed in the ectoderm and bilaterally at the node, by stage 5 cMidl is 
limited to the right side of the node, where it has been shown to stabilise asymmetric gene 
expression of BMP4 and Shh [96]. As the embryo develops cMidl can be seen to be 
expressed in the neural folds and in the somites at 4ss [96], by 10ss Midi is found in the 
mesenchyme adjacent to the hindbrain and mesencephalon and is also strongly 
expressed in r2/r3 [110]. Later in development cMidl is expressed in the developing 
trigeminal ganglia and also in the second branchial arch (37ss), by 40ss and into HH28 
cMidl is in the central frontal mass mesenchyme, and is also from HH24 strongly 
expressed in the limb bud, muscle tissue and cardiac muscle [110].
The expression pattern of Midi has also been examined in mice at a later stage of 
embryo development. Expression in the head region at E12.5-E12.5 mMidl is found 
rostrally in the CNS and highly expressed in proliferating neuroepithelium of telencephalic 
vesicles and is down-regulated where post-mitotic neurons are located. By E16.5 mMidl 
can be found in the outer layer of the neural retina where proliferating neuroblasts are 
located [111]. With regards to mMidl expression in the rest of the body at E14.5 mMidl is 
highly expressed in the developing kidneys, by E16.5 expression can also be found in the 
stomach, hindgut and small intestine, where mMidl is restricted to crypts where 
regenerating cells develop [111].
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3.1.5. Functions of Midi
As the craniofacial structure develops abnormally in XLOS, this implies that Midi is 
involved in correct craniofacial development. Indeed the expression patterns of Midi 
observed during development are in tissues which are involved in the correct development 
of craniofacial structures, such as the mesenchyme such as the mesenchyme, which 
contains cNCCs, making it of interest in my studies of cNCC development. To date two 
specific functions have been identified for the Midi protein. Firstly the Midi protein 
exhibits an ubiquitin ligase function on PP2A, thus targeting it for degradation (Section 
3.1.5.1). Secondly Midi has been shown to bind microtubules and provide stabilization 
from depolymerisation (3.1.5.2).
More generally, a particular role of Midi in early development has been proposed, as a 
regulator of Snail [96]. Snail is involved in regulating EMT through changes in gene 
expression patterns, therefore increases in signalling upstream, such as through Midi, 
may lead to increased EMT.
Fgf8
Midi
Snail
EMT
Bmp4
E-cadherin
Figure 3-2. M id i signalling cascade and induction of EMT
The Midi signalling cascade as outlined by Granata [96] (shown here in pink boxes). The 
diagram depicts how Snail is known to repress E-cadherin transcription and thus induce 
EMT.
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3.1.5.1. Midi Mediated Ubiquitination of PP2A
Protein Phosphatase 2A is a serine/threonine phosphatase involved in many cellular 
processes. It has been demonstrated that PP2A is involved in cell migration; since siRNA 
knockdown of PP2A leads to accelerated wound healing, migration and invasion by 
cancer cells [112]. Okadaic acid (OA) is a well known and extensively used inhibitor of 
PP2A, and the observation that OA acts as a tumour promoter has led to the suggestion 
that its PP2A target may act as a tumour suppressor [113]. This has also led to the 
suggestion that M id i, because it targets PP2A for degradation, may also act as a tumour 
promoter [114].
PP2A is bound by the cytosolic a4 protein, which negatively regulates the catalytic 
subunit of PP2A [115] (Figure 3-3). The a4 protein associates with Mid, specifically the 
B-Box1 domain [108], as shown through colocalisation, co-immunoprecipitation and yeast 
two-hybrid screening [116]. Upon binding to Midi, a4 is recruited to the microtubules. 
Through the binding of Midi to the a4 protein, Midi is able to execute its ubiquitin ligase 
activity upon PP2A [116]. Ubiquitin ligase (E2 enzyme) binds to Midi at the RING finger 
domain, therby facilitating the PP2A ubiquitin ligase activity of Midi, although more 
evidence to prove this is needed [104,117].
In the event that Midi is truncated and missing its C-terminus, it cannot associate with 
microtubules and therefore is not able to bind to PP2Ac via the a4 protein. Thus, PP2A 
remains intact and active, resulting in hypophosphorylation of microtubule associated 
proteins [104].
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Figure 3-3. Mechanism of the ubiquitination of PP2A by M id i
A -  Schematic diagram demonstrating the binding of functional M id i protein to the 
microtubules, mediating polyubiquitination of the PP2Ac protein. B -  Schematic diagram 
depicting loss of M id i binding to the microtubules due to truncation and the subsequent 
hypophosphorylation of microtubules due to a lack of PP2Ac ubiquitination. P -  
phosporylated protein, Ub -  ubiquitin, AB -  A and B subunit of PP2A, MAPx - microtubule 
associated proteins (unidentified as of yet)
Consistent with its proposed role in tumour metastasis, studies on PP2A have shown that 
it negatively regulates cell motility. PP2A colocalises and interacts with p. and m-calpains, 
when PP2A activity is disrupted there is an increase in the phosphorylation of these 
calpains, which then leads to an increase in wound healing, migration and invasion [112].
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This evidence suggests that PP2A is a suppressor of cell motility. Furthermore PP2A has 
been observed colocalized with E-cadherin and (3-catenin in cell-cell adhesion sites 
between adjacent cells in vitro and when OA is used to inhibit PP2A, there is a loss of cell­
cell adhesion [118]. It is thought that the B56 subunit of PP2A specifically is involved in 
the control of cell motility as truncation of the B56 subunit leads to increased cell motility 
through paxillin phosphorylation [119].
3.1.5.2. Midi Binding to Microtubules
Another well documented action of Midi is the binding to and stabilization of microtubules. 
At a subcellular level Midi has been shown to colocalise with microtubules through Midi - 
GFP fusion constructs and filamental staining [109]. It has also been shown that Midi 
extracts from XLOS fibroblasts cannot bind to microtubules, due to XLOS mutations being 
in the C-terminal end of the protein this was the candidate area for the binding domain. 
Indeed the C-terminus of Midi was found to be responsible for microtubule binding, as 
deletion of the domain leads to clumping of Midi protein in the cytoplasm instead of 
microtubule association [109]. Furthermore work has shown that monomers of Midi are 
unable to bind to the microtubules; Midi homodimers and Mid1-Mid2 heterodimers are 
required in order for Midi to bind to microtubules and also recruitment of the a-subunit of 
PP2A to microtubules [107].
Midi binding to the microtubules acts to stabilize them, incubation of cells in colcemid 
leads to depolymerisation of microtubules, in vitro cells expressing Midi show a 
resistance to colcemid treatment [109]. Another protein Mig12 is also recruited to the 
microtubules by M id i, and is thought to also aid in microtubule stabilization [120].
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3.1.6. Regulation of Midi function
There are several ways that the activity of Midi may be regulated, these include 
alternative splicing, protein interactions and phosphorylation of the Midi protein. Firstly, 
alternative splicing may regulate Midi activity, to date, 4 different Midi mRNA transcripts 
(3.5kB, 4.5kB and 2 at around 7kB) have been identified from both fetal and adult human 
tissue [105, 121, 122]. Some of these transcripts lead to production of a truncated Midi 
protein, which lacks the c-terminus and binds to the a4 protein in a dominant negative 
fashion [105].
Secondly, it is also possible that Midi translation could be regulated by a Midi protein 
complex. This protein complex has been shown to exist by yeast-two hybrid screening, 
immunofluorescence, affinity purification of the protein complex and immunoprecipitation. 
The components of this Midi protein complex have been shown to include elongation 
factor-1 (EF-1), Rackl, Annexin A2, Nucleophosmin and proteins of the small ribosomal 
subunits [123]. This protein complex has been postulated to have a translation-related 
function. Several proteins involved in translation have been found to associate with the 
complex, EF-1 is a protein translation regulatory factor and as the Midi mRNA has been 
found associated with the complex [123], it is possible that the Midi protein regulates its 
own translation through its protein complex.
Thirdly control of Midi function may also be through its protein interactions. As Midi 
interacts with a4 enabling it to bind to PP2A and target it for degradation, an absence of 
a4 would imply that Midi could not perform this function. As the a4 protein is not 
ubiquitously expressed but is instead expressed in a tissue specific manner [124], 
although its expression pattern in early development has not yet been characterised, this 
may be one way that Midi ubiquitination of PP2A is controlled. Furthermore the
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expression of Mig12 is also tissue specific [120], although its expression pattern in early 
head development has not been characterised to date. Because Midi recruits Mig12 to 
microtubules to aid in stabilization [120], it could be that when Mig12 is absent Midi may 
not be able to stabilize microtubules to the same degree.
Finally proteins are often activated by phosphorylation; Midi is a phosphoprotein, 
therefore the phosphorylation status of Midi may affect its activity. One finding which 
supports this theory is that the serine-threonine protein kinase, MAPK, has been shown to 
be required in order to sustain binding of Midi to the microtubules [108]. Overall, the 
mechanisms behind how Midi activity is controlled are still poorly understood.
3.1.7. Mid2
Mid2 is a homologue of M id i, indeed both Mid genes are located on the X chromosome 
and furthermore show a 92% similarity and a 77% identity [107]. Mid2 has been shown to 
exhibit some of the same functions as Midi and indeed the two proteins do show 
functional redundancy (See 3.1.8). In the case of XLOS, it is possible that Mid2 could 
make up for the loss of Midi functional protein, as long as the XLOS Midi protein does 
not exert any dominant negative effect over Mid2. However during craniofacial 
development the expression patterns reported do not overlap between Midi and Mid2. 
Thus Mid2 is unlikely to be able to sufficiently compensate for Midi loss of function and 
therefore is probably why XLOS patients still exhibit craniofacial abnormalities.
The expression pattern of Mid2 has been studied in chick, mouse and human tissue. The
early expression pattern of cMid2 has been found in the node, much like cMidl, but
mesodermal expression is absent. At HH4 cMid2 is found bilaterally at the node, by HH5
expression is restricted to the right side of the node and persists to 1ss when light
expression at the neural plate can be seen, however by 4ss cMid2 is down-regulated in
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the node but expression persists more strongly at the neural plate [97]. At a later stage of 
embryo development in mice at E10.5 Mid2 can be found expressed in the trigeminal 
ganglia and the DRG and also at low levels in the CNS and heart tissue. By E14.5 mMid2 
is expressed strongly in the heart and kidney tissue, however when compared to stage 
matched embryos of ISH for mMidl the expression is still weaker than that of mMidl 
[125]. Mid2 is also expressed in adult human tissue, it can be found in prostate, ovary 
and small intestine tissue [125].
3.1.8. Functional redundancy between Midi and Mid2
The midline proteins, Midi and Mid2 have been shown to be functionally redundant, Mid2 
studies to date have shown Mid2 functions in the same way as M idi. Mid2 can be found 
at the same subcellular location as Midi, bound to microtubules [125], and furthermore 
Mid2 can also bind a4 [107]. To further reinforce the theory that Midi and Mid2 are 
functionally redundant, in situations where Mid2 has been used to replace endogenous 
Midi knockdown, Mid2 can rescue defects normally caused by decreased Midi activity 
[97]. Moreover Midi and Mid2 can hetero or homo-dimerise to tether a4 to the 
microtubules [107], suggesting that they may act in the same fashion.
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3.2. Aims
Studies have previously examined the expression pattern of Midi throughout 
development in both chick and mice and the function of Midi during early chick midline 
development [96, 97]. To date there has been little focus on the function of Midi at a 
stage of development where the cranial neural crest is delaminating from the neural tube 
and migrating within the cranial mesenchyme.
Richman and Fu [110] have shown that Midi is expressed in the hindbrain at the level of 
r1/r2 and also in the mesenchyme adjacent to r1/r2 at 10ss. The published expression 
pattern is consistent with Midi being expressed in r1/r2 cNCCs. Therefore it is possible 
that Midi plays a role in the correct formation, EMT or migration of r1/r2 cNCCs.
As already described, there are two known functions of M idi, firstly it acts as an ubiquitin 
ligase targeting PP2Ac for degradation [116], secondly it has been shown to bind to and 
stabilise microtubules [107, 109, 120]. A lack of correctly-functioning Midi in XLOS 
patients could be due to either one or both of these functions of Midi being affected, or an 
as of yet unknown function of Midi being interrupted, which could lead to the XLOS 
characteristics.
As PP2A is widely expressed and involved in many cellular functions [114], it would be 
expected that any changes in PP2A activity would have significant effects on cell 
function/behaviour. Therefore it is possible that XLOS could be caused by interrupting the 
ubiquitin ligase activity of Midi and therefore altering the level of PP2A protein and so the 
activity level of PP2A.
However it is feasible that XLOS is caused, either completely or in part, by interrupting 
Midi microtubule binding activity. Midi also has been shown to not only bind to and
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stabilise microtubules but it also forms multi-protein complexes at the microtubules and in 
the cytoplasm. These protein complexes are thought to possibly be the mechanism 
through which Midi can be regulated by other proteins and also how it can regulate its 
own transcription as Midi mRNA transcripts have been found to be associated with these 
protein complexes as well as proteins involved in translation. As these proteins are 
involved in translation they could also regulate the translation of other unidentified 
proteins. Without a correctly functioning Midi protein the microtubule associated protein 
complex may not form or function correctly, this could therefore be the mechanism 
through which XLOS occurs.
The aim of this study was to more accurately define the spatio-temporal expression of 
MID genes during chick craniofacial development and then to use various expression 
constructs to alter Midi and PP2A activity in ovo, in order to elucidate the roles of Midi in 
the cNCCs of chick embryos during the period when cNCCs are delaminating from the 
hindbrain and migrating within the cranial mesenchyme. This was achieved by use of 
dominant negative Midi (DN-Mid1), or full-length Midi expression constructs in order to 
study the effects of inhibiting Midi function in r2 cNCCs (DN-Mid1) or ectopic expression 
of Midi in r4 cNCCs. It was also investigated whether alterations in Midi and PP2A 
function in cNCCs had an effect at later stages of development once the cNCCs have 
migrated from the neural tube and begin to differentiate. In order to further elucidate the 
mechanism through which Midi is involved in cNCC delamination, migration and 
differentiation both a PP2A expression construct and a PP2A inhibitor were used to clarify 
if Midi is acting through its PP2A ubiquitin ligase function.
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3.2.1. Chapter Overview
The findings in this chapter cover the following;
A. Midi and Mid2 expression pattern (3.3.1)
B. Knockdown of Midi activity in r2
a. Validation of the dominant-negative Midi expression construct function 
(3.3.2)
b. Abnormal cNCC migration pattern (3.3.3)
c. Delayed trigeminal ganglion formation (3.3.4, 3.3.5)
C. Ectopic expression of Midi in r4
a. Validation of the Midi expression construct and the PP2A inhibitor, OA 
(3.3.6)
b. Faster cNCC migration of cNCCs from the neural tube (3.3.7)
c. Premature epibranchial geniculate placode development (3.3.8, 3.3.10)
D. In vitro cNCCs treated with OA
a. Increased cNCC migration speed (3.3.12, 3.3.16)
b. Reduced cell adhesion (3.3.12.1)
c. Increased differentiation into neurons (3.3.13)
E. Mechanism of premature ganglion development following ectopic Midi expression 
or OA exposure
a. Not due to increased neuronal cell differentiation (3.3.13)
b. Premature placodal cell migration to site of ganglion development 
(3.3.14,3.3.15)
F. Changes in protease expression in OA exposed r4 (3.3.17)
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3.3. Results
3.3.1. Midi and Mid2 expression patterns during hindbrain 
development
In order to propose functions for Midi and Mid2 in craniofacial development, detailed 
analysis of their expression patterns were initially required. I used chick specific Midi and 
Mid2 antisense riboprobes [96] to study the expression patterns of the MID genes in 
embryos between 6-13ss, a time-window when cNCC are delaminating from the neural 
tube and migrating to their targets [126,127]. This time point in development is important 
in terms of correct craniofacial development, as any errors in cNCC migration at this time 
could have repercussions later in development, possibly leading to characteristics such as 
cleft lip/palate that are frequently seen in XLOS patients. So if the Mid genes are found to 
be expressed during this stage of development, it would provide evidence for their 
involvement in cNCC development, migration and/or differentiation and thus would be one 
way in which they are involved in craniofacial development.
3.3.1.1. Expression pattern of Midi in chick embryos
Midi is expressed in r2 at 10ss [110], although the expression of Midi in the r2 cNCCs is
unclear. Here the expression of Midi between 6-13ss was investigated as well as the
possible cNCC expression. The results of ISH (n=6 for all stages) showed that at 6ss
there is strong expression of Midi in the neural tube in the entire cranial region (Figure
3-4 A). By 10ss expression has concentrated more in the r2-r3 neural tube and is also
seen in the mesenchyme adjacent to the midbrain and r1-r2 (Figure 3-4 B). At 13ss the
expression was discrete within r2 and also in the cranial mesenchyme adjacent to r1-r2
and the midbrain in a pattern suggestive of the expression within the migrating cranial
neural crest. Double ISH with Midi and Sox10 (expressed by migrating NCCs) confirmed
that migrating r1/r2 cNCCs did express Midi (Figure 3-4 D,E). At all somite stages
investigated no expression was observed in r4. Transverse sections of these embryos
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additionally revealed that although the cNCCs adjacent to r1 showed double staining 
close to the neural tube, Midi expression was not observed in cNCCs further laterally 
from the neural tube (Figure 3-4 E,F), indicating that Midi becomes down-regulated as r2 
cNCCs enter the first branchial arch.
Figure 3-4. Expression pattern of M id i.
In situ hybridisation for M id i (Blue) and SoxlO (Red/Orange) of embryos at 6ss (A), lOss (B) 
and 13ss (C, D). Sections through a 13ss embryos at the level of rhombomere 1 (E,F) and 
rhombomere 4 (G,H). Dotted lines show level at which E-H were located. Arrow  indicates 
expression in r2. All images are representative, n=6 embryos for all stages.
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3.3.1.2. Expression pattern of Mid2 in chick embryos
Previous studies have shown that Mid2, a homologue of Midi, can compensate for Midi 
in the event that there is a loss of the protein [97]. In order to assess the extent of 
possible compensation from Mid2 in subsequent experiments, the expression pattern of 
Mid2 was also examined by ISH. The expression of Mid2 at 3ss (n=5), is seen in the 
neural plate and in extraembryonic tissue, this is in agreement with that observed by 
Granata [97]. By 6ss (n=6), Mid2 is expressed in a similar distribution to Midi, being 
strongest in the neural tube of the cranial region, but not the trunk (Figure 3-5 B). By 
10ss (n=6) Mid2 is strongest in the neural tube in the midbrain, but is weaker in the 
hindbrain neural tube (Figure 3-5 C). There was no detectable expression in any of the 
migrating neural crest. At 13ss (n=6), the expression remains strong in the midbrain 
neural tube, but also shows a distinct area of expression in the caudal part of r5, and also 
some expression around the developing otic vesicle (Figure 3-5 D). However it is 
possible that the expression of Mid2 is from the migrating r4 cNCCs, as the staining at this 
level and time point is similar to that of the NCC marker Sox10. If Mid2 is indeed being 
expressed by the r4 cNCCs the studies performed here are investigating the effect of high 
expression of Mid proteins on cNCC function, therefore a low expression level of Mid2 in 
these cells should not hinder the experiments.
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Figure 3-5. Expression pattern of Mid2.
In situ hybridisation for Mid2 (Blue) of embryos at 3ss (A) n=5, 6ss (B) n=6, lOss (C) n=6, and 
13ss (D, same embryo in both views) n=6. Double insitu hybridisation for Mid2 (Blue) -  
SoxlO (Red/Orange) at lOss and 13ss (E). OV -  Otic vesicle, red lines indicate midbrain. All 
images are representative.
The expression pattern of Mid2 in conclusion should not have a significant effect in 
following experiments as the expression pattern does not overlap with those of Midi in the 
mesenchyme. Furthermore it is possible that the DN-Mid1 construct would reduce Mid2 
function in r2 due to the known ability of Midi to heterodimerise with Mid2 [107], although
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there is no published evidence to prove a dominant-negative effect of the DN-Mid1 
construct on Mid2.
3.3.2. Knockdown of Midi activity in r2 leads to PP2A 
accumulation
In order to elucidate the function of Midi during the period of development when cNCCs 
are migrating, the next aim was to inhibit Midi function and study the effects on cNCCs. 
As I found that Midi is strongly expressed in r2, and r2 adjacent cNCCs, in all stages of 
development examined by ISH, r2 was selected to be the target of Midi function 
knockdown. This was achieved using a dominant-negative Midi (DN-Mid1) construct 
electroporated into r2 at the 8ss stage. This construct produces a truncated MidlAR 
protein, where the RING finger domain of Midi is disrupted, therefore preventing binding 
of Midi to ubiquitin transferase. As shown by Short etal. [107] Midi dimerises in order to 
function, both in binding to microtubules and also for targeting PP2Ac for ubiquitination. 
The DN-Mid1 protein binds to both endogenous Midi proteins and other DN-Mid1 
proteins, forming DN-Mid1 and endogenous Midi dimers, or DN-Mid1 homodimers. The 
ubiquitin ligase activity of the DN-Mid1 and endogenous Midi dimers is compromised, 
therefore leading to a knockdown in PP2AC ubiquitination. XLOS patients often have 
deletions in the C-terminus of the Midi protein (which includes the RING domain), 
preventing microtubule binding [103, 121, 128] (Section 3.1.3). Thus, the DN-Mid1 
construct closely resembles the genetic defect in XLOS.
Although the DN-Mid1 construct has been shown to inhibit the function of Midi [96, 97], it
has not been formally confirmed that this occurs through loss of PP2A ubiquitinylation and
subsequent impairment of PP2A proteasomal degradation. Thus, to validate the inhibition
of ubiquitin ligase function by the dominant-negative construct, r2 tissue was taken 6
hours post electroporation with the DN-Mid1 construct (n=30 r2s) and a homogenate of
tissue was run on a western blot and probed with a PP2AC antibody which recognises the
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catalytic subunit of PP2A. The blot was stripped and reprobed with a (3-actin antibody to 
provide a protein loading control. The chemiluminescent signal intensities of both PP2Ac 
and (3-actin were quantified for each sample and the ratio of PP2Ac:(3-actin signal intensity 
was calculated. The Western blot data showed that the r2 tissue transfected with the DN- 
construct had around a third more PP2AC protein present than when r2 tissue was 
transfected with the control GFP construct (Figure 3-6).
DN  
into r2
GFP  
control 
into r2
(B-actin
B 2.0-
.E
g 1.5-
0
1  1.0-
~  0.5- 
re OZ
0.0
Figure 3-6. Analysis of PP2A catalytic subunit protein levels following electroporation.
Western blot analysis of PP2A protein levels following DN-Midl or GFP control 
electroporations (A) and subsequent densitometry to compare ratios of PP2A (36kD) and (3- 
actin (B) (43kD), showing more PP2AC in the DN electroporated tissue. Tissue was pooled 
from r2 from 30 embryos for each electroporation, n=l.
3.3.3. Midi plays a role in correct cNCC migration
Midi was found to be expressed in the migrating cranial cNCCs from the r1-r2 region, it is
therefore possible that the Midi is involved in the migration or patterning of the cNCCs. In
order to investigate this possibility, a DN-Mid1 construct was used to inhibit Midi activity
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in r2 and therefore inhibit the PP2A-degradation function of M id i. The DN-Mid1 was 
unilaterally electroporated into r2 at 8ss, the contralateral unelectroporated side was used 
as an internal control. After 9 hours of incubation, embryos were fixed and processed with 
HNK1 antibody, a marker for migrating cNCCs. These time points were chosen for the 
following reasons: At 8ss there are still cNCCs in neural tube at the level of r2, enabling 
electroporation of the cNCCs before migration. The migration pattern of the cNCCs 
adjacent to the neural tube at the level of r2 showed that there was a region of the 
mesenchyme that was in deficit of cNCCs in comparison to the unelectroporated control 
side. The GFP control electroporated embryos showed no such asymmetric NCC 
distribution (Figure 3-7).
A
Figure 3-7. Neural crest staining following electroporation with the DN-Midl 
construct.
Embryos immunostained for HNK (red), a NCC marker, and GFP (green), following 
electroporation of the DN-Midl (A, n=3/8), or GFP (B, n=6/6), construct unilaterally into r2. 
Embryos were electroporated at 8ss and incubated for 9hours to 14ss. Embryos expressing 
the DN-Midl in r2 showed a lack of neural crest cells adjacent to r2 (arrow).
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To determine if the migration pattern observed was partially due to cell death, DN-Mid1 
electroporated embryos (+9hrs after electroporation) were processed with an Apoptag kit, 
which is based upon a TUNEL staining method to detect apoptotic cells. The stain was 
quite weak, and it is difficult to see at the wholemount level if there is a difference in cell 
death between the DN and GFP electroporated side and the contralateral 
unelectroporated side (Figure 3-8). The wholemounts do not show a detectable 
difference by eye, certainly not to the extent expected to cause the NCC migration 
phenotype observed. Therefore sections were taken of the embryos and scanned by 
confocal microscopy. As the staining was clearer in the sections and no obvious 
differences were observed, cell death was ruled out as a contributing factor to the NCC 
phenotype.
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Figure 3-8. Apoptag staining following electroporation with the DN-Midl construct.
Embryos stained using the Apoptag k it (red), to label cells undergoing apoptosis, and GFP 
(green) antibody staining, following electroporation of the DN-Midl construct unilaterally 
into r2 at 8ss and following incubation to 13-14ss (+9hrs, n=8). Embryos did not show an 
obvious left-right difference in the number of cells undergoing apoptosis. Panel A shows a 
wholemount embryo, Panel B shows confocal sections of the same embryo from A.
3.3.4. Inhibition of Midi function in r2 neural crest cells leads to 
delayed trigeminal ganglia formation
Cranial neural crest form much of the trigeminal ganglia (Figure 1-7), the rest of which is 
derived from placodal cells. In order to investigate if the deficit in cNCCs observed in the 
DN-Mid1 electroporated embryos was affecting ganglion development, embryos were 
unilaterally electroporated with DN-Mid1 at 8ss and incubated for 22 hours, to 22/23ss, a 
stage in development where early ganglia development should be well underway. As 
ganglia development occurs quite discretely and is well documented, any differences 
should be easily detectable by eye. Staining with a phosphorylation independent NF
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antibody, a marker for neurons, showed a decrease in the trigeminal ganglia, specifically 
the mandibular processes of the ganglia, which r1 and r2 cNCCs contribute to, when 
electroporated with the DN-Mid1 construct (Figure 3-9) in 3/6 embryos (50%). These 
embryos also appear to have a thinner ophthalmic branch of the trigeminal ganglia, which 
is also contributed to by the cNCCs (Figure 1-7). Embryos unilaterally electroporated with 
control GFP construct showed no difference in NF staining (6/6). A possible explanation 
of this observation is that the DN-Mid1 cNCCs are not migrating as quickly as normal and 
are therefore not reaching their destination and differentiating on a normal timescale, 
therefore development of the ganglia is delayed. If this is the case, then ganglion 
development following DN-Mid1 electroporation should eventually catch up with the 
contralateral control sides. To test this, embryos were incubated for longer, for 48 hours, 
to ~40ss. Consistent with the idea that NCC emigration is delayed in DN-Mid1 r2 NCCs, 
the cranial ganglia were now the same size on both electroporated and non­
electroporated sides in DN-Mid1 (4/4 100%) embryos, as was the case for control GFP 
electroporated (3/3 100%) embryos (Figure 3-9 C).
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Figure 3-9.Cranial ganglion development in embryos electroporated with the DN-Midl 
expression construct
Embryos were unilaterally electroporated into r2 at 8ss and incubated to 23ss before being 
immunostained for the neuronal marker neurofilament (Red) and GFP (Green). Left and right 
views of DN-Midl embryos (Panel A, n=3/6) depicting less neuronal staining of the maxillo­
mandibular branch (white arrows) and a thinner ophthalmic branch (blue arrows) of the 
trigeminal ganglion on the electroporated side. The GFP control embryos (Panel B, n=6/6) 
show no left-right differences. Panel C shows DN-Midl embryos after a 48 hour incubation 
showing left-right symmetrical ganglia development by this stage (n=3/3).
3.3.5. Increased PP2A activity in r2 leads to delayed trigeminal 
ganglion formation
PP2A is ubiquitinated by Midi [116], and targeted for degradation. Therefore it could be 
that because the DN-Mid1 prevents function of the endogenous Midi protein and 
therefore the active PP2A protein levels increase, the increased PP2A activity is 
responsible for the phenotype observed above. Therefore in order to increase the protein 
levels of PP2A without directly affecting Midi activity, a construct expressing PP2Ac was 
built, pCAB-PP2Ac-IRES-GFP (see materials and methods [100]). The original construct 
although published in several previous studies and shown to be functional [100, 129], was 
not optimal for expression in chick tissue and lacked an IRES-GFP cassette; therefore the 
PP2Ac was cut out of the original vector and placed into an empty pCAB-IRES-GFP. As 
this is the same vector used for DN-Mid1 expression it alleviates the problem of 
differences in expression from the DN-Mid1 expression construct due to varying vectors.
The neural tube of embryos were electroporated unilaterally at the level of r2 with the 
PP2Ac expression construct at 8ss, incubated for 22hours to 22-23ss and then stained 
with a NF antibody. By 22-23ss the development of the trigeminal ganglia is well
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underway, allowing any abnormalities in its development to be seen. The electroporated 
embryos showed the same underdevelopment of the trigeminal ganglia, particularly the 
maxillary processes (5/9 55.6%) as the DN-Mid1 embryos (Figure 3-10). Therefore this 
reinforces the hypothesis that M idi is acting through its PP2Ac ubiquitination function in 
this instance.
a |
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Figure 3-10. Cranial ganglion development in PP2A expression construct 
electroporated embryos.
Embryos were electroporated at 8ss unilaterally into r2 using the PP2A expression construct 
and incubated to 23ss. Embryos were then stained for neurofilament (A), to show neurons, 
and a GFP (B) antibody for electroporated cells. Each panel shows the right and left sides of 
the same embryo, showing the same DN-Midl phenotype of fewer neurons on the 
electroporated right side (arrows, n=5/9), and a dorsal view (C) showing the unilateral 
electroporation into the right side of the neural tube.
97
Chapter 3
3.3.6. PP2Ac protein levels decrease following Midi 
overexpression or pharmacological inhibition of PP2Ac
If the migration of the cranial neural crest that normally expresses Midi is impaired upon 
transfection with the DN-Mid1, thereby affecting development of the ganglia, then it is 
possible that ectopic expression of Midi in cNCCs that do not normally express Midi 
would lead to enhanced migration. Therefore the second approach for further 
investigation into the function of Midi involves the ectopic expression of Midi in r4 and its 
cNCCs.
Rhombomere 4 was selected as a target since it is the next caudal rhombomere to r2 that 
outputs cNCCs directly into the adjacent mesenchyme, but I found it does not express 
Midi mRNA to a level detectable with ISH, either in the neuroepithelium or in the cNCCs. 
It is therefore an appropriate target for studying the effects of Midi ectopic expression. In 
order to check the effectiveness of the Midi expression construct, a western blot was 
performed on r3-r5 neuroepithelium that had been electroporated with the Midi construct 
at 10ss and then incubated for 6 hours. The blots were probed for PP2Ac and (3-actin. 
The Midi electroporated neuroepithelia showed around half as much PP2Ac protein in 
comparison to GFP control electroporated neuroepithelia (Figure 3-11), confirming Midi - 
mediated PP2Ac destruction.
Evidence from the PP2A-expression construct results suggests that PP2A is the effector 
through which Midi is acting, OA, an inhibitor of PP2Ac, was used to mimic the ectopic 
expression of M id i. OA is a well characterised inhibitor of PP2A that binds the PP2Ac 
active site [130], although at higher concentrations it does have an inhibitory effect on 
other protein phosphatases. The IC50 value for PP2A is 0.1-1nM, whereas it is 20-50nM 
for PP1 and >5000nM for PP2B [114].
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Western blot analysis was performed on tissue exposed to 10nM OA at 10ss and 
incubated for 6 hours (n=30 r4s pooled). The results surprisingly showed a decrease in 
the protein level of PP2Ac (Figure 3-11). This was not expected and suggests that 
inactivated PP2Ac is targeted for degradation.
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Figure 3-11. Analysis of PP2Ac protein levels following M id i electroporation or 
Okadaic acid exposure.
Western blot analysis of PP2Ac protein levels following Midi or GFP control electroporations 
and OA exposure (A) and subsequent densitometry to compare ratios of PP2Ac (36kD) and (3- 
actin (43kD) (B). These results show less PP2Ac present in the presence of Okadaic acid and 
following electroporation with the Midi construct in comparison to the GFP control 
electroporated tissue. Tissue for western blotting was pooled r2 from 30 embryos for each 
condition (n=l).
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3.3.7. Ectopic expression of Midi promotes faster migration of 
r4 cNCCs from the neural tube
As we know that the migration pattern of cNCCs that endogenously express Midi was 
altered by DN-Mid1 expression, the next step was to determine if Midi had any affects on 
the migration pattern of r4 cNCCs that do not normally express M id i. Embryos were 
unilaterally electroporated with the Midi expression construct at 10ss and then processed 
at various times with a HNK1 antibody to determine if the cNCC migration pattern was 
affected. In the wholemount embryos, there was no evidence that the electroporation of 
Midi into cNCCs affected their migration pattern, as determined by HNK1 immunostaining 
9 hours following electroporation (8/8 100%) (Figure 3-12). However, at the whole-mount 
level, it appears that there may be an increase in the number of cells migrating in the r4 
stream of cNCCs, as it does seem to look wider than on the contralateral control side (6/8 
75%) (Figure 3-12). Thus, although the pattern appears not to be affected, cell migration 
speed could be altered; cells may be migrating faster and/or leaving the neural tube 
earlier.
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Figure 3-12. Neural crest cell pattern following M id i electroporation.
Embryos were electroporated with M id i (A, n=6/8) or GFP control (B, n=6/6) constructs at 
lOss and incubated for 9 hours to 16ss. Embryos were subsequently stained w ith anti-HNK 
(red) and anti-GFP (green). Panels show left, right and centre views of the same embryo for 
each electroporation. Arrows indicate r4 cNCC streams on electroporated side of the embryo.
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In order to see if cNCCs were undergoing EMT prematurely and therefore contributing to 
the r4 cNCC migrating stream earlier therefore leading to a slightly thicker stream of cells, 
embryos unilaterally electroporated with Midi were immunostained with a Pax3 antibody 
(labels premigratory and migratory cNCCs) to check if there were fewer cNCCs in the 
neural tube due to early delamination. Upon confocal analysis of sections, it was clear 
that the Pax3 staining was less on the Midi electroporated side of r4, but was unaffected 
in GFP electroporated embryos (Figure 3-13). This, along with the possibly thicker cNCC 
stream (Figure 3-12), supports the theory that Midi over-expression does promote early 
delamination of cNCCs from the neural tube.
Figure 3-13. Pax3 staining of Neural Crest cells in the neural tube following 
electroporation.
Embryos were electroporated with M id i (A) or GFP control (B) constructs at lOss and 
incubated for 6 hours to 14ss. Embryos were subsequently stained for Pax3 (red) and GFP 
(green). Sections showed a decrease in the number of Pax3 stained cells w ith in the neural 
tube on the electroporated side in the M id i expressing embryos. Sections were cut at 70 
microns and scanned using a confocal microscope, n=2/4.
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3.3.8. Ectopic expression of Midi in r4 neural crest causes 
premature geniculate ganglia development
At the level of r4, the cNCCs contribute to the acoustic ganglia, while the placodal cells 
from the epibranchial geniculate placode contribute to both the geniculate and acoustic 
ganglia ([72, 131], Figure 1-7). As demonstrated in Figure 3-9 and Figure 3-10, 
development of the peripheral nervous system was affected by an increase in PP2A 
activity, leading to delayed gangliogenesis, either by down regulating the activity of Midi 
through the DN-Mid1 construct or by using the PP2Ac expression construct. If regulation 
of PP2A activity via Midi is important for cNCC migration and gangliogenesis, then it 
could be predicted that inhibiting PP2A in r4, either by electroporating a Midi expressing 
construct or by pharmacological inhibition of PP2A, should have the opposite effect, 
leading to precocious ganglia formation. The geniculate ganglion begins to form at 
around 13ss, and by 20ss the development of the geniculate and acoustic ganglia is well 
underway [132]. Therefore viewing the peripheral nervous system at 20+ somites would 
be an appropriate time point to study if Midi has any affect on the development of the 
geniculate-acoustic ganglia. Embryos electroporated with the Midi construct were fixed 
at different time points in order to ensure there was a better chance of covering the correct 
period of development to observe any changes in nerve growth. Embryos were 
electroporated unilaterally into the neuroepithelium at the level of r4 at 10ss and incubated 
for 22hours to early 24-25ss and also 24 hours to late 26-27ss, before being stained for 
NF (a neuronal marker). Interestingly the embryos did show a distinct difference in the 
development of the geniculate ganglia, there was much more NF positive staining 
covering a larger area, in the Midi electroporated embryos (Figure 3-14), 9/14 (64%) at 
22 hours and 9/21 (43%) at 24 hours. As previous results showed that the ganglia 
development phenotype was transient, the experiment was repeated using the Midi 
construct electroporated into r4 at 10ss and incubated for 48 hours (~40ss). The embryos 
were then stained using the NF and GFP antibodies and the ganglia were found to be of
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the same size (3/3) (Figure 3-15), therefore the effect is transient, as was seen in longer- 
term DN-Mid1 electroporated embryos. At all experimental times, no obvious differences 
were observed in neuronal staining within the neural tube, therefore the Midi-induced 
changes are specific to the cNCC.
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Figure 3-14. Ganglia development following M id i electroporation.
Embryos were electroporated with M id i (A) or GFP control (B) constructs at lOss and 
incubated for 22 hours to 25ss. Embryos were subsequently stained for NF (red) and GFP 
(green). Panels show left and right views of the same embryo for each electroporation. The 
figures show that there is increased neuronal staining (compare white arrows) on the right 
side of the embryo, which has M id i positive neural crest (n=9/14). In comparison the GFP 
control embryos do not show a left-right difference in neuronal staining (compare blue 
arrows, n=8/8).
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Figure 3-15. Ganglia development following M id i electroporation.
Embryos were electroporated with M id i [A) or GFP control (B) constructs at lOss and 
incubated for 48 hours. Embryos were subsequently stained for NF (red) and GFP (green). 
Panels show left and right views of the same embryo for each electroporation and illustrate 
how the development of the ganglia is now left-right symmetrical by this stage, n=3/3 for 
both M id i and GFP embryos.
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3.3.9. Premature ganglion formation is not contributed to by 
cell death
The observations of changes in cNCC migration patterning, ganglion development and 
Pax3 staining are consistent with the hypothesis that alteration of active PP2A protein 
levels is affects the migration of NCCs and also the subsequent development of the 
peripheral nervous system. However it is possible that other mechanisms could be 
involved, cell death could be being altered, the NCCs expressing Midi may be being 
protected from dying therefore there are more available to affect development of the 
geniculate placode. The possible involvement of altered cell death in the observed 
ganglia phenotype was investigated in both Midi and GFP control unilaterally 
electroporated embryos. To test this, embryos were electroporated as usual at 10ss and 
incubated for 9hours to 16ss before being processed with an Apoptag kit, which labels all 
strands of DNA with breaks, in cells, thus labelling cells undergoing apoptosis with red 
fluorescence. The Apoptag staining of the embryos was not very strong, however some 
positively stained cells could be observed (Figure 3-16). It appears as though there was 
little difference in apoptosis at the placode region or in the r4 cNCC stream in all embryos 
(Midi 6/6, GFP 4/4). It is difficult to tell if there is a change in the rate of cell death in the 
neural tube as the GFP masks the red staining, although some increased cell death would 
be expected on the electroporated side in any case, as a result of the electroporation 
technique. Overall it does not appear as though the amount of apoptosis has been greatly 
affected by expression of either the Midi or GFP construct, as a reasonably large 
difference would need to be seen in order to lead to the changes in ganglia development, 
which should be identifiable, even with weak staining. Therefore apoptosis has been 
ruled out as the main cause of the premature ganglia phenotype.
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Figure 3-16. Cell death following electroporation.
Embryos were electroporated w ith M id i (A,B) or GFP control (C) constructs at lOss and 
incubated for 9 hours to 16ss. Embryos were then processed using an Apoptag k it (red) for 
cell death and GFP (green). Panel A shows a dorsal view of a M id i electroporated embryo, 
Panel B shows the same embryo as in A, left and right views showing no visible change in 
apoptosis following M id i electroporation. (n=9 M id i electroporated, n=6 GFP 
electroporated).
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3.3.10. Okadaic Acid delivery to r4 mesenchyme mimics the 
effects of ectopic Midi expression in r4 on premature ganglia 
development
Midi expression or OA treatment, both lower PP2Ac levels in r4. In order to determine 
whether premature geniculate ganglia formation in Midi-electroporated embryos was due 
to reduced PP2A, I used the pharmacological PP2A inhibitor, Okadaic acid (OA). Affi-blue 
resin beads soaked in OA, were applied to the surface of embryos at the level of the r4 
mesenchyme. The beads should allow a focal, slow release of OA to the surrounding 
tissue, therefore mimicking the constant presence of Midi in electroporated cells.
The OA concentration used to soak the affi-blue beads was 10nM. This is in line with 
previous studies using OA on NCCs or chick embryo tissue, which range from 0.1-20nM 
[113, 133-135]. Embryos were exposed to OA beads at 10ss for 22hrs to 24ss, as in the 
electroporation experiments. After staining with anti-NF, the OA-treated geniculate 
ganglia could clearly be seen to have the same premature development as in the Midi 
electroporated embryos (Figure 3-17). The general neuronal patterning within the neural 
tube did not appear to be affected, as was the case with the Midi electroporated embryos. 
Overall these results support the theory that a decrease in PP2A activity is the cause of 
the premature development of the ganglion.
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Figure 3-17. Okadaic Acid application to r4 mesenchyme mimics M id i over-expression 
in r4 NCC.
Embryos were incubated with a lOnM bead of OA over the r4 mesenchyme at lOss and 
incubated to 25ss. Panel A shows left and right views of an embryo processed for the neural 
crest marker, HNK (red, n=9/9). Panel B shows an embryo stained for the neuronal marker, 
NF (red, n=9/17), the dotted circle depicts the placement of the OA bead, blue arrows show 
the geniculate ganglia. In C an embryo was also stained for NF (red), but had the OA bead 
placed over r6 mesenchyme, instead of r4 mesenchyme, the dotted circle shows the otic 
vesicle and bead placement, white arrows show the location of the developing ganglion for 
comparison (n=4/6).
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In order to check that the changes in ganglion development are not exclusive to the 
geniculate ganglia following OA exposure, beads of OA were placed over the r6 
mesenchyme at 10ss and incubated for 22 hours, before immunostaining with anti-NF. 
Interestingly the neuronal staining adjacent to r6 showed the same phenotype of more 
neurons on the OA exposed side (Figure 3-17 C, white arrows n=4/6 embryos). 
Therefore it can be concluded that the effect of decreasing PP2A activity leading to 
premature ganglion formation is not exclusive to the r4 mesenchyme and geniculate 
ganglia.
3.3.11. Premature gangliogenesis is not due to diffusible cues 
from the neural tube
Because the neural tube is the target of the electroporations performed here, and the OA 
bead will most likely also be affecting the neural tube, the phenotypes I report could be 
due to altered secretion of molecules from the neural tube which could indirectly affect the 
cNCCs, in addition to the direct effect of Midi and OA on cNCCs. To test this, embryos 
were electroporated in r4 with pCAB.Midl or pCAB.GFP, as usual, or treated with OA 
beads, and allowed 6 hours incubation in order to allow GFP positive cells to migrate out 
of the neural tube and into the surrounding mesenchyme. After the 6 hour incubation, the 
neural tube and notochord of rhombomere 4 were removed and the embryos reincubated 
to 25ss before fixation. All embryos were stained for NF, and the electroporated embryos 
additionally for GFP. Midi (3/9 33%) and OA (4/9 44%) treated embryos showed the 
premature ganglia development phenotype (Figure 3-18), although this was not as 
pronounced as in unoperated embryos. This could be due to fewer Midi positive cells 
delaminating from the neural tube before its removal, and fewer cNCCs for the OA to have 
an effect on. However, if the phenotype were exclusively due to neural tube secretions,
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then far fewer embryos with phenotypes would be expected. For these reasons, the data 
suggest that the phenotype is due to cNCC-intrinsic changes.
Figure 3-18. Removal of the neural tube partway through incubation following M id i 
electroporation or OA exposure leads to premature ganglia development.
Embryos were electroporated w ith the M id i (A, n=3/9) construct or had a lOnM OA bead 
placed over r4 mesenchyme (B, n=4/9) at lOss and incubated for 6 hours before whole 
removal of rhombomere4 and re-incubation to 25ss. Embryos were then immunostained for 
Neurofilament (Red) and for the electroporated embryos GFP (Green) in addition.
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3.3.12. Decreased PP2A activity in cNCCs in  v itro  leads to 
increased cell speed and reduced substrate adhesion
To further investigate the theory that PP2A causes premature ganglia development by 
promoting cell migration, studies were conducted on cNCCs in vitro in the presence of the 
PP2Ac inhibitor OA. Okadaic Acid has been shown to be toxic to cells at high 
concentrations [136-138], so a range of concentrations (100pM, 1nM, 5nM, 10nM) were 
tested on cNCCs grown on fibronectin. 1 nM was found to be a workable concentration 
that did not induce a significant level of cell death (data not shown), cell morphology was 
also more similar to that of cells incubated without OA at this concentration.
Neural crest cells were obtained by explanting r4 from 10ss embryos or r2 from 8ss 
embryos, allowing cNCC to emigrate onto the culture substrate for 4hr and then removing 
the neural tube (to exclude any neural tube effects). The speed of the cells was then 
measured over successive 2 hour periods using time-lapse video microscopy. Cells in 
the r4 cultures increased in speed very significantly (p<0.001) when compared to before 
OA addition, and migrated around a quarter faster than before the OA was added to the 
culture media. After 2 hours, the r4 cNCCs with OA were still increasing their speed of 
migration in comparison to the r4 cNCCs without OA, at every time point the difference in 
speed from that before OA addition was highly significant (p<0.001). The r2 cNCCs 
showed no significant difference in cell speed with OA (Figure 3-19), which is expected as 
they already express Midi and therefore should have little PP2A to inhibit, in comparison 
to the r4 cNCCs, in order to affect cell speed. One observation made during these in vitro 
experiments was that untreated r2 cNCCs migrated significantly slower than the r4 
cNCCs. Furthermore the speed of the r2 cNCCs was unaffected by OA, implying that the 
r2 cNCCs were already migrating at their maximum speed, possibly due to their 
constitutive expression of M idi. This could explain why Midi is needed in the r2 cNCCs, 
if they are slow cells to migrate in the absence of Midi, the activity of Midi may be
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needed to speed them up in order for them to migrate to their correct destination in time 
for correct development. Therefore inhibiting Midi activity, through the DN-Mid1 
expression construct, should slow them down.
To test this and also reinforce the OA data, cells were transfected with the DN-Mid1 (r2 
cNCCs) or Midi (r4 cNCCs), by electroporating the appropriate construct into the correct 
rhombomere and then removing the tissue as in the OA experiments to allow the 
electroporated cNCCs to migrate into the dish for culture and subsequent time-lapse. 
This was not as successful as the OA time-lapse culture as many of the cNCCs that 
migrated out subsequently died, leaving very few cells to track. This was a problem with 
the technique and not due to the expression of M idi, as the same was observed with the 
control GFP construct. Another problem was that in order to track the electroporated 
cells, they needed to be immunostained for GFP at the end of the filming period, in order 
to identify the construct expressing cells, because the endogenous fluorescence of the 
GFP was too weak to be seen on a single cell level. As the electroporation method was 
unsuccessful, a lipofection approach was tried. However, once again the NCCs mostly 
died and there was still the same problem of needing to immunostain the cells after filming 
to identify GFP positive cells.
The behaviour and morphology of cells migrating in the presence of OA was quite 
different to that of the cNCCs in the absence of OA. Cells exposed to OA were more 
likely to round up, to be more spherical, and move quickly over the surface of the culture 
dish, compared to the more flat, slow moving cNCCs without OA.
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□  r2 NCC’s before OA □  r4 NCC’s before OA
I  r2 NCCs after OA addition □  r4 NCCs after OA addition
r4 cNCCs with okadaic acid r4 cNCCs without okadaic acid
Figure 3-19. Time-lapse analysis of r2 and r4 cNCCs in vitro, with and without the 
presence of Okadaic Acid.
Cranial neural crest cells were grown in vitro  on fibronectin coated tissue culture plates, w ith 
or w ithout the presence of InM  OA in the culture media. The first two hours of film ing were 
done without OA in both experimental and control cultures. A shows a graph of the average 
cell speed pm/hour, B shows a representative photo of tracked cNCC movements both w ith 
and without OA over the 10 hour period. P<0.001 (***), P<0.05(*). Numbers of cells tracked 
n = l l l  r2 prior to OA, n=16-48 r2+OA, n=93 r4 prior to OA, n=17-26 r4 +OA. The time lapses 
were performed on 4 separate occasions.
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3.3.12.1. OA reduces cNCC cell adhesion on fibronectin
A possible explanation of the observed motility behaviour is that it was caused by a lack of 
adhesion to the substrate, therefore allowing the cells to move more quickly. In order to 
test this hypothesis, cNCCs were incubated in the presence of OA overnight and then 
agitated for 1 hour on a shaker. The number of cells before and after agitation was 
counted. OA significantly increased the number of cells that could be detached from a 
fibronectin substrate. However when the cNCCs were grown on PLL, there was no 
significant difference in the loss of cells following agitation between the OA and non OA 
incubated cells (Figure 3-20). As no significant change in the number of cells is observed 
on PLL, it can be concluded that the changes in adherent cell numbers on other 
substrates is due to a loss of adhesion and not due to an increase in cell death, which 
would then lead to cell detachment.
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Figure 3-20. Okadaic Acid reduces cell adhesion to fibronectin, but not to PLL
Rhombomere 4 explants were cultured overnight before the addition of InM  OA to the 
culture media, the cells were photographed then placed on a shaker for 1 hour before being 
photographed again. A -  cNCCs on fibronectin before agitation, B -  cNCCs on fibronectin after 
agitation, C -  cNCCs on PLL before agitation, D -  cNCCs on PLL after agitation. E - Cell counts 
were taken and the percentage loss of cells during the agitation period were calculated. The 
average percentage loss was taken from 3 separate rhombomere explants in the same culture 
dish for cell counts for each condition. P<0.01 (**), P>0.05 (*), one-way ANOVA. Numbers of 
cells counted per frame before agitation, 3 frames per condition, 1 frame of view from each 
rhombomere, n=20-85 cells fibronectin -OA, n=21-223 cells fibronectin +0A, n=35-60 cells 
PLL -OA, n=41-96 PLL+OA. Scale bar -  50pm. This experiment was performed once.
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3.3.13. Decreased PP2Ac in r4cNCCs encourages a neuronal cell 
fate in vitro
In order to investigate if Midi has a role in cell fate decisions of cNCCs Midi 
electroporated r4 cNCCs, or normal r4 cNCCs we cultured in the presence of OA, and 
then stained for NF. (Figure 3-21). Pilot experiments in which cNCCs were cultured for 
24hours before fixation and subsequent immunostaining for NF showed no NF positive 
cells. However by day 5 in culture several NF positive cells had developed, therefore a 5 
day culture of cNCCs was used as the endpoint in this experiment. The counts 
demonstrated that the cells treated with OA or electroporated with Midi more readily 
differentiated into neurons than those electroporated with the GFP control construct. The 
conclusion here is that decreased PP2A activity could have a small effect on cell fate, but 
is probably not significantly contributing to the in ovo phenotype, unless environmental 
factors have a significant effect. If so, then sections through the ganglia should show 
more NF-GFP double positive cells in Midi electroporated embryos, than in GFP 
electroporated controls. Therefore sections were taken transversely through embryos 
showing the phenotype at wholemount level, the sections (4/4) mainly showed no NF-GFP 
double staining (Figure 3-22), with only 1 section showing 2 double stained cells. In 
conclusion Midi expression does not appear to be driving a cell-autonomous neuronal cell 
fate at this stage of development and so is not the mechanism behind the observed 
ganglion phenotype.
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Figure 3-21. Long-term exposure to Okadaic acid promotes neuronal differentiation in 
r4 NCCs.
Neural crest cell culture from r4, incubated w ith OA for 5 days and stained for Neurofilament 
(red) and Hoechst (Blue). Figure shows cells incubated at InM  OA (A), lOnM OA (B), Control 
(C) and a graph showing percentage Neurofilament positive cells in each condition (D). 
P<0.05 (*). Numbers of cells counted per frame, 3 frames per condition, n=1544-1983 cells at 
lOOpM, n=185-409 cells at InM, n=426-698 cells at lOnM, n= 901-1862 cells for controls. 
Results representative of 3 repeats of the experiment. Scale bars -  100|im.
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Figure 3-22. Confocal sections though the geniculate ganglia following M id i 
electroporation.
Embryos were electroporated with Midi [A, n=4/4) or GFP control (B, n=4/4) constructs at 
lOss and incubated for 22 hours to 25ss. Embryos were subsequently stained for NF (red) 
and GFP (green) then sectioned at 70 microns. Staining revealed a lack of double stained 
cells, implying that the M idi transfection is not encouraging cells to differentiate into 
neurons. Dotted white line shows location of neural tube.
3.3.14. Premature placode cell migration following Midi r4 cNCC 
expression
Cells of the epibranchial geniculate placode differentiate into the neurons of the 
developing geniculate ganglion; the acoustic ganglion is populated by neurons derived 
from neural crest cells from the r4 cNCC stream and also placode cells from the 
epibranchial geniculate placode [72] (see Figure 1-7). The epibranchial placode cells do 
not enter the mesenchyme and begin to migrate towards the site of ganglion development 
until the cNCCs migrate to them first [80]. The neural crest cells are required for the 
placodal cells to migrate, in the absence of cNCCs the cells of the placode remain there 
[80]. However, neural crest cells reach the placode well before placode cells enter the 
mesenchyme, suggesting that, whilst NCC are necessary, additional factors or
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maturational changes in NCC are also required before placode cell migration can occur. 
Breakdown of the basal lamina that separates the ectodermal placodes from the 
mesenchyme coincides with placode cell migration [70]. Thus it is possible that the 
premature ganglion formation observed in the Midi electroporated embryos is due to 
premature basal lamina breakdown, allowing release of placodal cells into the 
mesenchyme to form the geniculate ganglia sooner than normal. This could be caused 
by the OA exposed or Midi expressing r4 cNCCs secreting something that affects the rate 
at which placodal cells are able to leave the placode, such as proteases that break down 
the basal lamina.
In order to investigate the possibility that placodal cell migration was affected when PP2A 
activity is decreased, a cell tracker dye (CM-Dil) was used to label the placodal cells. This 
was achieved by covering the entire surface ectoderm of an embryo at 10ss which had 
been either electroporated with the Midi construct or an OA bead was placed over the r4 
mesenchyme. Embryos were incubated to 25ss, then removed and processed with a NF 
antibody, with or without a GFP antibody as appropriate, and sectioned. This end point 
was selected because the embryos are at a stage when the geniculate ganglia formation 
would be well underway, allowing any changes in their development to be more easily 
observed.
The sections showed that the placodal cells had indeed migrated further into the embryo 
with OA treatment or Midi electroporation (Figure 3-23). Sections through the Midi 
electroporated embryos show clearly that there is increased migration of the Dil (red) 
labelled placodal cells into the mesenchyme towards the neural tube on the 
electroporated side compared to the contralateral side. Moreover the Midi r4 
electroporated embryos and the OA treated embryos clearly show that the placodal cells 
are the cells contributing to the premature geniculate ganglia.
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Contralateral Control
Figure 3-23. Migration of placodal cells following electroporation
Embryos were electroporated with the M id i construct, 30 mins later the embryos were 
covered in CM-Dil (red) and then incubated from lOss to 25ss, before fixing and staining with 
GFP antibody (green). A,B -  wholemount view of embryos before antibody staining, arrows 
show position of placode and labelled placodal cells that can be seen migrating inwards 
(n=5/9), same embryo is shown in C,D the otic vesicles are outlined by the grey dotted line. 
Panel E shows sections through an r4 M id i electroporated embryo at the level of the placode, 
Panel F shows an embryo electroporated w ith the GFP construct at the level of r4 (n=6/6).
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3.3.15. Increased breakdown of basal lamina at the placode 
following OA treatment
The question at this point is how does Midi in r4 cNCCs cause placodal cells to 
prematurely form the geniculate ganglia? A few possible explanations are that the 
placodal cells could migrate earlier, they could be more motile or they could have a higher 
rate of proliferation. After electroporation, the number of cNCCs with detectable levels of 
GFP is small. However this small number of cNCCs could secrete molecules that 
promote placodal cell migration or increase cell proliferation rates. As placodal cell 
migration only occurs once the basal lamina has broken down enough for the cells of the 
placode to pass [70], it is possible that there may be an increase in protease activity 
caused by the presence of Midi electroporated cNCCs or exposure of the cells to OA. It 
is well-known that cranial neural crest cells secrete metalloproteases [83, 85, 86] that can 
break down the basal lamina around the placode, thus allowing the cells of the placode to 
migrate away. OA treatment or Midi expression could cause a change in the secretion of 
MMPS or other proteases by cNCCs, if this is the case, then it would be expected that the 
protease secretion would increase in order to break down the basal lamina faster. In 
order to test if there is a premature or more extensive basal lamina breakdown following 
Midi or OA exposure, embryos were treated with OA as before, incubated to 16ss and 
stained with a laminin antibody, to show the basal lamina, and Pax2, to stain the cells of 
the placode. The sections through these embryos showed that the OA-treated embryos 
have increased sub-placodal basal lamina breakdown on the treated side, in comparison 
to the contralateral side (Figure 3-24).
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Figure 3-24. Confocal sections though the geniculate placodal region following 
Okadaic Acid exposure.
Embryos were treated w ith Okadaic Acid beads over r4 mesenchyme (A,B) at lOss and 
incubated for 9 hours to 16ss. Embryos were then stained for NF (red) and Pax2-Lam(green) 
and sectioned at 70 microns. Panels show successive confocal images through the same 
section for both the OA bead treated side (A), and the contralateral untreated side (B). The 
sections illustrate an increased migration of the placodal cells inwards and an increased 
breakdown of the basal lamina (arrows) on the embryos treated w ith OA, but not the 
corresponding untreated side of the same embryo (n=2/4). Sections were taken 14pm apart 
from a confocal stack.
Okadaic Acid is likely to have a much faster effect on PP2A activity in comparison to
electroporation with M id i, as the cells take a few hours to begin expressing the protein.
Therefore one question is whether the OA bead could be applied at a later stage to the
placode and still have the same effect. To test this possibility beads were placed over the
r4 adjacent mesenchyme at 15-16ss and incubated to 25ss. After staining with NF it was
clear that there was no difference in development of the ganglia in experimental OA (9/9)
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and control (8/8) embryos. Therefore late inhibition of PP2A at the placode level was not 
effective. This result shows that it is the exposure of the cNCCs to OA, at an earlier stage 
of development, which causes the ganglion phenotype and not exposure of the placodal 
cells to OA before they migrate away from the placode. Therefore a change in PP2A 
activity levels in the placodal cells does not affect their normal migration or development.
3.3.16. Changes in the observed speed of cNCCs in vitro on 
different substrates following OA exposure
Proteases have different substrates (see Figure 1-9), so it is possible that the proteases 
involved here are targeting other matrix proteins, either in addition to or instead of laminin. 
Although the analysis of basal lamina breakdown in vivo described above focused on 
laminin, it is possible that disruption of other matrix proteins could lead to the breakdown 
of the basal lamina. To further test the hypothesis that the OA treated cNCCs are 
secreting additional proteases that break down the basal lamina, by degrading matrix 
proteins, the cNCCs were analysed by time-lapse microscopy in culture with and without 
OA addition on different substrates. As fibronectin was used in the previous time-lapse 
studies, these time-lapses were performed with laminin, collagen and PLL coated tissue 
culture plates. Collagen and laminin were chosen as both are components of basement 
membranes. The in vivo data showed that laminin was increasingly degraded in the 
presence of Midi electroporated cNCCs, therefore it is possible that there is increased 
degradation of laminin by the proteases, which may affect cell motility. PLL was used as 
a substrate as proteases should not have an effect, and therefore acts as a control for cell 
motility. Depending on which combination of substrates show differences in cell speed, if 
any, it should help to narrow down possible candidates of proteases with elevated 
secretion/activity.
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Overall the results showed that cells on collagen and PLL increased cell speed following 
OA exposure, however untreated cells moved faster on both PLL and laminin, but not on 
collagen. The collagen results show that there is a significant increase in the speed of the 
r4 cNCCs on collagen at every time-point after the first 2 hours in the presence of OA 
(Figure 3-25 A). There is a large increase in cell speed between 0-2 and 2-4 hours in the 
presence of OA and then the cell speed remains relatively constant until the end of the 
observed period. This mirrors the observations of the cells on fibronectin the closest.
When the cells are on grown on laminin the opposite occurs; the speed of the cNCCs in 
the presence of OA is slower than without; there is a significant difference in the cell 
speed at all time periods except 0-2 hours (Figure 3-25 B). In the absence of OA the 
cNCCs show a gradual increase their cell speed; however with OA the cell speed remains 
relatively constant with no significant differences in cell speed between the time periods 
observed. This could be indicative of a change in protease action in the presence of OA, 
perhaps there is an increase in laminin degradation which leads to the cells moving more 
slowly, possibly due to the action of membrane bound proteases.
When the cells are grown on PLL, there is no significant difference in cell speed at the 0-2 
hour and 4-6 hour time periods, but at the 2-4 and 6-8 time periods there is a significant 
difference (Figure 3-25 C). Overall the cells show a gradual increase in cell speed over 
time in both cell sets with and without OA, which is by the last time period, significantly 
faster than at the 0-2 hour time period (P<0.001 for both with and without OA cell groups).
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Laminin
I  r4 NCC’s with no OA 
□  r4 NCC’s with OA addition
Figure 3-25. Time-lapse analysis of r4 cNCCs in vitro on different substrates, with and 
without the presence of Okadaic Acid.
Cranial neural crest cells from rhombomere 4 were grown in vitro  on PLL (A), Laminin (B) or 
Collagen (C) covered tissue culture plates, w ith or w ithout the presence of InM  OA in the 
culture media. P<0.001 (***), P<0.01 (**), P>0.05 (*). Numbers of cells tracked per condition, 
n=17-19 Laminin +OA, n=18-21 Laminin -OA, n=21-26 PLL +OA, n= 27-34 PLL -OA, n=37-52 
collagen +OA, n=34-44 collagen -OA. Each experiment was repeated twice and had 3 separate 
rhombomeres for each condition. At least 3 different fields of view for each condition from 
different rhombomeres were analysed.
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3.3.17. RT-PCR analysis of OA treated r4 tissue
In order to determine more specifically which, if any, proteases were up-regulated in 
response to OA exposure, RT-PCR’s were performed on tissue exposed to OA (RT-PCR 
was performed by Jon Golding, Figure 3-26). We chose to analyse the expression of 
proteases known to be expressed by neural crest and/or with substrate specificities for 
fibronectin, collagen and laminin, which had demonstrated OA-dependent changes in 
time-lapse analyses. Rhombomere 4 was dissected from embryos at 10ss and then 
incubated in media for 5 hours, with or without the presence of 1nM OA. RT-PCR’s were 
performed using primers for cMMPIO, cMTI-MMP, cTIMP-2, cADAMIO and cGAPDH. 
Interestingly cMMPIO, is down-regulated following OA incubation, while cADAMIO is up- 
regulated. There also appears to be a reduction in the expression of cTIMP2, however 
not as marked as the others. GAPDH was used here as a control as it is a constitutively 
expressed housekeeping gene, the similar quantities of cMMP2, cADAMIO and the high 
level of cTIMP-2 to GAPDH implies that there is a high level of expression of these 
proteases in r4 tissue. Other RT-PCR’s performed that did not show any changes 
include, MMP1, MMP2, MMP13 and ADAM13. These results show that changes in the 
expression of the MMP’s and related proteins may well be responsible for the phenotypes 
observed.
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| r4 | r4+0A | r4 | r4+0A | r4 | r4+0A | r4 | r4+0A | r4 | r4+0A |
MW  | cMMPIO | cADAMIO | CMT1-MMP | CTIMP2 | cGAPDH |
Figure 3-26. RT-PCR of r4 tissue following OA exposure
Rhombomere 4 was dissected out of 10 embryos for each condition. The tissue was then 
incubated in complete DMEM, either with or without the presence of InM OA in the culture 
media, for 5 hours. The tissue was then used for RT-PCR analysis, using primers for chick 
MMP10, MT1-MMP, ADAM10, Timp2 and GAPDH. Control PCR's were executed for each 
different probe in the absence of reverse transcriptase C"RT). n=l, RT-reverse transcriptase. 
MW -  molecular weight marker.
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3.4. Discussion
Because of its potential role in regulating very many cellular processes (i.e. via its effects 
on microtubules and PP2A), the precise roles of Midi in cranial development have 
remained unclear. The work shown here demonstrates for the first time how defects in 
Midi could affect cranial morphogenesis. Changes in cell migration and protease activity 
of the cranial neural crest affect the development of the cranial ganglia as shown here. 
Although the effects on ganglia formation appear temporary, they may have longer-term 
consequences, especially considering that I made only transient transfections into 
individual rhomomeres. Furthermore, since Midi is re-expressed in the frontonasal 
processes at the time of midline fusion, these findings could provide a basis for the 
understanding of how Midi-regulated protease activities remodel the cranial mesenchyme 
during face formation.
The gene expression pattern of Midi as described here is in agreement with the findings 
of Richman (2002) that Midi is expressed in rhombomere 2 at 10ss [110]. Furthermore 
my results show that Midi is also expressed by the cNCCs migrating into the 
mesenchyme adjacent to r1/r2, but Midi expression is then down-regulated as cNCCs 
migrate further away from the neural tube. PP2A is ubiquitously expressed throughout 
development [139], therefore where there is no Midi activity, it could be expected that 
PP2Ac activity would increase. For example as Midi is down regulated in cNCCs the 
branchial arches, it is reasonable to believe that the level of PP2Ac activity would be high 
in these cells compared to the cNCCs closer to the neural tube, leading to 
hypophosphrylation of the microtubules. Down-regulation of genes in neural crest cells as 
they enter the branchial arches has been observed before; expression of both Slug and 
RhoB have been found to be down-regulated as cNCCs migrate further away from the 
neural tube [140]. Moreover RhoB and Slug have been implicated to be involved in 
delamination of the cNCCs from the neural tube [141, 142]. Interestingly a protein
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interaction survey has shown that RhoB interacts with PP2Ac [143]. This possible 
RhoB/PP2A interaction, along with the decreased number of Pax3 positive stained cells in 
the neural tube and down regulation of Midi as cNCCs migrate further from the neural 
tube, implies an involvement of Midi in EMT.
The Midi homologue, Mid2, can compensate for the loss of Midi in early embryo 
development [97], therefore to check that Mid2 was not being expressed in r4 cNCCs and 
that its expression was not in the r1/r2 migrating cNCCs or in r2 ISH were performed for 
Mid2. The results showed a low expression of Mid2 throughout the neuroepithelium and 
slightly stronger expression in the midbrain at 10ss. No expression was observed in the 
r4 cNCCs at 10ss, however there is some expression of Mid2 at 13ss in the r4 adjacent 
mesenchyme, although this appears to be possibly from the developing otic vesicle from 
the curved pattern of expression.
Western blots were carried out using total cell lysates from rhombomeres 2 or 4 that had 
been electroporated with either the experimental or control constructs as well as 
rhombomere 4s that had been exposed to OA. Although these constructs have been 
used in previous studies, no verification of the effect of these constructs on PP2A protein 
levels has been published. The changes in PP2A protein levels following electroporations 
were as expected, with reduction in PP2A protein following Midi construct electroporation 
and an increase in PP2A protein following DN-Mid1 electroporation in comparison to the 
control GFP electroporated tissues. Interestingly there was a reduction in the level of 
PP2A protein following treatment of rhombomere 4 tissue with OA, even more so than that 
of the Midi electroporated tissue. As OA is an inhibitor of PP2A it was unexpected that it 
would affect the level of protein and not just the protein activity. However as the OA 
appears to have reduced the level of PP2A and hence mimics the effect of Midi over­
expression it is therefore serving its intended purpose.
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Although PP2A has been shown to autoregulate in the presence of OA [144], this activity 
was not observed in the western blots presented here. This difference from previously 
published work could be attributed to the difference in the methods used, Baharians and 
Schonthal [144] maintained the cells in culture for 24-48 hours in the presence of OA, 
whereas in the present study the tissue was only exposed for 6 hours to OA before 
removal. The concentration of OA used here was also significantly lower, only 10nM in 
comparison to the 50nM used in the Baharians and Schonthal study. The autoregulation 
of PP2A may be a dose dependent response, therefore at the lower concentration shown 
here, PP2A autoregulation may not be triggered.
3.4.1. Neural crest and changes in Midi activity
Less Pax3 staining, and therefore less cNCCs, were observed within the neural tube 
following Midi construct electroporation. Furthermore a wider r4 cNCC stream was 
observed on the Midi electroporated side than the contralateral control side of the neural 
tube. These results imply that the Midi positive cNCCs are delaminating sooner than the 
control unelectroporated cells. This is backed up by the observations made when DN- 
Mid1 is expressed in r2 and its cNCCs, the cNCCs on the DN-MID1 electroporated side 
failed to migrate into the r2 adjacent mesenchyme. A likely explanation is that cells are 
not delaminating from the neural tube and expression of the DN-Mid1 is affecting
delamination, migration or EMT of the cNCCs. Together with the DN-Mid1 results, it can
therefore be concluded that Midi is likely to be involved in the delamination, migration or
EMT of the cNCCs from the neural tube.
The mechanism by which Midi affects the delamination, migration or EMT of cNCCs,
could either be by PP2A ubiquitination or microtubule stabilization, but it is most likely due
to the PP2A function. This is because it has been found in previous studies that when
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microtubules are destabilised there is an increase in EMT [145], however Midi has been 
shown to be responsible for the stabilisation of microtubules [109]. Therefore if this was 
the mechanism through which Midi affects EMT it should be expected that reduction in 
Midi activity would increase EMT as the microtubules would be less stable.
Cell death was considered as a possible reason for the decrease in cNCCs in the neural 
tube observed. The transcription factor Foxol has been found to be, expressed in 
migrating cNCCs of mice embryos; it has also been shown to be inhibited by 
phosphorylation upon inhibition of PP2A, which leads to a decrease in Foxol mediated 
cell-death [146]. Therefore Midi activity would be expected to increase cell survival, 
which would not explain the lack of cNCCs in the neural tube, and in addition no obvious 
differences were observed with the Apoptag staining following Midi electroporation of r4.
One possible mechanism through which changes in PP2A activity, by M id i, could lead to 
alterations in EMT is the BMP4 pathway as proposed by Granata [96]. As summarised in 
Figure 3-27, BMP4 has been shown to induce EMT in vitro [147] and further down the 
signalling pathway, Snail has long been known to induce EMT by repressing transcription 
of E-cadherin [148]. As Midi acts upstream of both BMP4 and Snail, an increase in Midi 
activity could therefore lead to an increase in BMP4 and Snail activity, which would then 
increase EMT, which is in line with the observations made here. During the course of this 
thesis several attempts were made to prove that changes in Midi activity were affecting 
EMT, through immunostaining wholemounts and sections for E-cadherin, Occludin and 
Claudin, however no working protocol could be found for these antibodies. Therefore no 
changes in tight junctions between the cNCCs in the neural tube could be studied. In 
conclusion Midi probably affects cNCC delamination or EMT through its PP2A 
ubiquitination function.
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Wnt
Fgf8
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Pax3
Msx1
Bmp4
Confocal sections of the neural tube
-  less Pax3 observed on Midi 
electroporated side
Snail
E-cadherin
EMT
Immunostaining of wholemounts and 
confocal sectioning using 
E-cadherin, claudin and occludin 
antibodies
-  results inconclusive
Immunostaining of wholemounts with 
cNCC marker HNK
-w id er r4 cNCC stream following 
Midi electroporation
Figure 3-27. M idi signalling cascade and induction of EMT
The Midi signalling cascade as outlined by Granata [96] [shown here in pink boxes) and 
Monsoro-Burg [149] [shown in blue boxes). The experiments tried over the course of this 
PhD, and their outcomes, to address points of the cascade are shown in yellow boxes.
3.4.2. PP2A and its affect on ganglia development
The results shown here provide evidence that PP2Ac activity plays a role in cranial
ganglion development. Increases in the level of active PP2Ac by decreased Midi leads to
delayed trigeminal ganglion development, while an increase in Midi activity or OA
exposure, and therefore a decrease in PP2Ac, leads to premature development of the
geniculate ganglia. In order to test the path through which Midi is acting OA was used to
treat cNCCs at the same stage of development as the Midi construct was electroporated
into cNCCs of r4. Okadaic acid is an inhibitor of PP2A [150], therefore if Midi is acting
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through its PP2A ubiquitination function, application of OA would be expected to mimic the 
premature ganglia formation observations. Indeed the OA did mimic Midi electroporation, 
confirming that Midi is most likely acting through its PP2A ubiquitination function.
As cells of the placode form much of the geniculate ganglia [72], and cNCCs are required 
for the correct migration of the placodal cells from the geniculate placode to the point of 
ganglia formation [80], it was hypothesised that the PP2Ac inhibited/decreased r4 cNCCs 
may have changed their behaviour somehow, perhaps through a change in secretions, 
and therefore initiating placode migration prematurely. Using a method similar to that of 
Begbie and Graham 2001 [80], the placodal cells were labelled with a lipophilic 
fluorescent dye, the results showed that more cells of the placode were prematurely 
migrating towards the ganglia site on the Midi electroporated/OA treated side compared 
to the contralateral control side. Therefore it can be deduced that the cells of the placode 
are in fact the cells forming the premature ganglia.
3.4.3. Regulation of protease activity by Midi
There are a few ways that the increased Midi in r4 cNCCs may initiate placodal cell
migration. First the cNCCs may be migrating faster and the increased numbers of cNCCs
in the vicinity of the placode may be enough to initiate migration. Secondly as MMPs are
required for cNCC detachment from the neural tube [88], it is possible that changes in
MMP activity by altering Midi expression could be leading to the increased migration of
the cNCCs and also the premature breakdown of the sub-placodal basement membrane
and subsequent detachment of the cells of the Placode. The increased protease activity
could also be the reason for the increased EMT from the neural tube, as observed with
the Pax3 staining, possibly by breaking down the cell-cell contacts, between premigratory
NCCs. Therefore if there is an increase in MMP activity the basal lamina of the placode
may be broken down sooner, which means the placodal cells would be able to migrate
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away from the placode earlier. It was observed that there was an increased breakdown of 
the basal lamina at the placode and the following premature influx of placodal cells from 
the placode confirmed that changes in MMP activity may well be involved in the premature 
migration of the cells of the placode.
Furthermore the time-lapse results on different substrates gave indication that both cell 
speed and changes in MMP activity may well be involved in the premature ganglion 
development. As different MMPs have different substrate specificities the multiple time- 
lapse observations on collagen, fibronectin, laminin and PLL were used to try to narrow 
down possible candidates. PLL was used as a control as protease activity will not affect 
it, and although no real changes in cell speed were expected, there were some significant 
increases in cell speed following OA exposure. This suggests that there are also changes 
in cell motility following PP2A inhibition, which has been observed before [112]. A 
possible explanation for this finding is that BMP4 is up-regulated by OA, as has been 
observed in Xenopus [151], which leads to an increase in cell motility [147]. Although this 
mechanism could be involved here, the changes in cell motility are not as striking on PLL 
as on the other substrates or on r2 cNCCs. Therefore changes in MMP activity could be 
the main change in cNCC properties upon OA exposure, leading to premature ganglia 
development, rather than cell motility.
Of the known MMPs and their substrates, one is known to digest all 3 of collagen, 
fibronectin and laminin, this is MMP10 in chick, and its orthologue in human and rodents, 
MMP3 [152]. Interestingly MMP3 has been shown to be upregulated in the presence of 
OA in fibrosarcoma cells [153]. It is viable that the observations in the time-lapse studies 
may not be due to one MMP alone but a combination of several proteases or related 
proteins. Therefore RT-PCRs were performed to look at the expression levels of different
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MMPs and related proteins that were candidates for changed expression, which were 
chosen due to known expression at this stage of development.
AdamIO has been found to be expressed in avian neural crest cells [85] and has been 
shown to be involved in the breakdown of N-cadherin, which in turn stimulates neural 
crest delamination from the neural tube [154]. Therefore an upregulation of AdamIO, as 
observed in the RT-PCR results, would be expected to increase cNCC emigration from 
the neural tube, such as that observed following Pax3 staining of the neural tube following 
Midi expression.
MT1-MMP is expressed in the cranial neural crest tissues in Xenopus [86] and in cardiac 
neural crest cells in chick [83] and its substrates are both laminin and collagen. Timp2 is 
expressed in migrating cardiac neural crest cells, but not the cNCCs from r2 or r4, it is 
also expressed in the neural tube in rhombomeres 5 and 6 [83]. MT1-MMP, along with 
low levels of Timp2, is responsible for the cleavage and subsequent activation of MMP2, 
which in turn promotes migration of the cNCCs [83, 92], an absence of Timp2 action with 
MT1-MMP leads to decreased NCC migration [83]. A high level of Timp2 inhibits the 
action of MT1-MMP [155] and therefore reduces the amount of active MMP2 which would 
then decrease migration. Therefore there must be a delicate balance between having a 
low level of Tlmp2 required for MMP2 activation and then too low or too high a level of 
Timp2 leading to a lack of NCC migration. There was little change observed in the 
expression of MT1-MMP in the RT-PCR, however there was a decrease in the expression 
level of Timp2, therefore predicting an increase in MMP2 activity which would increase 
migration. This is in line with the observations made by the time-lapse studies in vitro. 
Although it has been observed that a low level of Timp2 prevents cardiac NCC 
delamination [83], an increase in AdamIO may be able to compensate for the Tlmp2 
action. Furthermore the level of Timp2 may have to be extremely low for it to have a
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delamination inhibiting effect, as the previously recorded data was seen using a 
morpholino to knockdown expression, and there is still a reasonably detectable level of 
Timp2 detected using RT-PCR.
MMP10 was an obvious candidate due to its ability to digest all 3 substrates used in the 
time-lapse experiments. The transcription factor Mef2 is expressed in the neural tube of 
mice embryos at E9.5 (21-29ss) [156] and appears to be in chick cranial mesenchyme at 
the level of r2 and r4 at 16ss [157], as Mef2 is able to directly activate expression of 
MMP10 [158], it is possible that MMP10 is also expressed at this stage in the neural tube. 
This was confirmed by the RT-PCR results, showing MMP10 expression without OA, and 
undetected MMP10 following OA exposure. MMP10 has been shown previously to 
enhance migration in keratinocytes in mice, therefore it would be expected that an 
increase in MMP10 would be observed following OA exposure to increase cell migration. 
However MMP10 does not have to be the effective MMP in this case, other MMPs may be 
the responsible proteins for the observations made in vitro.
The results of the in vitro time-lapse analysis in the presence of OA and the subsequent 
RT-PCR results give strong evidence that Midi has a role in regulating MMP expression 
and this may be related to the observed changes in NCC speed in ovo and in vitro. 
These observations raise the possibility that PP2Ac plays a similar role in other cell type 
migration, cell fate, invasiveness and protease activity [159]. In other tissues or stages of 
development, PP2Ac activity could be regulated in other ways, such as by growth factors. 
Previous work has shown that growth factors are able to phosphorylate PP2A leading to 
transient loss of activity [160]. Overall these changes in protease activity levels could be 
the mechanism by which Midi controls the development of craniofacial structures as it is 
present at the stage of craniofacial tissue remodelling.
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3.5. Conclusions
The spatio-temporal expression and functions of Midi in the hindbrain during 
development have until now been unclear. The data shown here provides evidence that 
Midi is not only expressed in the hindbrain but also in the migrating cranial neural crest 
cells in the r1/r2 adjacent mesenchyme. Midi appears to be responsible for maintaining 
the correct cell speed of the cNCCs and also is involved in the secretion of MMPs, which 
may be important in both EMT from the neural tube and also in breakdown of the basal 
lamina at the placodes. The results also show that the function through which Midi is 
having these effects is probably by its PP2A ubiquitination function and not through 
stabilisation of the microtubules. This work provides evidence that PP2Ac activity 
regulation is important for correct cNCC migration and cNCC developmental cell biology. 
Overall these data provides evidence for an important role in the correct migration of the 
cranial neural crest and also in the development of the peripheral nervous system at the 
very first stages of its initiation.
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3.6. Future work
The data provided here depicts many novel findings; however there are several lines of 
research that remain open for further investigation. Firstly it would be interesting to 
perform some real-time RT-PCRs on the proteases; this approach would allow further 
insight into the levels of increases or decreases in the expression level of these proteins 
necessary to provide a phenotype caused by OA exposure or Midi construct 
electroporation. Following this, further artificial mimicking of the MMP changes observed 
here, by RNAi or expression constructs, in order to see if this would also produce the 
same observed changes in peripheral nerve development, would further elucidate the 
involvement of each individual MMP or combinations of the MMP proteins.
In order to further understand the possible effect of OA or Midi expression level changes 
on EMT or emigration of cNCCs from the neural tube and also sub-placodal basal lamina 
breakdown it would be beneficial to perform time-lapse confocal microscopy on sections 
of embryos in culture. A method has been developed by Wilcock and Swedlow [161] 
allowing slices of embryos to be cultured and studies by time-lapse, which would allow 
tracking of neural crest cells as they go through EMT or would allow interactions between 
cNCCs and the placode to be monitored. Therefore any changes in how the cells behave, 
such as morphology or cell-cell interactions would be able to be clarified.
It would also be beneficial to confirm the breakdown of the basal lamina in Midi 
electroporated embryos at a later time point. At 16ss no obvious differences were 
observed in the breakdown of the basal lamina, especially when compared to the OA 
treated embryos. This could be due to the possibility that OA can act immediately, 
whereas Midi needs more time to be expressed before it can be active
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Use of a Mid2 construct to express Mid2 in r4 cNCCs would also be interesting, other 
studies have demonstrated the functional redundancy between the Mid proteins in other 
situations, it would be interesting to see if Mid2 can also mimic Midi in these 
circumstances.
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4. Elucidation of the tissues responsible for retinoic 
acid-mediated defects in the migration pattern of 
cranial neural crest cells
4.1. Introduction and aims
It has been well documented that the hindbrain neural tube, the cranial mesenchyme and 
the surface ectoderm, each provide essential patterning information to direct the migration 
of cranial neural crest cells (cNCCs) (See Figure 1-2, section 1.3). When any of these 
patterning cues are disrupted, normal cNCC development, survival, migration and cell fate 
can be affected, resulting in craniofacial deformities [1]. An example of environmental 
effects which can lead to cNCC patterning disruption is retinoic acid embryopathy, 
pregnant ladies given a retinoid containing treatment for acne gave birth to babies with a 
range of congenital defects, such as cleft lip/palate, which can be caused by underlying 
cNCC defects [44].
Exposure of a developing embryo to retinoic acid (RA) can cause cranial neural crest cells 
to mismigrate (see section 1.6). When chick embryos are globally exposed to RA, crest 
begins to mismigrate into r3 mesenchyme and in 65% of embryos the r4 crest stream and 
the r2 crest stream are joined in a Typel phenotype (Figure 1.5). A localised injection of 
RA into only r4 also induces a Typel phenotype (in 54% of embryos) and causes the 
ectopic expression of Krox20 in r4, thus causing r4 to take on a more r3-like identity [45]. 
Injections of RA into r3 have no detected effect on crest patterning. Although the neural 
tube was the target of RA application, in the experiments quoted above, but it is by no 
means clear which tissue(s) are involved in responding to RA, to cause cNCC 
mismigration and, for this reason, I chose to focus on elucidating the tissues responsible 
for RA-induced cNCC migration defects.
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Previous work has described tissues that are required for maintenance of a correct cNCC 
migration pattern (Figure 1.5). Removal of r3 or removal of the r3 surface ectoderm 
before cNCC migration leads to cNCCs incorrectly migrating through the mesenchyme 
adjacent to r3 in a Typel phenotype [7]. Moreover several molecules, which are 
expressed within r3, have been identified as being essential for correct cNCC patterning, 
including ErbB4 [17, 24] and Cyp26s [68, 162]. However, although ErbB4 and Cyp26s 
have been identified as being involved in cNCC migration patterning, little more is known 
about how r3 is involved in cNCC migration patterning or the specific effectors.
ErbB4, a member of the EGF family of receptor tyrosine kinases, is required during 
development for axon and neural crest guidance and, in the hindbrain, is expressed in r3 
and r5 [22, 23]. Furthermore previous work has shown that RA exposure can alter the 
expression levels of ErbB4 in breast carcinoma cells in vitro [163]. An ErbB4 ligand, 
neuregulin (NRG), is expressed in the developing chick hindbrain in r4 [22, 23]. This 
spatial arrangement of ligand and receptor suggests it is highly likely that interactions 
occurring between these rhombomeres activate the ErbB4 receptor. Loss of ErbB4 
receptor activation leads to Typel crest mismigration, with r4 cNCCmigrating through r3 
mesenchyme to join the r2 cNCC stream as demonstrated by, a) the dominant negative 
loss of ErbB4 signalling in chick r3 [17], and b) absence of ErbB4 in knockout mice (Box1) 
[24]. ErbB4 is not expressed by cNCCs and the absence of ErbB4 or ErbB4 signalling 
alters the environmental signals to which migrating NCCs respond. Thus when wild-type 
r4 NCCs are transplanted into ErbB4 knockout mice, they still mismigrate. Conversely, 
when ErbB4 knockout cNCCs are implanted into a WT mouse r4, they migrate normally 
[24].
When the RA catabolizing enzyme, Cyp26C, is knocked out in mice, the NCCs show a
Typel phenotype, similar to that seen in the absence of ErbB4 [164], suggesting that
ErbB4 and Cyp26C may be in the same pathway. Although r4 does not express
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detectable Cyp26C, it is produced in a segmented pattern within the r3 and r5 
mesenchyme [67], and could therefore have a role in the maintenance of these crest-free 
zones. RA is also able to regulate the expression of the Cyp26 genes, down-regulating 
Cyp26C [165]. If Cyp26C is involved in preventing crest from entering r3 mesenchyme 
then its downregulation could make r3 mesenchyme less inhibitory to NCCs.
Because the observed cNCC mismigration patterns fit into two types (categorised in this 
thesis as Typel or Type 2 defects (Figure 1.5), the work presented in this chapter aims to 
investigate the tissues involved in responding to RA which then leads to a Typel 
phenotype. Furthermore this work aims to further elucidate if there is a common 
mechanism involved in Typel phenotypes.
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4.2. Results
4.2.1. Effects of retinoic acid on the neural tube and patterning 
neural crest cell migration
All-trans retinoic acid (at-RA), a well known teratogen [43], has been previously shown to 
cause cNCC mismigration, depicting a Typel phenotype [45, 166]. The aim of this study 
was to better define which tissues respond to RA to give the Typel mismigration 
phenotype and whether identifying these tissues could provide further information about 
common signalling pathways underlying this phenotype.
4.2.1.1. Optimising retinoic acid delivery and dose
Initially the method employed by Gale and Prince [45] was used, at-RA and Dil were co­
injected unilaterally into the dorsal part of r4, where the premigratory cNCCs reside, at 
10ss and the eggs were incubated for a further 24 hours. Dil is a lipophilic fluorescent dye 
that incorporates into the cell membrane allowing cNCCs to be tracked as they migrate 
away from the neural tube into the mesenchyme. The use of Dil allowed single cells that 
had mismigrated to be visualised, however the Dil labelling was variable and did not 
consistently label the entire cNCC population, as confirmed by subsequent Sox10 ISH 
processing of the embryos. The Sox10 ISH allowed the majority of the cNCC population 
to seen and allowed robust aberrant migration to be seen, but it was not possible to see 
individual ectopic cNCCs. Sox10 ISH was used as the basis for determining whether 
NCC mismigration had occurred, with Dil being used as an indication of correct injection 
site targeting and providing a backup for the Sox10 data. The concentrations of at-RA 
initially used were 10mM and 20mM, chosen because 16mM at-RA was used by Gale and 
Prince. However, neither concentration used replicated their findings of 55-65% NCC 
mismigration. Instead a very infrequent 4.2% (n=24) partial Typel at 20mM and no
phenotypes at 10mM (n=9) (Figure 4-1) were observed. The mismigration phenotypes
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observed were either catagorised into either partial or full Tpe1 phenotypes, the partial 
Typel shows cNCCs migrating into r3 adjacent mesenchyme from the r4 cNCC stream, 
but not all the way to the r2 cNCC stream. A full Typel phenotype was recorded when 
the cNCCs were seen to have joined the r2 and r4 cNCC streams in a thin band through 
r3 mesenchyme. Therefore the concentration of injected at-RA was increased to 50mM, 
although this is a very high concentration of at-RA to be using in comparison to other 
studies, it was a test to see if this method of injection could work. Even at this high 
concentration the rate of incidence of a Typel phenotype was only 22.5% (n=27). There 
are a number of reasons why this method may not have been effective. Firstly the RA 
may kill the cNCCs in the surrounding area or reduce their ability to delaminate [167,168]. 
Secondly, the at-RA could be leaking out of the injection site, and so not be present for 
long enough to have an effect. Finally it is likely that variable volumes of the at-RA were 
injected into each embryo, this most likely the case for other published RA injection data 
too, as the same method is used and no indication of volume is given.
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50mM
injection
1mM
bead
RA delivery 
method
Concentration of 
RA
Total number of 
sides w ith a 
phenotype %
Embryo sides with  
a partial type 1 
phenotype { % )
G-test
Significance
Injection 50mM 6/27(22.2) 5/27(18.5) Yes
Injection 20mM 1/24(4.2) 1/24(4.2) Yes
Injection lOmM 0/9 (0.0) 0/9 (0.0) Yes
Bead -  F 16mM 4/12(33.3) 4/12(33.3) No
Bead-H lOnM 6/16(37.5) 5/16(31.3) No
Bead -  F Im M 3/8 (37.5) 3/8 (37.5) No
Figure 4-1 Neural Crest Cell Migration patterning defects following all-trans retinoic 
acid exposure.
Exposure of r4 to RA by either injection (50mM RA, A-D same embryo) or RA soaked beads 
(Im M  RA formide bead, E-H same embryo) at the lOss. The migration pattern of the NCCs 
were tracked by both Dil labelling of the cells at lOss (A,B,E,F), and by subsequent processing 
by ISH for the NCC marker SoxlO (Blue, C,D,G,H). Table I shows the percentage occurrences 
of a Typel mismigration phenotype, G-test of association was used to determine significance. 
(G=3.8, p<0.05, d.f.=l). Dotted grey line -  bead placement. Arrows indicate mismigrating 
cNCCs. Bead types, F-formamide, H-hydroxide.
As there was a poor rate of cNCC mismigration phenotypes observed with the injection
method, an alternative method of RA delivery to the neural tube was used, by an ion-
exchange resin bead soaked in RA. The method of utilising a bead soaked in RA for
hindbrain implantation has been used previously [169], but not to study the migration
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pattern of cNCCs. It has been shown that this delivery method gives a slow release of the 
different RA isoforms [101]; it would be anticipated to give prolonged and focussed 
exposure of the tissue to the RA as opposed to the injection of RA, which might have 
been able to more rapidly diffuse away from the injection site. As this method was likely 
to give a more prolonged exposure, lower concentrations of at-RA were tested, from 
16mM down to 1mM. Two types of bead were also used, a formamide and a hydroxide 
ion-exchange resin bead. The hydroxide form of the bead has been used in previous 
studies where RA bead implants have been utilised [101, 170-172]. The formamide form 
of the bead more readily releases the negatively charged compounds it is loaded with 
(e.g. RA) in comparison to the hydroxide form of the bead [173]. As beads are placed 
centrally in the neural tube, both sides of the embryo should receive the same dose of RA, 
therefore each side of the embryo was treated as an individual experiment. It was found 
that hydroxide beads loaded with 10mM at-RA (n=16 sides, 8 embryos) or the formamide 
beads loaded with 1 mM at-RA (n= n=16 sides, 8 embryos) both gave 37.5% of embryo 
sides showing a partial or full Typel phenotype (Figure 4-1). Some embryos showed a 
bilateral response to the RA beads, this could have been due to beads moving towards 
one side of the rhombomere as the neural tube expands during growth. Increasing the 
concentration of at-RA to 16mM gave only 33.3% (n=12 sides, 6 embryos) of embryos 
showing a Typel phenotype, suggesting that there could be a threshold above which a 
higher RA concentration does not necessarily result in a higher proportion of embryos with 
a Typel cNCC migration defect. Previous work has also shown that high concentrations 
of RA can inhibit cNCC migration [174]. This could be a factor here too, if the highest 
levels of RA prevented the cNCCs from emigrating from the neural tube and therefore 
prevent them from showing a Typel phenotype even though they are affected by the RA.
These results show that the two administration routes lead to different results even when
the same concentration of RA is used. The injections show a dose-response to the RA
and are likely to give a high immediate dose, but then the effective dose decreases as the
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RA leaches away from the injection site, which could mean the RA is free to affect tissues 
other than that targeted. The beads however give a better frequency of a Typel 
phenotype at a lower concentration, presumably due to a longer, more constant release of 
RA to the targeted area than the injections.
4.2.1.2. Multiple retinoic acid isoform effects on cranial
neural crest migration patterning
Within a few minutes of UV or white light exposure, at-RA is photo-converted to other 
retinoid isoforms, including the biologically-active 9-cis RA and 13-cis RA [175], eventually 
producing a mix of at--RA (25%), 9-cis-RA (10%), 11-cis-RA (10%), 13-cis-RA (30%) and 
9,13-di-cis-RA (5%) after 30 mins of light exposure [176]. Therefore, it is likely that 
several isoforms of RA were present in previously published work using at-RA, even if in 
small amounts, since few studies state the lighting conditions under which the 
experiments were performed. Because these different RA isoforms can stimulate a wider 
repertoire of receptors than at-RA, they could potentiate the overall RA signal or produce 
a different array of phenotypes.
In this work, care was taken to use yellow filtered cold light at every stage of RA 
administration and live embryo manipulation, greatly reducing the possibility of 
photoconversion to different RA isoforms. A lower proportion of embryos with NCC 
mismigration phenotypes was found here than in published studies, which suggests that 
at-RA may not be the most effective RA isoform in initiating cNCC mismigration in r4 and 
that much of the mismigration effect could be caused by RA photoconversion products. 
In order to investigate whether photoconverted RA gave a more robust NCC mismigration 
phenotype, 50mM at-RA was exposed to strong daylight for 8 hours in order to cause 
breakdown into other forms. Light-exposed RA was used to inject r4 in 10ss embryos. It 
was found that the injections of 50mM light-exposed at-RA gave a much higher proportion
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of embryos with a Typel phenotype, 71.4% (n=7, not significant G-test), than had been 
observed using injections of 50mM at-RA (22.5%, 6/27 embryos).
4.2.1.3. Effects of the 9-cis retinoic acid isoform on the 
observed rate of a Typel phenotype
As light-exposed RA showed a higher proportion of Typel phenotypes when injected into 
r4, the question is if another isoform of RA could be involved in the mediation of a Typel 
phenotype. There has been a lot of previously published work to show that the 9-cis 
retinoic acid isoform is biologically active [59]. Furthermore it is possible that different 
receptor activation may affect the frequency of a Typel phenotype occurring, the 9-cis 
isoform of RA has been reported to bind with a high affinity to the RXR receptor, one that 
at-RA does not (see section 1.6.3). In order to investigate whether 9-cis RA could be 
more effective than at-RA in inducing a cNCC patterning defect, 9-cis RA was 
administered to r4, by either injection or beads, to give a comparison with the at-RA 
results.
It was found that the beads again gave better results than the injections, which gave only 
a 33.3% occurrence at best compared to 58.3% observed using the beads, both beads 
and injections at a 50mM concentration (Figure 4-2). At lower concentrations, 9-cis RA 
caused a phenotype in 23.5% of embryos at 1 mM and in 20.0% of embryos at 1.6mM on 
formamide beads (Figure 4-2). This incidence was lower than that observed with the at- 
RA at the same concentration, however at higher concentrations 9-cis RA was much more 
effective. This difference may be due to 9-cis and at-RA having different receptors and/or 
different binding affinities to the RXR and RAR receptors. Furthermore at high 
concentrations it is possible that 9-cis RA has a greater effect on RAR receptors, as 9-cis 
can bind to both RXR and RAR, although its interaction with RAR is at a much lower 
affinity than with RXR [59].
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1.6mM hydroxide bead 1mM formamide bead
E
RA delivery 
method
Concentration 
of RA
Total number of 
sides with a 
phenotype (%)
Embryo sides with  
a partial type 1 
phenotype (%)
G-test
Significance
Injection 50mM 4/12(33.3) 4/12(33.3) No
Injection 1.6mM 0/5 (0.0) 0/5 (0.0) Yes
Bead-H 1.6mM 4/20(20.0) 4/20(20.0) Yes
Bead-F 50mM 7/12(58.3) 7/12(58.3) No
Bead -  F Im M 8/34(23.5) 7/34(20.6) Yes
Figure 4-2. Neural Crest Cell Migration patterning following 9-cis retinoic acid 
exposure.
Rhombomere 4 exposure to 9-cis RA from hydroxide beads soaked in 1.6mM RA (A,B) or 
formamide beads soaked in ImM RA (C,D) at the lOss. The migration pattern of the NCCs 
were shown by ISH for the NCC marker SoxlO (Blue A-D). Table E shows the percentage 
occurrences of a Typel mismigration phenotype in injected and bead-treated embryos G-test 
of association was used to determine significance. (G=3.8, p<0.05, d.f.=l). Dotted grey line -  
bead placement. Arrows indicate mismigrating cNCCs. Bead types, F-formamide, H- 
hydroxide.
4.2.2. Exposure of r4 cranial neural crest cells to retinoic acid 
affects their migration pattern
Although previous work has focused on the effect of RA on the neural tube, injections of 
RA can probably leak out of the injection site, therefore other neighboring tissues could be 
affected by RA, and so could be involved in cNCC migration patterning. The cNCCs 
themselves, the mesenchyme, or the surface ectoderm could each be responding to RA.
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4.2.3. Cell autonomous control of cNCC migration pattern
As the cNCCs are the cell type showing a mismigration phenotype, an experiment to
assess the effects of RA on cNCCs, rather than the neural tube was devised; this involved
exposing just the cNCCs of r4 to RA. As 9-cis RA and at-RA both can cause a Typel
phenotype and both have different nuclear receptors, a mix of both isoforms of RA was
used, in an attempt to achieve the highest impact on the cNCCs. The dorsal part of r4,
containing the premigratory cNCCs, was removed at 10ss and then incubated in a mix of
1pM at-RA and 1pM 9-cis RA for 1 hour, before reimplantation back into a host embryo.
The embryos were then incubated for 24 hours before viewing. The RA media in which
the dorsal r4 tissue was incubated contained a green tracker dye, and the host embryo
cNCCs were labelled with a red tracker dye 30 mins before removal of its dorsal r4 and
implantation of the donor tissue, therefore the host neural tube and cNCCs appear red
and the donor RA treated cNCCs green. Embryos that had the RA-treated tissue
implanted showed a weak Typel phenotype (3 out of 7 embryos). Furthermore not only
had the green cells mismigrated, some of the red labelled donor cells had also followed
the same migration pattern (Figure 4-3). The control embryos, transplanted with vehicle-
only-treated r4, showed no migration patterning defects (4 out of 4 embryos). As RA has
the ability to affect the identity of rhombomeres, embryos were further processed by ISH
for the r3/r5 marker Krox20. Interestingly 4 out of 6 embryos that had been transplanted
with at-RA-treated r4 showed reduced or absent Krox20 expression in r5, although r3
Krox20 expression was unaffected (Figure 4-3C). Embryos transplanted with vehicle-
only-treated r4 showed no changes in Krox20 expression (Figure 4-3G). This raises the
question of whether the RA-treated transplanted tissue acted like a slow-release bead and
affected surrounding tissues, or whether the results were due to direct effects on the
cNCCs. In relation to the bead experiments, the proportion of embryos displaying a
Typel phenotype was higher (42.8%) than the 1mM at-RA (37.5%) or 1mM 9-cis RA
(23.5%) beads. Although the concentration used was 1000-fold lower (1pM as opposed
to 1 mM), the tissue was being incubated in it directly, therefore the RA, did not have far to
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diffuse to reach all cells. Furthermore, the proportion of embryos with a phenotype could 
be higher because a mix of at-RA and 9-cis RA was used, meaning that the effect could 
also be more potent. Overall it is difficult to compare these results to the beads because 
different concentrations and a mix of isoforms were used.
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Figure 4-3. Effects on migration of neural crest cells exposed to retinoic acid.
The dorsal half of r4 was removed at lOss and incubated in lpM  at-, 9-cis mixed RA, before 
reimplantation into a host lOss embryo at the level of r4. A-E shows an embryo implanted 
w ith RA-treated r4, F-H shows an embryo implanted with a control non-RA-treated r4. The 
donor tissue was labelled with a green tracker dye (A, F) and the host tissue and NCCs w ith 
Dil (red, B), C shows an overlay of A and B. After 5 hours the green donor cells that were 
exposed to RA had migrated into the r3 mesenchyme (n=3/7). Embryos were subsequently 
processed by ISH for Krox20 (red-orange) on both the RA experimental embryo (D,E) and a 
control embryo (G,H), green shows residual green tracker dye indicating placement of the 
transplanted tissue. RA-treated r4 embryos showed a reduced or absent expression of 
Krox20 in r5(n=4/6). Arrows indicate mismigrating cNCCs. GFP controls n=4/4
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4.3. Control of cranial neural crest migration patterning by 
the mesenchyme
The results described in the previous section indicate that it is possible that the cNCCs 
are directly affected by RA. If so, this evidence supports the theory that other tissues than 
the neural tube can be affected by RA to cause the Typel phenotype. As the 
mesenchyme and surface ectoderm are situated adjacent to the neural tube, these could 
both be exposed to RA upon injections or bead placement. Both the mesenchyme and 
the surface ectoderm contain patterning information for r4 cNCCs and in the absence of 
these cues a Typel phenotype is seen [7] (see section 1.5), and these tissues could be 
involved here by reacting to RA exposure. In order to further investigate which tissues 
respond to RA to give the cNCC mismigration phenotype, resin beads soaked in at-RA or 
9-cis RA were placed in the mesenchyme at different locations (Figure 4-4). By placing 
the RA beads at different positions relative to the r4 cNCC stream, the effective dose of 
RA to different tissues could be investigated. First of all beads soaked in RA were placed 
in the r3 adjacent mesenchyme, as this is close to the r4 mesenchyme and r4 cNCCs 
without interfering with the cNCC migration physically. RA-soaked beads were also 
placed in the r5 adjacent mesenchyme, in theory RA that diffuses from beads in this 
position would mainly affect the cNCCs of the r4 stream and would not be able to affect 
the mesenchyme adjacent to r3 as efficiently. Beads were also placed in the r2 
mesenchyme, the premise being that the RA would be able to affect the r3-adjacent 
mesenchyme, but not the r4 cNCCs as successfully (Figure 4-4).
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A B C
Figure 4-4. Schematic diagram depicting the different RA bead positions in the 
mesenchyme.
This diagram shows the hindbrain from rhombomeres 2 to 5 (blue) and the adjacent 
mesenchyme (pink). The hypothetical concentration gradient of RA from the bead (red) is 
shown by the hazed red area when the bead is placed in the r3 (A), r2 (B) and r5 (C) adjacent 
mesenchyme.
Embryos had either a hydroxide or formide RA-soaked bead implanted into the r3- 
adjacent mesenchyme at stage 10 and then were incubated for 24 hours, before 
processing by ISH for Sox10. When hydroxide ion exchange resin beads soaked in 1mM 
at-RA were placed in the r3 mesenchyme, an unusual cNCC migration pattern was 
observed (Figure 1-1 A-C). The r4 stream of cNCC appeared to be split in two rostro- 
caudally (60%). However when the formide ion exchange resin beads soaked in 1 mM at- 
RA were implanted into the r3 mesenchyme, a Typel phenotype was observed (Figure 
1-1,D 55.6%). This effect was still observed at lower concentrations of at-RA formide 
beads (Figure 4-5, E,F); at 10pM and 1pM the rate of incidence of a Typel phenotype 
were 28.6% and 35.7% respectively. As 1pM 9-cis RA had shown to be effective at 
causing cNCC mismigration when the neuroepithelium was exposed to it, 1pM of 9-cis RA 
was also used to soak formamide beads and implanted into the r3 mesenchyme. 
Interestingly this gave a very robust phenotype with 80% occurrence (4/5 embryos), 60% 
of which were full Typel phenotypes, compared to neural tube exposure of 7.1% of the
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1pM at-RA on the same bead type (Figure 4-5 K). These data suggests that the 
mesenchyme is actually the primary tissue responding to RA to give a Typel phenotype, 
if this is the case, then the RA targeting to the neural tube gave better results at higher 
concentrations due to leakage of the RA into the mesenchyme, which then affected cNCC 
migration patterning, rather than the neural tube having a direct effect.
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r3-adjacent 
mesenchyme 
bead - Hydroxide
r3-adjacent 
mesenchyme 
bead - Formamide
r2 or r5-adjacent 
mesenchyme 
bead - Formamide
J
Total number of Embryo sides with a
Mesenchyme Concentration sides w ith a partial type 1 G-test
Area of 9-Cis RA phenotype (%) phenotype (%) Significance
r3 lpM (F ) 4/5 (80.0) 1/5 (20.0) No
r2 lpM (F ) 0/5 (0.0) 0/5 (0.0) No
r2
10pM (F) mix 
with all-trans RA
1/6(16.7) 0/6 (0.0) No
r5 lpM (F ) 1/2 (50.0) 1/2 (50.0) No
K
Mesenchyme
Area
Concentration 
of all-trans RA
Total number of 
sides with a 
phenotype (%)
Embryo sides w ith a 
partial type 1 
phenotype (%)
G-test
Significance
r3 Im M  (F) 5/9(55.6) 4/9 (44.4) No
r3 lOpM(F) 2/7 (28.6) 2/7(28.6) No
r3 lpM (F ) 5/14(35.7) 4/14(28.6) No
r3 Im M  (H) 3/5 (60.0) Type2 like 0/5 (00.0) No
r2 lpM (F ) 1/6(16.7) 1/6(16.7) No
r5 luM (F ) 0/6 (0.0) 0/6 (0.0) No
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Figure 4-5. Neural Crest Cell Migration patterning following targeted exposure of the 
mesenchyme to retinoic acid.
The mesenchyme was targeted at different levels by implantation of a RA-soaked bead into 
the tissue at the 10 somite stage. Hydroxide beads soaked in ImM at-RA implanted into the 
r3 mesenchyme (A-C) resulted in a unique cNCC migration phenotype, whereas formamide 
beads soaked in ImM (D) or lpM (E,F) at-RA gave the Typel phenotype. F-control side of E. 
The r2 (10pM concentration of each at— 9-cis RA mix, G) and r5 (lpM  at-RA, H,I) were also 
targeted The NCCs were visualised by either ISH for soxlO (blue, A-F) or by Dil labelling at 
the time of bead implantation. Tables J and K show the frequency of a Typel phenotype with 
either 9-Cis RA(J) or at-RA (K) and different bead placements, G-test of association was used 
to determine significance. (G=3.8, p<0.05, d.f.=l). Dotted circle -  bead placement. Arrows 
indicate mismigrating cNCCs. Bead types, F-formamide, H-hydroxide.
When beads soaked in either 1 pM 9-cis or at-RA were placed in the mesenchyme next to 
r5, the at-RA showed no effect in this position, whilst the 9-cis RA showed 1 out of 2 
embryos with a weak Typel phenotype (Figure 4-5). In the mesenchyme adjacent to r2 
beads of 1pM at-RA showed a 16.7% Typel occurrence, but beads soaked in 9-cis RA 
had no effect. As a preliminary experiment, a 10pM mix of at-RA and 9-cis RA was 
loaded onto formamide beads and placed into the r2-adjacent mesenchyme; this should 
theoretically activate both the RAR and RXR receptors, giving a more effective response. 
The rate of occurrence was not too high at 16.7% (n=6), but the migration pattern 
observed was extremely strong (Figure 4-5 G), hence in order to get a more robust 
phenotype perhaps a mix of 9-cis and at-RA should be used. Although it is worth noting 
that the concentration of each RA isoform was 10 times higher than used on beads loaded 
with only one isoform. With regards to the bead placement, it appears as though the 
mesenchyme of r3 may respond most strongly to RA. Although it is possible that the 
cNCCs may still respond directly to the RA, to aid in producing a Typel phenotype, their 
response is probably not as strong as the mesenchyme response.
159
4.4. Changes in Cyp26 expression patterns following 
removal of r3
The Cyp26 group of retinoic acid metabolising proteins, Cyp26A, Cyp26B and Cyp26C 
are all expressed in the developing head (See section 1.6.3.2). A study by Uehara in 2007 
[68] showed that Cyp26A-Cyp26C double knockouts have a Typel phenotype. Cyp26C, 
which is expressed in the r3 mesenchyme, is down-regulated by at-RA, whereas Cyp26A 
is upregulated by at-RA [165]. As Cyp26A and Cyp26C expression can be altered by at- 
RA, and Cyp26C is expressed in the r3 mesenchyme, it follows that they and other 
mesenchyme-expressed genes could be involved in maintenance of the r3 mesenchyme 
cNCC free zone. If, in the absence of r3, Cyp26C expression is no longer maintained in 
r3-adjacent mesenchyme, then the local level of RA would increase. The data presented 
here indicate that locally high levels of RA in r3-adjacent mesenchyme cause a Typel 
phenotype. Therefore, Cyp26 expression in response to unilateral r3 removal was 
investigated, in order to determine if Cyp26 might be the mediator between r3-specific 
cues and NCC migration patterning cues in the adjacent mesenchyme.
Embryos were processed by double ISH for expression of the Sox10 and Cyp26C at 5, 8 
and 24 hours following unilateral r3 removal. Five hours was chosen as the first time point 
to be examined, as this is when cNCCs have been observed to begin migrating into the r3 
mesenchyme following r3 removal [7]. Any strong changes in Cyp26C gene expression at 
5 hours would suggest that Cyp26G acts upstream or in parallel with the cNCC barrier 
cues. By 8 hours following r3 removal, the Typel phenotype will be quite strong [7], so 
any changes in Cyp26C gene expression at this time would imply an involvement of 
Cyp26C in either reinforcement of the phenotype or downstream to disruption of the NCC 
barrier. Taking embryos at 24 hours allows the analysis of any longer term changes in 
gene expression. If changes in Cyp26C expression are causing cNCC mismigration, it 
would be expected that at this 5 hour time point Cyp26C changes would have already
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occurred in the lead up to the cNCC mismigration. At the 5 hour time point, by eye, there 
seems to be no change in the expression of Cyp26C in the r3 adjacent mesenchyme on 
the operated side in comparison to the control side of the embryo (Figure 4-6). By 8 
hours, a slight reduction in Cyp26C expression can be observed in the r4 mesenchyme 
area. All other expression of Cyp26C at the 8 hour time point appears to be the same on 
both sides of the embryos. At 24hours the expression pattern of Cyp26C looks even. In 
all cases the Sox10 staining confirms that the cNCCs have shown a Typel phenotype 
(Figure 4-6).
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5hrs after 
r3 removal
8hrs after 
r3 removal
24hrs after 
r3 removal
Figure 4-6. Expression pattern of Cyp26C following unilateral removal of r3.
Rhombomere 3 was removed unilaterally from embryos at the lOss. Embryos were then 
incubated for 5 hours (A-C], 8 hours (D-F] and 24 hours (G-I]. Embryos were processed by 
ISH for Cyp26C (orange bright field and red fluorescence] and SoxlO (Blue, A-I only]. J-K 
Cyp26C expression at 16ss (J) and 22s (K], as published by Reijntjes 2004 [67]. Note th a t] is 
developmentally comparable to the +8hr embryos in D-F, whilst K is developmentally 
comparable to the +24hr embryos in G-I. These images are representative from 9 embryos 
per time point.
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Although the previous hypothesis was that r3 regulates Cyp26C expression in r3 adjacent 
mesenchyme, it also could be that, as r3 expresses Cyp26C [67], r3 itself is a source of 
Cyp26C in the r3 adjacent mesenchyme; Cyp26C reaching the mesenchyme by diffusion. 
Therefore if r3 is removed from the hindbrain, a potential source of Cyp26C in the 
mesenchyme is also removed, thus leading to less RA degradation and so causing a 
higher local concentration of RA of r3 in the mesenchyme. So it is possible that removal 
of r3 mimics the implant of a RA soaked bead. However in the absence of an antibody 
against Cyp26Cor immunohistochemistry, this cannot be easily tested.
Similar experiments were also performed to look at any changes in the expression 
patterns of either Cyp26A or Cyp26B mRNA following unilateral r3 removal. Firstly, there 
was no change in Cyp26A expression at 5 and 8 hours post surgery, although Sox10 
staining did show that the r4 cNCCs had mismigrated. By 24 hours there appeared to be 
increased expression of Cyp26A on the r3 removal side in comparison to the contralateral 
control side of the same embryo, at the level of the geniculate epibranchial placode at the 
top of the second arch (Figure 4-7). With regards to the Cyp26B expression pattern, at 5 
hours post r3 removal the expression pattern does not seem to have been affected, 
however by 8 hours the expression at the tip of the tissue growth into the r3 void area 
shows stronger expression than the contralateral control side (Figure 4-8). At 24 hours 
the expression of Cyp26B looks slightly stronger in r4 on the experimental side, whereas 
the rest of the expression pattern looks even. It is possible that Cyp26B expression is 
increased upon removal of r3 in an attempt to compensate for the lack of Cyp26 proteins 
being produced by r3, which was removed, leading to less diffused Cyp26s in the 
mesenchyme. If Cyp26 protein levels become lowered in r3-adjacent mesenchyme, the 
regional RA concentration could be high, mimicking the RA r3 mesenchyme bead 
experiments. Therefore, if this is the case then a Typel phenotype may be observed
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following r3 removal, particularly close to the neural tube as this is the area which will be 
depleted of r3 derived Cyp26s the most.
5hrs after 
r3 removal
8hrs after 
r3 removal
24hrs after 
r3 removal
A
Figure 4-7. Expression pattern of Cyp26A following unilateral removal of r3.
Rhombomere 3 was removed unilaterally from embryos at the lOss and incubated for 6 
hours (A-C, n=6), 8 hours (D-F, n=6) and 24 hours (G-K, n=5). Embryos were processed by 
ISH for Cyp26A (orange bright field B,E,G and I and red fluorescence A,B,H and J) and SoxlO 
(Blue C,F and K).
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5hrs after 
r3 removal
8hrs after 
r3 removal
24hrs after 
r3 removal
J I 4 6
Figure 4-8. Expression pattern of Cyp26B following unilateral removal of r3.
Rhombomere 3 was removed unilaterally from embryos at the lOss and incubated for 6 
hours [A-C], 8 hours [D-F] and 24 hours (G-I). Embryos were processed by ISH for Cyp26B 
(orange bright field A,D,G and red fluorescence B;E,H) and SoxlO (Blue C,F,I). J - Cyp26B 
expression pattern (Blue) at 26ss, comparable to the +24hr embryos, as published by 
Reijntjes 2003 [66], showing the same expression pattern. These images are representative 
from 9 embryos per time point. Bg-branchial groove
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4.5. Rhombomere to rhombomere signalling and its 
importance in maintaining correct cranial neural crest 
cell migration patterning
As a loss of ErbB4 signalling gives rise to a Typel phenotype [17, 24], it is likely that 
ErbB4-NRG signalling is important in cNCC migration patterning. As ErbB4 is expressed 
in r3, and NRG is expressed in r4 (and to a lesser extent in r2), an impermeable barrier 
between the two would prevent signalling, and if the ErbB4-NRG signalling pathway is 
important, a Typel phenotype should be seen. In order to investigate this possibility, an 
experiment was performed using 3 embryos, which had a piece of foil placed unilaterally 
between r3 and r4 as a barrier at stage 10 and then incubated for 24 hours before being 
processed by ISH for Sox10. Of these 3 embryos, 2 showed a Typel phenotype (Figure 
4-9). In order to ensure that the identity of the rhombomeres was not affected, additional 
embryos were processed by double ISH for Sox10 and either HoxB1 (n=3) or Krox20 
(n=3). Unfortunately, although these embryos showed no changes in rhombomere 
identity, they also did not portray any cNCC mismigration. Overall the proportion of 
embryos depicting a Typel phenotype was therefore 2 out of 9.
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Figure 4-9. The affect of an impermeable barrier between r3 and r4 neuroepithelium  
on neural crest cell migration.
Foil barriers were placed between r3 and r4 unilaterally at the lOss and embryos were then 
incubated for 24 hours. Neural crest cells were visualised by ISH for the NCC marker SoxlO 
(Blue, A,B,C), the migration pattern showed a Typel phenotype (arrows) on the side w ith the 
barrier in place, the contralateral control side (C) showed normal crest migration (n=2/3).
4.6. Changes in ErbB4 expression and mismigration 
patterning
Studies by Golding et al [17, 24] have showed that ErbB4 is important in regulating the 
correct migration pattern of cNCCs. It has also be found in a separate study that RA 
exposure can alter the expression levels of ErbB4 in breast carcinoma cells in vitro [163]. 
Therefore it is possible that changes in the expression of ErbB4 may be linked to the 
mismigration of cNCCs upon exposure to RA. To test this, a preliminary experiment was 
set up in which embryos were injected with 50mM at-RA into r4 at stage 10 and then 
incubated for 24 hours before fixing and processing for ErbB4 and SoxlO expression by 
double ISH. Of these embryos 2 out of 3 showed discrete ectopic expression of ErbB4 
around the area of RA delivery inr4, identified by residual Dil at the injection site (Figure 
4-10). However in these embryos no cNCC phenotype was observed. As part of this 
preliminary experiment, beads of 1pM at-RA or 1pM 9-cis RA were implanted into the
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neural tube at the level of r4 and incubated for 24 hours before double ISH processing for 
SoxlO  and ErbB4 expression. For both conditions none of the 3 embryos in each 
experiment had any changes in ErbB4 expression, or showed any cNCC phenotype. As a 
high concentration of at-RA (50mM) was used when the ErbB4 ectopic expression was 
observed, there is a possibility that the identity of the rhombomere was being altered to be 
more like r3 or r5, where ErbB4 is expressed. The injections were repeated with a view to 
checking rhombomere identity by studying expression of Krox20 (r3,r5 marker) and 
HoxB1 (r4 marker), however out of the 6 embryos injected none showed the ectopic 
ErbB4 expression pattern, or changes in rhombomere identity. In-situ hybridisation was 
also performed for neuregulin, but the probe signal was too weak to allow any conclusions 
to be drawn. Overall it has been concluded that the ectopic ErbB4 expression observed 
following RA injections was probably due to changes in rhombomere identity, although 
this could not be confirmed here. Furthermore, the lack of ectopic ErbB4 expression in r4 
following bead implantation could have been due to a lower initial dose of RA, rather than 
the high immediate does of RA required for changes in rhombomere identity.
Figure 4-10. Expression pattern of ErbB4 following exposure of r4 to at-RA.
Embryos were injected w ith a 50mM at-RA -D il mix and incubated for 24hours before 
fixation and processing by ISH for ErbB4 and SoxlO. A-D shows the same embryo at different 
points of processing. A-ErbB4 (Blue), B- Residual Dil at the point of injection following ErbB4 
ISH, C- Double ISH for SoxlO (Orange) and ErbB4 (blue), D- Fast red fluorescence of SoxlO 
ISH. Arrows indicate injection site. n=2/3
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4.7. Discussion
The work shown here has helped to further the understanding of the complex 
mechanisms involved in controlling correct NCC migration patterning in head 
development. For the first time a novel role for the 9-cis RA isoform in the presentation of 
a Typel phenotype has been shown, as well as the interaction of RA with the r3 adjacent 
mesenchyme in maintaining correct cNCC migration patterning. These data have also 
provided evidence that signalling between r3 and r4 neuroepithelium is important for 
maintenance of the r3 adjacent mesenchyme cNCC-free zone. Here possible 
mechanisms involved in initiating a Typel phenotype are discussed.
Previous studies have shown that exposure of the hindbrain to at-RA causes cNCCs to 
mismigrate in a Typel fashion. Lee and Osumi-Yamashita in 1995 showed that embryos 
incubated in vitro that were exposed globally to at-RA showed r1 and r2 cells migrating 
ectopically to the second branchial arch and geniculate ganglion [166]. The data 
presented here shows that a much higher proportion of embryos exhibiting aTypel 
phenotype are found when RA is used to target the mesenchyme adjacent to r3, instead 
of targeting the neural tube. Furthermore it was found that a lower concentration of RA 
was required in the mesenchyme to initiate a Typel phenotype compared to r4 targeting. 
Therefore I have concluded that the mesenchyme is the tissue that is most affected by 
RA, not the neural tube. Although the neural tube, and the cNCCs directly, may respond 
to the RA to aid the Typel phenotype, the mesenchyme is most likely the driving tissue 
involved.
Ion-exchange beads were used, in addition to injections, as a form of RA delivery as they 
have been shown to give a slow steady release of retinoids over a period of time [101]. 
Two forms of the ion-exchange resin beads were utilised, a hydroxide and formide form, 
the latter gave the better results, possibly due to its enhanced ability to release the RA
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over the incubation time [173], therefore giving a higher effective dose in comparison to 
the hydroxide beads.
As many papers in this field do not state the lighting conditions used during preparation, 
surgery and incubation, it is possible that the at-RA used in many publications may have 
been exposed to light. This exposure could have significant effects, because it has been 
demonstrated that at-RA degrades upon exposure to normal room lighting conditions, 
giving a mix of at--RA (25%), 9-cis-RA (10%), 11-cis-RA (10%), 13-cis-RA (30%), 9,13-di- 
cis-RA (5%) and an unidentified compound (20%) after 30 mins of light exposure [176]. 
The effect of light is rapid; it only takes 15mins for photoconversion of the at-RA to other 
isoforms, [176, 177], the percentage of each RA isoform in solution then equilibrates by 
30mins in room lighting conditions. Moreover it has been observed that 4.5% 9-cis RA 
can be obtained from a pure at-RA solution in just 0.6s of exposure to a 100W mercury 
lamp. Therefore it is feasible that previous studies involving use of at-RA could have 
unintentionally exposed their at-RA supply to room lighting and therefore have a 
significant amount of biologically active 9-cis, or other RA isoforms in their solutions. If 
this is the case a 16mM ‘at-RA’ solution, as used by Gale [45] could actually contain 
0.75mM 9-cis RA, as well as low levels of other RA isoforms, if exposed to light for just 
0.6s. As different isoforms of RA have been shown to be biologically active in other ways 
to at-RA, it has to be considered a possibility that in other studies other non-at-RA 
isoforms may well be contributing to any observations found. In this work, the cold light 
sources used during microsurgery had yellow light filters, in order to minimise 
photoconversion of the at-RA used.
At-RA and other isoforms of RA bind to their cognate receptors with different affinities. At-
RA is best at binding to the RAR receptors and not the other retinoid receptors RXR [59].
For these reasons it would be expected that a mix of RA isoforms would give a higher
proportion of the Typel phenotype. Thus delivery of light-exposed RA to cells should
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activate both RAR and RXR, in a multitude of homo and hetero-dimer forms, therefore 
giving a comprehensive RA response. Preliminary results using an at-RA and 9-cis RA 
mix also showed an enhanced effect on isolated cNCCs when transplanted in ovo. These 
results imply that the Typel phenotypes observed when RA is added to the developing 
embryos could be the result of multiple hetero and homo-dimer activation therefore 
leading to the transactivation of their multiple gene targets (see section 1.6.3).
In order to investigate if signalling through the RXR instead of the RAR would make a 
difference to the cNCC mismigration phenotype, 9-cis RA was used in place of at-RA in 
the same experiments. As 9-cis has a stronger affinity for the RXR receptor, around 35- 
40x more than the RAR receptor [59, 178], it was an appropriate isoform to use here. 
Although 13-cis RA is also biologically active, it is only known to function through RAR 
receptors [175], and not RXR, and because of this similarity with at-RA, 13-cis RA was 
therefore not used in these experiments. The results showed that the 9-cis RA was more 
effective at inducing ectopic migration of the cNCCs under certain conditions. As the 
RXR receptor can both homodimerise and also heterodimerise with not only RAR but also 
other receptors such as the PPAR-y receptor [60], it could be that the 9-cis RA is 
activating the RXR receptor either as a homodimer or as part of a heterodimer that does 
not include RAR (Figure 4-11). As RXR can be activated in other heterodimers, but 
cannot be activated in a RXR-RAR heterodimer without co-activation of the RAR receptor
[60], it is possible that 9-cis RA is not acting in the same fashion as the at-RA. However 
some activation of the RXR-RAR heterodimers is possible as 9-cis RA is able to activate 
the RAR receptor, although it binds to it at a much lower affinity than to the RXR receptor
[59]. Therefore it could be that upon exposure to 9-cis RA both the RXR-RAR and other 
RXR heterodimers are being activated, which is why 9-cis RA is more effective at causing 
ectopic cNCC migration.
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Figure 4-11. RXR activation by 9-cis RA
The schematic diagram demonstrates the conditions in which 9-cis RA is able to activate 
nuclear receptor activation. When hetero-dimerised with RAR, at-RA is normally required for 
activation, however 9-cis can activate RAR to a lesser extent. RXR homo-dimers are activated 
in the presence of 9-cis alone, and also when RXR is hetero-dimerised with other nuclear 
receptors such as PPARy.
One more point that needs to be taken into consideration is that it has been previously 
reported that as time increases so does the isomerisation of at-RA to 13-cis RA upon 
release from the AG1-X2 resin beads used here [101]. The 13-cis isomer has not been 
shown to interact well with the RAR receptor [178]; therefore it could be acting through 
another, as yet undiscovered, mechanism. This possibility perhaps needs to be more of a 
consideration for the hydroxide bead experiments rather than the formamide bead 
experiments, because the hydroxide beads adsorb the RA more strongly and therefore
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the RA is released more slowly. There have not yet been reports of at-RA isomerising 
when released from the formamide beads or of the 9-cis isomerising upon release from 
either type of bead.
These data provide further evidence that cNCCs can deviate from their normal path of 
migration when exposed to RA. However as the Krox20 ISH results demonstrate, there 
may be flaws in the experimental design, in that it is possible that the transplanted tissue 
was itself acting as a delivery vehicle for RA to the surrounding environment. As studies 
have shown that administration of RA to embryos or cells can change the expression level 
or pattern of Krox20 [45, 163], and changes in Krox20 mRNA expression were observed 
here, this has to be considered as a real possibility for the cause of the cNCC 
mismigration. Another interesting observation on the RA treated r4 transplanted embryos 
is that the host cNCCs also migrated with the transplanted RA-treated cNCCs. There are 
two possible explanations for this observation; firstly the donor RA-treated cNCCs may be 
using their cell-cell contacts with the host cNCCs to change their trajectory to a path of 
migration into the r3 mesenchyme. In support of this theory it has been observed that 
cNCCs can change direction to follow a neighbouring cell’s path through its short range 
contacts of lamellipodia and short filopodia [14]. If this is the case, green donor cells 
would be at the forefront of the mismigrating cNCC stream leading the red host cNCCs. 
From the wholemount images it is difficult to see if the green labelled cells are indeed 
leading, in order to determine if this is the case, sections would need to be taken through 
the embryos in order to see individual cells. However it is possible that there are more 
green ectopically migrating cells than red, as the green stream of ectopic cells does look 
thicker and more substantial than the red stream of ectopic cells, implying that the RA was 
having an effect on the cNCCs directly. A second theory, as mentioned above, is that the 
transplanted tissue is releasing RA into the surrounding tissue and acting in a similar 
fashion to a bead of RA, acting on the neural tube or, as it has unobstructed access, also 
the r3 mesenchyme and thus causing a Typel phenotype.
This is the first systematic study to specifically target the rhombomere adjacent 
mesenchyme of the developing head with retinoic acid to study its effects. The results 
show that, on an equimolar basis, 9-cis RA is more effective than at-RA at causing a 
Typel phenotype (80% vs 35.7%) when r3 mesenchyme is targeted with formamide 
beads loaded with 1pM of either RA isoform. Alternate bead positioning in r2 adjacent 
mesenchyme or r5 adjacent mesenchyme gave a Typel phenotype less frequently, 
implying that the r3 adjacent mesenchyme is indeed the tissue being affected (see Figure 
4-4 for schematic summary of RA targeting), as beads implanted into r5 mesenchyme 
would be expected to cause a phenotype just as frequently as beads implanted into the r3 
mesenchyme, if the r4 cNCCs were the targets. However fewer embryos showed ectopic 
cNCCs, although experimental numbers were also low. When beads were placed into the 
r2 mesenchyme, there was also a low occurrence of mismigrating cNCCs, but when a 
phenotype was observed it was stronger than the r5 mesenchyme bead phenotypes, 
particularly when a mix of 9-cis-at-RA was used. These data are consistent with the 
hypothesis that the r3 adjacent mesenchyme is the affected tissue as the r5 adjacent 
beads had little effect and they are equidistant from the r4 cNCCs as the r3 adjacent 
mesenchyme beads, therefore if r4 cNCCs were the main target an equal proportion of 
Typel phenotypes should have been observed. Furthermore as the r2 adjacent beads 
caused the cNCCs to show a stronger Typel phenotype than the r5 adjacent beads, it 
supports the theory that the r3 adjacent mesenchyme is responsible, since r3 
mesenchyme lies closer to r2 than r5.
The findings that an equal mix of 9-cis RA and at-RA can give such a strong Typel
phenotype further supports the hypothesis that the RXR nuclear receptor is important in
cell migration patterning. Both the RXR and RAR receptors are found in the mesenchyme
during cNCC migration [179], meaning that it is possible that a mix of RA isotypes could
have a more potent effect, as both RAR and RXR are activated, as opposed to just one
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RA isotype activating only one RA nuclear receptor. In addition it has previously been 
suggested that the mesoderm/mesenchyme has a role in cranial patterning, following 
observations that cNCCs show plasticity when transposed from one rhombomere to 
another, meaning that there is an environmental effect that maintains the rhombomere 
specific identity of isolated cNCCs [3]. As the surrounding environment has the ability to 
maintain correct rhombomere and cNCC identity following transplantation to another 
position it follows that it should also have the ability to affect migration patterning. One 
possible weakness of the experiments described here is that the concentration of the RA 
used for the r2 and r5 beads may not have been high enough to allow for diffusion to the 
r3 mesenchyme or the r4 cNCCs to give an effective concentration. In support of the 
mesenchyme being the actual target of RA in this situation is the observation that the 
rhombomeres need a much higher concentration of RA than the mesenchyme to have an 
effect on the cNCC migration pattern, therefore suggesting that a high concentration is 
needed in order to ‘spill over’ into the mesenchyme. Overall these results give a good 
basis for the theory that the mesenchyme actively directs cNCC patterning. This has 
been previously suggested following observations that transposition of small populations 
of cNCCs in the hindbrain observes local environmental patterning cues from the 
mesenchyme [3].
Another interesting observation from this set of results is the unique migration pattern of 
the neural crest following implantation with a hydroxide bead of at-RA. One possible 
explanation for this observation is that as the at-RA is released more slowly and therefore 
over a longer period of time, than from the formamide beads, there may well be increased 
isomerisation of the at-RA to 13-cis RA [101]. The 13-cis RA therefore could be the active 
form of RA that is causing this unique phenotype. 13-cis RA is an isotype that is present 
endogenously [180, 181], however its interactions with RAR receptors have been found to 
be very poor in comparison to 9-cis which has a weak binding affinity [178].
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The embryos injected with RA showed an interesting gene expression pattern of ErbB4, 
with ectopic ErbB4 mRNA at the point of RA administration following injection with a high 
concentration of at-RA. A study by Gale and Prince in 1996 [45] proved that within 6 
hours of exposure to RA there was ectopic expression of Krox20, a marker of r3 and r5 
identity [182, 183]. Another study by Offerdinger and Schnieder in 1999 demonstrated 
that following incubation in RA, breast carcinoma cells in vitro reduced their protein 
expression of ErbB4 by 30-60% of the controls. Therefore it is feasible that in this case 
the identity of rhombomere 4 was altered to be more r3/r5 like, where ErbB4 is expressed 
during normal development [23], rather than the cells upregulating ErbB4 expression due 
to RA exposure. Further support for this hypothesis is that a Typel phenotype occurs 
when ErbB4 is either knocked out or the activity reduced through a dominant negative 
construct [17, 24], so a reduction in ErbB4 mRNA expression would be expected to 
contribute to cNCC mismigration and not an upregulation. RA can down-regulate ErbB4 
protein [163], if this is also true of cells in the rhombomere then the RA could decrease the 
amount of ErbB4 protein in r3. Although no changes were observed in ErbB4 gene 
expression following RA injections, the protein level of ErbB4 may have been reduced by 
the RA through an unknown mechanism, which would not be reflected by the mRNA 
levels immediately.
If r4 becomes more r3-like, it is possible that the mesenchyme adjacent to r4 would
become less hospitable to the cNCCs migrating through it, much like the r3 adjacent
mesenchyme. In which case, the cNCCs could be expected to migrate away from the r4
adjacent mesenchyme and perhaps into the r5 adjacent mesenchyme. However this was
not observed, as only a small proportion of the whole rhombomere was expressing ErbB4,
it may be that the rest of the rhombomere 4 which was not expressing ErbB4 and
therefore not r3-like is able to compensate for its presence, therefore maintaining normal
cNCC migration. To summarise, as no abnormal cNCC migration phenotype was
observed it is possible that this observation was a side-effect of the exposure to a high
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concentration of RA changing the identity of the immediate surrounding tissue and not 
involved in patterning the migration of the cNCCs.
Results here also show that signalling between r3 and r4 is involved in the maintenance of 
the r3 mesenchyme cNCC-free zone by blocking signals between the two rhombomeres. 
It is possible that the barrier is preventing RA or RA metabolism-related molecules from 
diffusing from r3 to r4, thus leading to a Typel phenotype. However another candidate is 
neuregulin (NRG), which is expressed in rhombomere 4 during hindbrain development 
[22, 23]. NRG is a ligand for the receptor ErbB4, which is expressed in rhombomeres 3 
and 5 [23,184] at the same point of development. ErbB4 knockout embryos and embryos 
where ErbB4 activity was suppressed in r3 via a dominant-negative strategy display 
Typel phenotypes [17, 24], demonstrating the importance of ErbB4 in maintenance of the 
neural crest free zone in the mesenchyme next to r3. Thus it is possible that the 
candidate protein, neuregulin, diffuses or is transported from rhombomere 4 to its 
neighbouring rhombomeres and then activates the ErbB4 receptor, which in turn 
maintains correct cNCC migration through its downstream responses.
At the same point of development other proteins are available for ErbB4 signalling, such 
as HB-EGF, which is expressed ubiquitously throughout the hindbrain [185], although it is 
unlikely that HB-EGF can compensate for the absence of neuregulin signalling. A study 
by Hoshino and Uchida in 2007 [185] has demonstrated that cNCC mismigration and 
cranial nerve defects in the absence of HB-EGF signalling, by use of siRNA for either HB- 
EGF or its transporter CNIL, cannot be rescued by neuregulin. It can therefore be 
concluded that perhaps both neuregulin and HB-EGF signalling are required to maintain 
correct cNCC migration and loss of signalling from either one cannot be compensated for 
by the other.
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The RA metabolising proteins Cyp26A1 and Cyp26C1 have been documented to be 
involved in cNCC patterning and cranial nerve patterning, as Cyp26A1-Cyp26C1 double 
knockouts show defects in both [68], while Cyp26A1 knockouts show ectopic axon 
projections [164], much like those seen following a Typel cNCC phenotype. The Cyp26 
inhibitor Fluconazole has also been used to globally inhibit Cyp26s in rat embryos, which 
then developed Typel phenotypes [162] further supporting their importance in cNCC 
patterning. Although experiments were tried targeting r3 with a saturated solution of 
Fluconazole on a bead at 10ss, no patterning defects were observed 6 or 24hours later. 
This result could be due to local compensating upregulation of Cyp26s, therefore perhaps 
a much higher concentration of Fluconazole would be required for local targeting than 
when the whole embryo is exposed to Fluconazole, as a low global presence of 
Fluconazole would prevent compensating Cyp26 activity.
The results reported here suggest that the Cyp26s, although involved in cNCC migration
patterning, are most likely further down the signalling pathway than the immediate effector
responsible for the cell’s migration pattern, as changes in expression pattern, if any, are
only observed after the cNCCs have begun to migrate into the r3 mesenchyme. Although
the Cyp26A1 and Cyp26C1 are involved in cNCC migration patterning, in the event of
removal of r3, they are probably not initiating the mechanism behind mismigration and
changes in their expression levels are not necessary before mismigration can occur.
Conversely the protein levels or activity of the Cyp26s may be altered before cNCC
mismigration, and therefore could be involved, but mRNA expression may not be changed
until later. This uncertainty could be resolved by analysis of protein activity and levels of
the Cyp26s following r3 removal. Furthermore it still needs to be considered that r3 is
itself a source of Cyp26s [67], therefore it could be that r3 expresses Cyp26s , which then
are able to diffuse into the mesenchyme, which then aids in maintaining the r3 cNCC-free
zone. So when r3 is removed, although the mRNA levels of Cyp26s in adjacent tissues
may not change, a source of Cyp26 proteins (r3) has been removed, therefore lowering
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available Cyp26 protein in the r3 adjacent mesenchyme. This change then could lead to 
an increase in local RA concentrations, which then leads to the Typel phenotype, as 
observed when beads of RA are implanted into the r3 adjacent mesenchyme. In 
conclusion it is possible that in Typel phenotypes, particularly with regards to the r3 
removal and Cyp26 knockouts, that the mechanism is indeed similar, both leading to 
increased local RA in r3 adjacent mesenchyme, which has been shown here to cause a 
Typel phenotype.
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4.8. Conclusions
The data presented here show a novel role for 9-cis RA in the presentation of a Typel 
phenotype, and also demonstrate how a slow, long-term exposure to RA isoforms, either 
9-cis or at-RA, is more effective at altering the pattern of cNCC migration than a single 
injection. In addition, the work shown here provides evidence for the involvement of the 
mesenchyme of r3 in maintaining correct cNCC migration patterning and perhaps the 
cNCCs themselves also.
Figure 4-12 gives an overall schematic summary of changes in Cyp26s following r3 
removal and which tissues were affected the most by RA in order to initiate cNCC 
mismigration. The involvement of mesenchyme adjacent to r3 is shown not only by the 
RA experiments, but is also implied by the Cyp26 gene expression patterns observed 
following r3 removal, which could lead to an increase in local RA concentrations due to 
decreased RA metabolism. If both the r3 removal and Cyp26 gene expression data and 
the RA data are taken together, then the tissues involved in Typel phenotypes are the r2, 
r4 and particularly the mesenchyme adjacent to r3 and also r2 and r4 neural tube. Finally 
it has been demonstrated that signalling between rhombomere3 and rhombomere 4 is 
also important in maintenance of the r3 mesenchyme cNCC barrier.
These data demonstrate a possible common mechanism through which changes in local 
RA concentration lead to a Typel phenotype. The results presented here further 
elucidate the complex mechanisms controlling the migration patterning of the cranial 
neural crest cells during development and provide many directions for further study.
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Figure 4-12. Schematic diagram representing the changes in gene expression of the 
Cyp26s following r3 removal and the effectiveness of RA exposure at the tissue to 
cause a cNCC mismigration phenotype.
The diagram represents the hindbrain from rhombomeres 2-5 and the adjacent mesenchyme 
area. Panels A and B shows the expression pattern observed when r3 is removed on the left 
side of the embryo and then incubated for a further 5 (A) or 8 (B) hours, the right side of the 
image shows normal gene expression when r3 has not been removed. Panel C represents the 
areas where gene expression was altered following r3 removal at both 5 and 8 hours after 
surgery, orange shading shows areas where gene expression has decreased and red shading 
shows areas which have increased gene expression. Panel D depicts the observed 
effectiveness of RA at initiating a Typel phenotype, the deeper the shade of green, the more 
effective the RA was when applied to that tissue at causing cNCC mismigration. grey areas - 
there is no experimental data shown here for RA application to these areas. Mes- 
Mesenchyme, NT- Neural tube, r- rhombomere
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4.9. Future Directions
These data have opened a number of interesting avenues for further investigation into the 
mechanisms controlling the migration pattern of the cranial neural crest. The finding that 
9-cis RA is as effective, if not more so in some conditions, as at-RA at initiating a Typel 
phenotype is novel in itself, however the preliminary results that imply that a mix of both 
the at-RA and 9-cis RA is even more effective begs further investigation. Initial 
experiments could be performed through delivery of the RA mix, by bead implants and 
injections, both to rhombomere 4 and also to the r3 mesenchyme. The finding that the r3 
mesenchyme may also be involved in its own right as a control of cNCC patterning also 
provides an avenue for further work. It would be interesting to see if the expression of 
genes in the r3 mesenchyme is altered following RA administration. This possibility could 
be investigated by ISH, or perhaps it would also be useful to investigate the level and 
activity of r3 proteins by removing tissue at time points following RA bead implantation 
and using western blot analysis or 2D gel electrophoresis. This approach would allow 
study of changes in protein activity in addition to changes in gene expression, alterations 
in which may be delayed.
Further experiments to elucidate if cNCCs can also be affected by RA directly with 
regards to their migration pattern would also be interesting. Changes to the experimental 
design would probably be needed in order to reduce the possibility that RA might be 
transported with the cells. This could be achieved by either implanting only cells and not 
tissue, or perhaps using smaller tissue transplants and washing the tissue for longer 
periods, in all cases though the identity of the surrounding rhombomeres would need to be 
checked, particularly Krox20 expression. Another possible method would be to examine 
the migration pattern of RA treated cells on cryosections of hindbrain, similar to that used 
by Golding et al [184]. As patterning cues are still evident in cryosections, and 
furthermore they cannot respond to RA exposure as the tissue is dead, this approach
182
would allow the cNCCs to migrate following RA exposure without the question of affecting 
the environmental cues.
The present results indicate that activation of different RA receptors RAR and RXR or a 
combination of the two could be responsible for the variation in the number of embryos 
displaying a cNCC mismigration phenotype. In order to clarify this possibility, and allow 
specific identification of the receptors responsible for the Typel phenotype, various 
agonists and inhibitors which are commercially available for specific RXR and RAR 
receptors could be used. These could be applied using the same bead implantation 
method.
Another interesting avenue for further investigation is the possible changes in ErbB4 
protein expression following RA exposure. This analysis could be performed on embryos 
with r3 adjacent mesenchyme RA beads to see if ErbB4 protein levels could be involved 
in the Typel phenotype. Although immunostaining of wholemount embryos would be a 
good way of studying this possibility, it was attempted unsuccessfully before the ISH for 
ErbB4 was chosen in the present study. Therefore in the event this problem could not be 
resolved, western blot or FACS analysis could be tried.
Finally, although no evident change in the expression pattern of the Cyp26s was observed 
before the cNCCs began mismigrating, it would still be useful to look at the protein levels 
and activity of the Cyp26s in order to make a successful conclusion with regards to their 
involvement in this situation. Changes in the protein activity may be occurring but the 
mRNA expression levels may not reflect that possibility.
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5.Thesis Summary
The aims of this PhD were to study the tissues and molecules that regulate the migration 
of cranial neural crest cells in the chicken embryo, with particular focus on the roles of 
Midi and retinoic acid.
Midi is mutated in XLOS, causing congenital malformations of the midline, including cleft 
lip/palate, widely spaced eyes (hypertelorism) and broad nasal ridges, all of which could 
be caused by cNCC defects. To date studies have focused on the role of Midi in very 
early development or its role in cell biology. The main cellular functions of Midi identified 
so far are its ability to bind to microtubules, its ability to form multiprotein complexes and 
its ubiquitination of PP2A.
During development the role of Midi has not been widely studied, however some mRNA 
expression pattern work on Midi has shown that it is expressed from as early as 4 
somites through to E16.5. Furthermore Midi is expressed in the hindbrain and adjacent 
mesenchyme of developing embryos at 10ss, leading to the possibility that Midi is 
involved in the developmental biology of the cNCC, defects in which could contribute to 
the craniofacial deformities as observed in XLOS.
Here I provide novel evidence that Midi is involved in several cNCC cell functions, 
including cell migration speed, protease secretions and initiation of placodal cell migration. 
These lead to premature geniculate ganglia development when cNCCs from r4 are made 
to over-express M idi, the mechanism of which is shown here to be due to premature 
migration of cells from the placode, possibly due to changes in cNCC protease secretions.
This thesis has also focused on further elucidating the control of cNCC migration
patterning. Several situations have been published to cause cNCC mismigration
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phenotypes, here I have grouped all conditions which lead to a very similar phenotype of a 
thin stream of cNCCs migrating through the r3 adjacent mesenchyme into one common 
phenotype, termed Type 1. The conditions in which a Type 1 phenotype occur include 
exposure of the embryo to all-trans RA or removal of r3.
The work here has focused on the role of retinoic acid and has shown a novel role for the 
r3 adjacent mesenchyme as a potent responder to RA, needing only low concentrations of 
RA in comparison to the rhombomeres to cause a Type 1 mismigration phenotype. 
Furthermore I have shown that the cNCCs themselves may also be directly responding to 
RA exposure, leading to a disregard of local environmental cues which normally maintain 
the r3 adjacent mesenchyme cNCC free zone. I also provide evidence that the 9-cis RA 
isoform is more effective at causing a Type 1 phenotype than the traditionally used all- 
trans RA isoform, this is most likely due to the initiation of different RA nuclear receptors.
Overall, the data shown in this thesis provides several novel findings and therefore new 
avenues for study. Through further investigation, the role of Midi in regulating cNCC 
protease activity could provide insight into the mechanism behind not only the changes in 
placodal cell migration timings, but also the development of craniofacial abnormalities, as 
Midi is re-expressed later in development in the frontonasal prominence of embryos at a 
time when the geniculate structures are being formed.
The migration patterning data has also opened up some new leads for analysis. The 
finding that 9-cis RA is a more potent isoform than at-RA at initiating a Typel phenotype 
leads to questions about how 9-cis RA causes different downstream signalling responses 
to at-RA. Furthermore it would be interesting to explore how cNCCs would respond to 
exposure to a cocktail of both 9-cis RA and at-RA, particularly when the r3 mesenchyme 
is targeted.
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